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Diabetes mellitus is characterized by hyperglycaemia. The origin of type 1 diabetes 
mellitus (T1DM) arises from loss of pancreatic β cells in response to an autoimmune 
reaction. This results in a state of absolute insulin deficiency. The current state of the art 
research in T1DM involves developing a strategy to protect pancreatic β cells from 
immune system attack while restoring physiological insulin responsiveness to blood 
glucose variations for transplantation. This thesis aims to develop a new 
immunoprotective microenvironment based on hyaluronic acid (HA) for insulin-
producing cells to treat T1DM. Therefore, biomaterial development is fundamental to the 
success of creating an immunoprotective microenvironment. This project investigates 
new routes to chemically modify and crosslink HA. Bis(β-isocyanatoethyl) disulphide 
(BIED) has been synthesised to crosslink HA of low and high molecular weight (0.1 and 
1.2 MDa, respectively) through the formation of urethane bonds. Chemical, physical, 
mechanical, and biological characterization of the HA hydrogels were performed. Results 
show that 0.1 MDa gels have higher crosslinking densities and consequently, higher 
tensile and storage loss moduli. Both high and low molecular weight gels show 
biocompatibility. Gels maintain cell viability and they do not incite activation of the 
immune system as observed by low GM-CSF and TNFα cytokine secretion. Moreover, 
results show that 1.2 MDa gels have increased bacteriostatic activity against 
Staphylococcus aureus. Subsequently, reduction of the disulphide bond of these 
hydrogels resulted in new HA derivates bearing thiol groups and pyridine groups. A novel 
cell encapsulation technique was then developed, utilising the latest cell surface 
modification methodologies, and conformal multilayer deposition of these HA derivates 
via a disulphide exchange mechanism in physiological conditions. Pancreatic beta cells 
from the MIN-6 lineage were encapsulated and displayed normal function with improved 
immunoprotection in vitro. Female mice from the black 6 (C57BL/6) strain were induced 
with diabetes by five consecutive low dose streptozotocin (STZ) injections. Following 
diabetes induction, mice were transplanted with surface engineered MIN-6 and 
encapsulated MIN-6 cells under the kidney capsule. Due to sex dimorphism and hormonal 
variances, female mice showed to be more resistant to the inducing effects of STZ, where 
hyperglycaemia was achieved in 48% of the cohort. Moreover, single-cell encapsulation 
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did not revert hyperglycaemia after transplantation due to the lack of cell-cell interactions 
Overall, materials research from benchwork to final animal testing showed great potential 
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In this chapter an outline of the background information on the architecture of the 
pancreas, insulin metabolism and regulation with emphasis in beta cell functionality and 
its importance in diabetes mellitus pathogenesis is discussed.  
1.2.Architecture of the Pancreas 
Diabetes mellitus is a disease that primarily affects the pancreas. The pancreas is a 
glandular organ that exerts two functions, one involves exocrine cells (acinar and ductal) 
organized in acini, and the other involves endocrine cells organized in small islets (islets 
of Langerhans). The exocrine component of the pancreas occupies over 95% of the organ 
and it produces enzymes such as trypsinogen, pancreatic lipase and amylase that help 
with food digestion (Grapin-Botton, 2005). Pertaining to the endocrine component, 
pancreatic islets consist of five distinct cellular types which are responsible for the 
synthesis and secretion of distinct peptide hormones involved in the metabolism 
regulation (Figure 2.1). 
Glucagon, insulin, somatostatin, ghrelin, and pancreatic polypeptide are secreted by the 
α cells, β cells, δ cells, ɛ cells and PP cells, respectively (Sakata et al., 2019).  However, 
the pancreatic islets are not just comprised of the endocrine cells (mentioned above), they 
also contain numerous other cell types, such as vascular cells, other stromal cells, immune 
cells, and neural elements (Jansson et al., 2016). Stromal and immune cells play a key 
role in the development of diabetes and β cell obliteration, which will be discussed in 




Figure 2.1. Structure of the human pancreas: Endocrine pancreas, islet of Langerhans. 
Each islet contains approximately 1,000 β cells, accounting for 60% of all cells in the 
islet. The remaining 40% of cells are divided in α cells (30%) and the remaining 10% 
includes the δ cell, ɛ cell and PP cells (Da Silva Xavier, 2018). However, cell composition 
is known to vary according to pancreatic anatomical location and also changes amongst 
different species (shown in Table 1.1). Moreover, the proportion of different hormone-
producing cells in the pancreas also differs between males and females of the same 
species. Studies suggest that islets from women have an average of 6% more β cells than 
islets from men (Gannon et al., 2018).  
Table 1.1: A comparison between mouse and human pancreas (Dolensek et al., 2015) 
Scale Property Mouse Human 
Organ Anatomical shape Diffuse/dendritic, lobular, 
soft 
Solitary, compact, firm 
 Ducts Main duct joins with the bile 
duct proximal to the entry 
into duodenum 
Main duct joins with the 
bile duct proximal at the 
point of entry into 
duodenum 
  Numerous accessory ducts A single accessory duct 





In the present study, focus is given to the β cell and its product, insulin, owing to its 
important role in the regulation of carbohydrate, fat and protein metabolism (Wu et al., 
2015). The insulin gene encodes a precursor peptide known as preproinsulin, which 
contains a N-terminal signal peptide (24 amino acids), a C peptide (30 amino acids) and 
insulin (Figure 1.2). Before being secreted by the β cells, insulin first loses the N-terminal 
signal peptide sequence which converts preproinsulin into proinsulin. Then proinsulin is 
enzymatically cleaved and converted into insulin and free C peptide, the latter being co-
secreted with insulin in equimolar amounts (Ashcroft and Ashcroft, 1992). 
Insulin, the active hormone, has a molecular weight of 5.8 kDa. It consists of two 
polypeptide chains, an A chain (21 amino acids) and a B chain (30 amino acids), 
 Diameter of islets Single cells to 500-700 µm Single cells to 500-700 
µm 
 Number of islets 1,000-5,000 1,000,000-15,000,000 





system also present 
insulo-acinar system 
prevails 
 Order of perfusion Centre-to-periphery (66%), 
polar 
Most likely polar 
Cells % of β and α cells  β cells: 60-80% β cells: 50-70% 
  α cells: 10-20% α cells: 20-40% 
 Microarchitecture 
of islets 
Mantle islets predominate Trilaminar islets 
predominate 
 Sympathetic fibres Scarce innervation of 
exocrine tissue 
Rich innervation of 
exocrine tissue 
  In contact with α cells and 
vascular smooth muscle 
cells 
In contact with vascular 
smooth muscle cells 
 Parasympathetic 
fibres 
Scarce innervation of 
exocrine tissue 
Rich innervation of 
exocrine tissue 
  In contact with all types of 
endocrine cells 
In contact with β and δ 
cells, possibly α cells. 
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connected by two interchain disulphide bridges between cysteine residues at A7-B7 and 
A20-B19 positions with one intrachain disulphide bridge at residues A6-A11 (Ryle et al., 
1955, Brown et al., 1955, Sanger et al., 1955).  
Insulin, at a concentration of 40 mM, is stored in granules within the pancreatic β cells 
(Zhuo et al., 2013). A mouse pancreatic β cell is reported to contain as many as 13,000 
insulin granules. However, only 1% of these granules are readily accessible to be released, 
whereas the remaining granules are stored as reservoirs (Pagliuca and Melton, 2013). 
 
 
Figure 1.2. Insulin hormone: signal sequence (preproinsulin), C peptide 
(proinsulin), A and B chains (insulin). 
1.3.1. Insulin Secretion Mechanism 
Carbohydrates are a most important source of energy, and insulin plays a key role in 
glucose homeostasis. Glucose absorption in the intestine increases blood glucose 
concentration (above 7-10 mM), which increases insulin secretion by the release of 
gastrointestinal hormones such as glucagon-like-peptide 1 (GLP-1). In the pancreas, β 
cells sense the higher blood glucose levels and transport glucose inwards via a facilitated 
diffusion process mediated by a transmembrane protein called GLUT2. Inside the β cell, 
glucose is metabolized by entering the oxidation pathway and generates energy in the 
form of adenosine triphosphate (ATP). Higher intracellular ATP concentration will 





Figure 1.3. Action of glucose on insulin secreting β cells. [1] Uptake of glucose through 
GLUT2. [2-3] Glucose is metabolized to convert adenosine diphosphate (ADP) into the 
generation of ATP. [4] Increase in ATP induces the closure of KATP channels, followed 
by the depolarization of the plasma membrane (PM). [6-7] Aperture of voltage-gated 
calcium  channel (VDDC) and influx of Ca2+, which triggers the [8] release of insulin 
by exocytosis. (Wang and Thurmond, 2009). 
1.3.2. Regulation of Carbohydrate Metabolism 
Not all tissues are insulin sensitive (brain, kidneys, and intestine) but those that are (striate 
muscle and adipose tissue) will share specific insulin receptors on their cell membranes. 
The insulin-sensitive tissues will only take up glucose in the presence of insulin. This is 
due to a different glucose transporter that is insulin dependent, named type 4 (GLUT4). 
In these tissues, insulin binds to the insulin receptor of the cell membrane. This generates 
an intracellular cascade response that activates the translocation of GLUT4 from internal 
membrane vesicles to the plasma membrane (Figure 1.4) (Lehninger et al., 2013). 
Only after GLUT4 is translocated in the plasma membrane, glucose uptake is performed. 
In the cytosol, glucose enters the glycolytic pathway to generate lactate. Most of the 
lactate produced in the muscle is then utilized by the liver and converted to glycogen, via 
gluconeogenesis. The conversion of lactate to glycogen in the liver and the continuous 
formation of lactate from glucose in the other tissues of the body represent the cyclical 




Figure 1.4. Insulin activates the translocation of GLUT4 protein to the cell membrane 
for the uptake of glucose on striate muscle and adipose tissues. 
1.4.Autoimmunity 
When the immune system experiences a biological imbalance, several chronic and acute 
inflammatory conditions can be triggered. For example, when the immune system loses 
the ability to differentiate between potentially harmful foreign antigens and self-antigens, 
the autoimmune response unfolds. In this case, autoreactive T cells escape detection by 
central tolerance mechanisms. Although several peripheral tolerance mechanisms exist as 
a safety mechanism such as anergy, deletion, T cell suppression through the induction of 
regulatory T cells (T regulatory), and anatomical barriers such as the blood-brain barrier 
(Kelly et al., 2017) to remove or suppress any such autoreactive T cells, in autoimmunity 
one or more of these also fail. 
More than 80 autoimmune diseases have been diagnosed, with half of these considered 
rare. The auto immunological reactivity can be against any cell type, thus leading to 
diseases with different degrees of severity. It is estimated that autoimmune diseases, such 
T1DM, inflammatory bowel disease or rheumatoid arthritis affect 7.6–9.4% of the 
population worldwide (Gutierrez-Arcelus et al., 2016). Recent studies have shown that 
76% of autoimmunity traits present a predominantly heritable influence, whereas 24% 
are mostly influenced by environment, such as diet and infections (Mangino et al., 
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2017) (Figure 1.5). Furthermore, both innate and adaptive immune system alterations 
are associated with environmental factors (Hotamisligil, 2017), however the mechanisms 
of which these factors may regulate the homeostasis of the immune system are still 
poorly understood (Brodin and Davis, 2017).  
Several studies suggest that the genetic mechanisms underlying autoimmune diseases are 
related to the major histocompatibility complex (MHC), such as the human leukocyte 
antigen (HLA) (Opdenakker et al., 2016) and the toll-like receptors (TLRs). These belon 
to the family of pattern recognition receptors (PRRs) that recognize a wide range of 
pathogen-associated molecular patterns (PAMPs) (Chen et al., 2016, Jimenez-
Dalmaroni et al., 2016). In addition to these mechanisms, the genome-wide association 
studies (GWAS) have identified 90 shared genetic regions associated with celiac disease, 
rheumatoid arthritis, multiple sclerosis, and T1DM (Fortune et al., 2015).  
 
Figure 1.5. Genetic, Environmental, and Immunological Factors Impacting the Initiation 
and Progression of Autoimmune Diseases (reprinted with permission of (Opdenakker et 
al., 2016)). 
1.5.Diabetes Mellitus 
Diabetes mellitus is a disorder characterized by hyperglycaemia, where levels of blood 
glucose are persistently raised above the normal physiological range. This 
hyperglycaemic state arises from a complex interaction of genetic, environmental and 
lifestyle factors that impairs pancreatic β cell activity. 
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In 2014, the global economic burden of diabetes was estimated at approximately USD 
612 billion, representing 11% of total global health expenditures (da Rocha Fernandes et 
al., 2016). The expenditure varies by region, age group, gender, and country's income 
level (Zhang et al., 2010). 
Diabetes mellitus can be subdivided into two main subtypes, which differ from their 
aetiology. In T1DM, the destruction of pancreatic β cells in response to an autoimmune-
mediated reaction eventually leads to a state of absolute insulin deficiency (Watkins, 
2003). Whereas, in type 2 diabetes mellitus (T2DM), pancreatic β cells are not destroyed, 
but their responsiveness to glucose via the GLUT2 receptor is defective. Moreover, in 
T2DM, peripheral tissues have a reduced sensitivity to insulin uptake (known as insulin 
resistance), contributing to a higher glycaemic level in the blood (Watkins and Watkins, 
2003).  
T1DM has been effectively treated with exogenous insulin replacement following the 
discovery of insulin in 1922. Despite this, even with good metabolic control and 
considerable improvements in the quality and delivery of insulin, diabetes is associated 
with significant morbidity, mortality and overall reduced life expectancy. Microvascular 
complications associated with T1DM include retinopathy, nephropathy and neuropathy, 
while macrovascular complications include ischaemic heart disease, stroke and peripheral 
vascular disease. These complications further contribute to the financial burden of the 
health care system, emphasizing T1DM as an important public health matter  (Zamboni 
and Collins, 2017). 
In contrast, T2DM can be treated with an array of oral therapies in conjunction to lifestyle 
modifications to attain optimal glycaemic control. Initially, T2DM is treated with a 
monotherapy, usually using oral hypoglycaemic agents, such as metformin (Rhee et al., 
2017). However, if normoglycaemia is not achieved, a polypharmacy approach is 
prescribed. The introduction of this oral combination therapy (multiple drug regimen) 
targets the control of hyperglycaemia through their different pharmacological 
mechanisms of action (Lavernia et al., 2015). These include insulin sensitizers, insulin 
secretagogues, thiazolidinediones, GLP-1 analogues, dipeptidyl peptidase-4 inhibitors, 
and others. If none of the above therapeutic regimens are able to control hyperglycaemia, 
exogenous insulin therapy is advised (Marín-Peñalver et al., 2016).  
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In this landscape, due to the immune-mediated aetiology of T1DM and the lack of 
treatment options to control hyperglycaemia, restricted only to exogenous insulin 
replacement therapy, the focus of this work is on the development of novel strategies to 
treat T1DM. 
1.6.Pancreatic β Cell Replacement and Immunoisolation 
Latest trends in T1DM treatment are shifting towards pancreatic β cell replacement, 
envisioning to restore physiological insulin responsiveness to blood glucose variations.  
Beta cell replacement strategies include the transplantation of islets and genetically 
engineered insulin secreting cells. Pancreatic islet transplantations infused through the 
portal vein of the liver (Edmonton Protocol) have demonstrated improved glucometabolic 
control, reduced hypoglycaemic episodes and cessation of complications resulting from 
diabetes (Maffi and Secchi, 2015). However, the major drawbacks associated with islet 
transplantation, like in any other organ transplant, include the shortage of donors and the 
danger associated with pharmacological immunosuppression. In this landscape, 
immunoisolation of cellular grafts has been proposed to avoid transplant rejection and 
diabetes reoccurrence (Lim and Sun, 1980). 
When pancreatic β cells are immunoisolated within a semipermeable matrix, cells receive 
the essential nutrients and oxygen needed for their survival. Furthermore, they are 
protected from immune system recognition and rejection while restoring physiological 
insulin responsiveness to blood glucose variations (Figure 1.6). Thence, it is possible to 
perform allo- or xeno-transplants without immunosuppression.  
Amongst all immunoisolation strategies, growing interest is being given to nano 
encapsulation of pancreatic β cells in ultra-thin coatings. The combination of surface 
engineering and the deposition of multiple layers of biomaterials through conformal 
coating provide effective mass transport while still conferring protection from the 
immune attack (Zamboni and Collins, 2017). 
Various natural and synthetic materials have been used to encapsulate pancreatic β cells 
(table 3.1). Although alginate is still the gold standard for islet cell encapsulation and it 
is perceived as biocompatible (Krishnan et al., 2014, Calafiore et al., 2006), alginates with 
high mannuronic acid or impurity content are potentially immunogenic (Lee and Mooney, 
2012). Moreover, the short-term stability of ionic-crosslinked alginate hydrogels, due to 
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the leaching of ions to the outer environment, demonstrates the need to study other 
biomaterials for cell encapsulating purposes. 
In this scenario, polymers naturally present in the extra cellular matrix (ECM) of tissues 
seem to outperform other materials as they closely resemble the native environment and 
have a decisive effect on cellular signalling, immune regulation, and vascularization 
(Zamboni et al., 2018b). These biomaterials, like HA, collagen and others, form hydrogels 
with long-term stability and controllable permeability by customizing the polymeric 
concentration, the type of crosslinking agent or varying the polymeric molecular weight 
and monomeric ratio (Gasperini et al., 2014). 
HA is a natural carbohydrate polymer of increasing significance to bioengineering and 
biomaterials science and is finding applications in wide ranging areas. HA properties, 
both physical and chemical, together with its versatile processability (in solution, film, or 
hydrogel forms), are extremely attractive for various technologies concerned with body 
repair (Collins and Birkinshaw, 2013a). In physiological conditions, HA is under constant 
remodelling and reorganization in response to the surrounding microenvironment. The 
degradation of HA into low molecular weight (LMW) fragments provides signalling cues 
known to promote angiogenesis and inflammation in the surrounding tissue, whilst high 
molecular weight (HMW) HA possess intrinsic anti-inflammatory, insulinotropic effects 
and antimicrobial properties (Zamboni et al., 2018a, Li et al., 2006). 
The inherent property of HA is to promote angiogenesis and vascularization, along with 
the ability to modulate the immune response without the need of additional 
functionalization bearing therapeutic drugs or biological factors. This makes HA the 
material of choice to enable successful encapsulation of pancreatic β cells. 
Vascularization of encapsulated pancreatic cells is of primary importance for effective 
oxygenation and transportation of glucose and insulin in and out the capsule when these 
are transplanted in extravascular sites. 
To date, there has never been any report on nanoencapsulation systems derived from HA 
conformal coatings for pancreatic β cell encapsulation. Several chemical modifications 
have been developed to protract HA degradation, and tailor its mechanical integrity. 
However, only a few chemical modifications can be safely exploited for cell 
encapsulation without hampering cell viability and without causing any cellular damage 
or cytotoxicity. Thiolation of HA is one of these cell-friendly HA modifications that can 
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create reversible crosslinking bonds via thiol/disulphide bond formation through a 
disulphide exchange mechanism. This method facilitates the sequential deposition of 
several polymeric layers on the surface of pancreatic islets to tailor optimal capsule 
performance. Disulphide exchange mechanism is a covalent crosslinking method that 
gives more robust and stable coatings. Covalently crosslinked layer-by-layer systems 
create stiffer coatings with increased Youngs modulus thereby, outperforming ionic 
crosslinking coatings (Amorim et al., 2020). 
In this context, we developed a new cell encapsulation strategy to aid the treatment of 
T1DM. This work envisages the creation of a biofunctional engineered immunoprotective 
environment with the ambition of restoring insulin competence, making this the central 
argument for this project. 
 
 
Figure 1.6. Encapsulation of insulin-producing cells within a semi-permeable hydrogel 
matrix allows nutrient, oxygen, and glucose diffusion while preventing immune cells, 
cytokines and antibodies activation and mediated-cell death. 
1.7.Objectives 
The project core aim is to develop a new immunoprotective microenvironment based on 
HA for the encapsulation of pancreatic β cells to aid the treatment of T1DM. The project 
is divided into 6 main objectives: 
a) Materials development: selection (high vs. low molecular weight), synthesis of a 
novel biocompatible crosslinking agents (di-isocyanate compound) and the 
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utilization of the new di-isocyanate based crosslinker to crosslink HA and produce 
gels; 
b) Biological characterization assessment of newly crosslinked HA hydrogels; 
c) Chemical modification of HA to thiol-bearing and pyridine-bearing HA derivates 
for layer-by-layer (L-b-L) assembly and crosslinking; 
d) Surface modification of pancreatic β cells through PEGlation for subsequent HA 
layer anchorage site; 
e) Conformal encapsulation of pancreatic β cells using layered HA derivates; and  
f) Transplantation of encapsulated cells into a T1DM animal model.  
1.8.Thesis Outline 
Chapters 2, 3 and 4 are an in-depth review of the literature on T1DM, cell encapsulation 
and HA, respectively, which are critical topics in this thesis. The following chapters 
compile the experimental work. As outlined in Figure 1.7. Chapters 5 and 6 were grouped 
into the experimental work package 1, while Chapter 7-8 and chapter 9 encompass 
experimental work packages 2 and 3, respectively. 
For the attainment of the first objective of the project, chemical, physical, and mechanical 
characterizations of the novel synthesized di-isocyanate crosslinker, bis(β-
isocyanatoethyl) disulphide (BIED), and HA derivates were performed. Technologies 
included freeze drying, scanning electron microscope (SEM), Fourier-transformed 
infrared (FT-IR) spectroscopy, solid-state proton nuclear magnetic resonance (NMR) 
spectroscopy, differential scanning calorimetry (DSC), dynamic mechanical analysis 
(DMA) rheometer, and atomic force microscopy (AFM). Results are compiled in Chapter 
5.  
Once these materials were fully characterized, biological assessments were carried out. 
For the achievement of the second objective, fibroblast lineages were used to evaluate 
cell proliferation and cytotoxicity, while macrophages were used to assess immunological 
response, via macrophage activation and production of pro-inflammatory cytokines. The 
antimicrobial activity of HA was also evaluated using Staphylococcus aureus. These 
results are compiled in Chapter 6. 
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Subsequently, objectives 3, 4, and 5 were achieved utilizing pancreatic β cells from the 
MIN-6 lineage, which were surface modified through PEGlation (Chapter 7). The 
evaluation of the cell encapsulation with the different HA derivates developed in the 
chapters 5 and 6 was assessed for cytotoxicity, cell proliferation, glucose challenge, and 
insulin release profile studies for both surface engineered and encapsulated cells. These 
results are compiled in Chapter 8. 
For the achievement of the last objective, an in vivo study was performed, where 
encapsulated cells were transplanted into the kidney subcapsule of female mice of the 
black 6 (C57BL/6) strain. Prior to the transplantation, a T1DM model in mice was 
developed using five consecutive low-dose STZ injections. To access the successful 
transplantation of the cells, blood glucose levels were monitored, and histology was 
conducted to evaluate transplant rejection via localized immunological infiltration. These 
results are compiled in Chapter 9. 
 









2.1.T1DM Aetiology and Pathophysiology 
T1DM is an autoimmune disease where selective destruction of pancreatic β cells leads 
to a state of absolute insulin deficiency. Post-mortem studies of pancreata showed that in 
recently diagnosed type 1 diabetics, patients displayed lymphocytic infiltration of islets, 
which is part of the autoimmune process (Willcox et al., 2009). The β cells are reduced 
in number and eventually disappear completely. Then, islets consist predominantly of α 
cells. It is, therefore, not surprising that patients are insulin dependent. 
The peak of incidence is usually during early childhood (5-9 years of age) or during early 
teenage years and decreases drastically after 13 years of age  (Harjutsalo et al., 2008). 
The early onset of diabetes in younger children is presumed to be due to premature 
exposure to environmental factors (Weets et al., 2002).  These factors will be discussed 
in more depth in section 2.2. Nonetheless, it is worthwhile to mention that there is a 
further subtype of T1DM affecting an older demographic group known as Late Onset 
Autoimmune Diabetes of Adults (LADA) (Kapustin, 2008). 
The currently accepted model of T1DM (Figure 2.1) describes it as a condition primarily 
occurring in people with an underlying genetic susceptibility, combined with disease-
inciting environmental factors. This in turn triggers an autoimmune reaction in the 
pancreatic β cells, also known as insulitis. It can be identified by the presence of 
autoantibodies to the islet components in the blood. Hyperglycaemia and diabetes only 
become evident after more than 80% of the β cells are destroyed. The end result of this 
process results in complete loss of β cells and, therefore, loss of insulin production  




Figure 2.1. Modern model of the natural history of T1DM (Atkinson and Eisenbarth, 
2001) 
Susceptibility is highly associated with the HLA genes and linked to a lesser extent with 
other non-HLA genes. The HLA genes encode the MHC proteins. They are subdivided 
in three main classes: class I, class II and class III. Class I antigens are expressed in the 
cell membrane of all cells and they bind to CD8+ cells (T cytotoxic), being responsible 
for the cellular lyses associated with viral infection. Class II antigens are expressed on 
antigen-presenting cells and bind to CD4+ cells (T helper cells). Class III are associated 
with the action of the complement system (Heinonen et al., 2015). Class I (HLA-B8 and 
B15) and class II (HLA-DR3 and DR4) are associated with increased risks for T1DM. In 
contrast, class II (HLA-DR2) appears to protect against diabetes (Erlich et al., 2008). 
In the period preceding the onset and diagnosis of T1DM, there is continual ongoing 
immune-mediated β cell destruction, with the remaining insulin secreting β cells 
preventing overt hyperglycaemia. This period is clinically silent and characterized by β 
cell stress, β cell destruction, insulitis, and autoimmunity (Eisenbarth, 1986). At this 
stage, biomarkers can be identified, such as islet cell antibodies (ICA), glutamic acid 
decarboxylase antibodies (GADA), insulin auto antibodies (IAA) and insulin antibodies 
(IA). People that have two or more antibodies have higher risk (up to 88%) of developing 
T1DM (Watkins et al., 2014). 
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Many diabetic patients develop circulating IAA and the majority of patients develop IA 
upon initiation of insulin treatment. IAA production is associated to HLA-DR3 and/or 
DR4, in contrast to IAA, it seems that high levels of IA are associated with the expression 
of HLA-DR4 and/or DR7.  
The interstitial space that surrounds the islet during inflammation shows an infiltration of 
antigen-presenting cells, such as mononuclear cells (macrophages and dendritic cells). 
These cells express on their membrane surface HLA class II antigens. They also secrete 
high amounts of pro-inflammatory cytokines, such as interleukins (IL) and tumour 
necrosis factor alpha (TNFα). These cytokines in conjunction with interferon gamma 
(IFNɣ), produced by T cytotoxic and T helper cells, enable the immunological destruction 
of β cells (Chiarelli et al., 2019). 
2.2.Environmental factors in T1DM 
The development of T1DM cannot solely be explained by genetics alone. Environmental 
factors are also thought to contribute to the pathogenesis of T1DM. Many theories have 
been developed regarding environmental factors that could possibly trigger T1DM: viral 
infections, nutritional factors (breast feeding, cow’s milk components and gluten), 
vaccinations, toxins  (N-nitroso derivatives), drugs, psychological stress, maternal and 
intrauterine factors, lack of sunshine (vitamin D) and climatic influences (Tuomilehto, 
2013). 
Longitudinal studies have been conducted to assess environmental triggers in T1DM, 
such as the Babydiab/Babydiet, The Environmental Determinants of Diabetes in the 
Young (TEDDY), Trial do Reduce IDDM in Genetically-at-Risk (TRIGR), Viruses in 
the Genetically at Risk (VIGR), Norwegian Environmental Triggers of Type 1 Diabetes 
(MIDIA), Diabetes Prediction in Skåne (DiPiS), Diabetes Autoimmunity Study in the 
Young (DAISY), and Environmental Determinants of Islet Autoimmunity (ENDIA) 
(Ziegler et al., 2012) (Hagopian et al., 2006, Krischer, 2007) (Akerblom and Grp, 2011) 
(Yeung et al., 2012) (Tapia et al., 2015) (Larsson, 2008) (Frederiksen et al., 2013, Penno 
et al., 2013). Despite ongoing trials none of these environmental factors were proven to 




2.3. T1DM Pathophysiology: ECM Remodelling 
The ECM is the non-cellular component of all tissues, responsible for the provision of 
physical support to cells and for the regulation of diverse cell functions through 
biochemical and biomechanical cues. ECM is composed of water and fibrous-forming 
proteins, such as collagen, elastin, and fibronectin; glycoproteins; proteoglycans; and 
glycosaminoglycans (GAGs) (Theocharis et al., 2016). ECM composition varies from 
tissue to tissue, as a result of multiple signals, that dictate the ECM structure and its 
biomechanical properties. 
The ECM is a very dynamic structure, which is continuously remodelled by matrix-
degrading enzymes, in a controlled manner. When this balance is compromised, due to 
genetic abnormalities or in pathological conditions, matrix composition changes. This 
ECM change can promote critical implications on disease development and progression 
(Theocharis et al., 2016, Frantz et al., 2010).  
In the pancreas, the pericellular membrane surrounds each acinar cell, pancreatic islet, 
and blood vessel, while the interstitial matrix is a thin layer subjacent to the peri-islet 
basement membrane. The interstitial matrix confers tensile strength and elasticity to 
tissues mainly due to the presence of fibrillar collagens. The basement membrane is a 
highly crosslinked sheet-like layer that provides an anchoring platform for epithelial cells, 
preventing them from rupture via the formation of hemidesmosomes (Bogdani et al., 
2014). The basement membrane is composed of collagen (type IV), laminins 
(particularly, laminin 511) and proteoglycans. Laminins provide cell adhesion sites and 
transduce signals to cells that impact cell proliferation, migration, and differentiation, 
while collagen stabilizes the overall structure. While linker molecules interconnect 
collagen and laminin networks (Theocharis et al., 2016).  
ECM remodelling plays an important role in T1DM pathogenesis by promoting immune 
cell activation, islet invasion and destruction of pancreatic β cells. The degradation of 
ECM components by proteases, such as matrix metalloproteinases (MMP), are 
responsible for the generation of ECM bioactive fragments (also called matrikines). These 
matrikines fine tune inflammatory responses by influencing the activity and/or function 
of both infiltrating and resident cells (Jiang et al., 2011). HMW HA (> 1000 kDa), present 
in normal pancreatic tissue becomes degraded into LMW HA (250 kDa) during the 
disease process  (Li et al., 2006). These LMW HA fragments promote leukocyte 
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recruitment and adhesion by activating TLRs (Vigetti et al., 2014, Shakya et al., 2015). 
Moreover, HA fragments can be crosslinked into structures that impact leukocyte 
function by the interaction with a diverse group of HA-binding proteins, known as 
hyaladherins. HA-hyaladherin structures are stable complexes in solution and enhance or 
induce HA binding to the cell surface receptor CD44 on lymphocyte cell lines (Baranova 
et al., 2011). 
Islet invasion starts with neutrophil diapedesis towards the pancreas. It occurs within the 
post-capillary venules that surround the islets, where haemodynamic shear forces are 
minimised. After passing through the capillary endothelium, leukocytes penetrate the 
peri-islet basement membrane before they gain access to the β cells. The transmigration 
of leukocytes through the peri-islet basement membrane is hypothesized to involve three 
mechanisms: a) the proteolytic digestion of the membrane; b) the use of mechanical force; 
and/or c) preferred basement membrane sites of variant composition (Bogdani et al., 
2014). The variability in the composition of the basement membrane is mainly attributed 
to laminin, where α5 deficient regions facilitate leukocyte diapedesis (Hallmann et al., 
2015).  
In developing pancreatic islets, β cells are confirmed to express α1β1 receptors which are 
a specific type of laminin receptor.  The α1β1 receptors are co-localized with collagen IV 
in the basal membranes of juxtaposed endothelial cells. The β cell α1β1 integrin 
interaction with collagen IV promotes β cell migration and potentiates insulin secretion 
(Kaido et al., 2004). However, upregulation of integrin α6β1 by leukocytes has been 
suggested to facilitate cell transmigration through the peri-islet basement membrane. 
Leukocyte migration through the interstitial matrix occurs via collagen-mediated  actin-
myosin system (Sorokin, 2010). 
The proteoglycan composition of the peri-islet basement membrane has also been 
studied, showing the presence of heparan sulphate proteoglycans (Cheng et al., 2012a). 
Syndecan-4 (a membrane-associated heparan sulphate proteoglycan) is also observed 
on β cells. Interestingly, the inhibition of heparan sulphate degradation is shown to 




2.4.Disease Incidence and Prevalence 
The International Diabetes Federation (IDF) has estimated that the global prevalence of 
diabetes mellitus in 2015 for people aged between 20 and 79 years old was 8.8%, with 
over 414.7 million people diagnosed with the condition. By 2040 IDF estimates that this 
will increase to over 642 million people, with the overall prevalence increasing to 10.4% 
(Federation, 2015). The estimation of the number of people with diabetes in different 
regions worldwide is presented in table 2.1. The main driving forces for the increased 
diabetes incidence around the world are associated with unhealthy eating habits, obesity, 
and increasingly sedentary lifestyles (Patterson et al., 2014). 
Table 2.1: Estimative of the number of people (aging from 20 to 79 years old) 
with diabetes in the year 2015 and 2040 (Federation, 2015). 















Africa 441 14.2 3.2 926 34.2 3.7 
Europe 660 59.8 9.1 663 71.1 10.7 
MENA*  387 35.4 9.1 635 72.1 11.4 
NAC* 344 44.3 12.9 413 60.5 14.7 
SACA* 315 29.6 9.4 411 48.8 11.9 
Southeast 
Asia 
926 78 8.5 1310 140 10.7 
Western 
Pacific 
1600 153 9.3 1800 215 11.9 
Total 4720 414.7 8.8 6160 642 10.4 
*ABBREVIATIONS: Middle East and North Africa (MENA); South American and 
Central America (SACA); North America and the Caribbean (NAC) 
Currently, there are 1.9 billion children in the world, of those, 542,000 children (0-14 
years old) have T1DM (Federation, 2015). Each year 86,000 new cases are diagnosed 
with an annual incidence increase of 3% (Patterson et al., 2009, Bessaoud et al., 2006). 
The United States of America currently has the highest number of children with diabetes 
in the world (84.100 children), with Finland being the country with the highest number 
of new cases of T1DM in children (62.3 new cases per 100.000 population per year) (table 
22 
 
2.2). Ireland is in 7th place, with an incidence of 26.8 new cases in every 100,000 children 
per year. The causes of the rapid change in the T1DM incidence rate are unknown, and 
they are unlikely to be due to shifts in genetic background alone. Hence, environmental 
agents are also presumed to contribute to this incidence increase (Patterson et al., 2014).  
Table 2.2. Rank of countries for number of children with T1DM and rank of 
countries for number of new cases of kT1DM per 100000 children per year.  
Top 5 countries for number of children 
with T1DM 
Top 5 countries for new cases of T1DM in 
children 
Rank Country Number of 
cases 
Rank Country Number of new 
cases/100000 
children/year 
1 USA* 84100 1 Finland 62.3 
2 India 70200 2 Sweden 43.2 
3 Brazil 30900 3 Kuwait 37.1 
4 China 30500 4 Norway 32.5 
5 UK** 19800 5 Saudi Arabia 31.4 
*United States of America, **United Kingdom. 
2.5.Diagnosis 
T1DM symptoms include increased diuresis (polyuria) and nocturia, this is primarily 
because the renal threshold for glucose reabsorption is exceeded. Further symptoms 
include dehydration; polydipsia (thirst); weight loss; and fatigue. In the absence of more 
specific biological markers to define diabetes, the measurement of plasma glucose levels 
and glycated haemoglobin are the only diagnostic criteria established so far. 
In insulin competent individuals, fasting plasma glucose levels are below 6.1 mmol.L-1 
(normoglycaemia). Higher fasting glucose levels ranging from 6.1 to 6.9 mmol.L-1 are 
classified as intermediate hyperglycaemia and may be considered for diabetes prevention 
intervention (2020a). Note that fasting is defined as no caloric intake for at least 8 hours. 
Traditionally, diabetes is diagnosed when venous plasma glucose levels exceed 7 mmol.L-
1. 
Summarized in table 2.3 are the glycaemic values used to diagnose diabetes as defined 
by the World Health Organization (WHO). Measurement of glycated haemoglobin 
(HbA1c) reflects the average plasma glucose level over a period of 12 weeks. This is an 
23 
 
excellent indicator of glucose control over time and is used in the  monitoring of 
glycaemic control in patients with diabetes (Organization, 2011). 
Table 2.3: WHO criteria values for T1DM diagnosis (WHO/IDF, 2006). 
Diabetes mellitus Venous plasma glucose 
Fasting ≥7.0 mmol/L (126 mg.dL-1) 
Random plasma glucose* ≥11.1 mmol/L (200 mg.dL-1) 
Oral glucose tolerance test ≥11.1 mmol/L (200 mg.dL-1) 
HbA1c ≥6.5%  
       *in presence of diabetes symptoms. 
2.6.Secondary Complications 
2.6.1. Ketoacidosis 
Diabetic ketoacidosis (DKA) is a potentially life-threatening metabolic derangement that 
occurs from severe insulin deficiency in untreated T1DM (American Diabetes, 2013). 
After a meal containing carbohydrates, glucose accumulates to abnormally high levels in 
the blood. Since adipose tissue (an insulin-dependent tissue) is unable to take up glucose 
due to lack of insulin, adipose cells increase lipase activity in order to breakdown 
triacylglycerols. 
The free fatty acid chains released after lipolysis are exported to the liver where they are 
oxidized into acetyl coenzyme A (CoA). Acetyl-CoA instead of entering the citric acid 
cycle, it is diverted to the formation of “ketone bodies”. Acetoacetate is decarboxylated 
to give acetone or alternatively β-hydroxybutyrate. Acetone is released by the lungs and 
acetoacetate and β-hydroxybutyrate are transported by the blood to tissues other than liver 
(extrahepatic tissues), where they are converted to acetyl-CoA and oxidized in the citric 
acid cycle, providing energy to be used as fuel as a glucose substitute (Foster and 
McGarry, 1983). 
The overproduction of acetoacetate and β-hydroxybutyrate leads to their accumulation in 
the blood and urine (ketosis) which can subsequently, decrease the blood pH level to as 
low as 6.8 (acidosis) (Owen et al., 1982). DKA is accompanied by dehydration, potassium 
depletion, respiratory compensation and metabolic acidosis, impaired consciousness, 
vomiting, leucocytosis and hypothermia (Gallo de Moraes and Surani, 2019). 
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2.6.2. Micro and Macrovascular Complications 
Persistent hyperglycaemia over many years, incite well known secondary complications, 
such as retinopathy, neuropathy, and nephropathy. These complications considerably 
reduce life expectancy and quality of life of patients (Ramasamy et al., 2006). The toxic 
effects of hyperglycaemia might be explained by the formation and accumulation of 
glycosylated proteins and lipids which induce oxidative stress in target tissues (Feener 
and King, 1997).  
Nearly all patients with T1DM develop retinopathy later in life. Retinopathy will 
eventually lead to complete eyesight loss and it is responsible to approximately 4.8% of 
all cases of blindness in the world (Resnikoff et al., 2004). 
Neuropathy is a result of autonomic and peripheral nerve damage in patients with 
diabetes, which is one of the main causes for the diabetic foot. First small neural fibres 
are damaged by demyelination. The accumulative effect is most apparent in the long 
nerves, causing peripheral loss of sensation. The inability to sense trauma and abnormal 
pressure on skin can lead to skin ulcers and infections. Infections are treated with 
antibiotics but can lead to amputation in patients with more  extensive gangrene or limited 
gangrene in presence with sepsis (Tesfaye, 2014). 
Patients with diabetes can develop subsequent renal pathology, characterized by capillary 
closure and tissue ischaemia. The progression of renal disease occurs over many years 
leading to proteinuria, this typically occurs when the albumin to creatine ratio (ACR) is 
above 30 mg/mmol/L. Preventative treatment is by controlling the blood pressure, 
primarily with angiotensin-converting-enzyme inhibitors (enalapril and ramipril) or 
angiotensin-2 receptor antagonists (losartan and olmesartan) (Suissa et al., 2006). If there 
is progression to end stage renal failure, patients may end up requiring  dialysis and / or 
renal transplantation (Smets et al., 1999). 
2.6.3. Management of Secondary Complications 
Diabetic patients are advised to maintain tight glycaemic control with the aim of keeping 
their HbA1C levels below 7%, in order to reduce micro- and macrovascular complications. 
Five years following the diagnosis of T1DM, follow-up appointments are recommended 
annually for screening and assessment of the development and progression of 
nephropathy, retinopathy and polyneuropathy (2020f). 
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Adults with diabetes are also advised to perform at least 150 minutes a week of moderate-
intensity aerobic activity (50–70% of maximum heart rate), in 3 days a week. Studies 
have shown that physical activity can improve glucose levels, reduce cardiovascular risk 
and prevent complications in diabetes (2020b). 
2.7. Blood Glucose Monitoring 
To maintain good glycaemic control, patients need to be attentive to their lifestyle and 
assess the response to their insulin therapy by measuring their blood glucose 
concentrations. This is routinely done by pricking the tip of a finger with a needle (or 
lancet) and placing the blood into a capillary strip containing an enzyme, such as glucose 
oxidase or glucose dehydrogenase. The glucose concentration is determined by either an 
electrochemical or colorimetric readout system (Heller and Feldman, 2008). New studies 
are being developed in order to produce more accurate and less inconvenient glucose 
monitoring sensors, such as non-enzymatic glucose sensors (Tian et al., 2014). 
The American Diabetes Association guidelines suggest that people with T1DM should 
monitor blood glucose levels  a minimum of three times a day, particularly prior to meals 
and snacks and also at bedtime (2020c). When low blood glucose is suspected, their blood 
glucose levels should be assessed prior to exercise and critical tasks such as driving. After 
the correction of low blood glucose, achieved usually by ingesting a sugary snack or 
drink, self-monitoring should be performed until normoglycaemia is achieved. Real-time 
continuous glucose monitoring (CGM) is also available through the measurement of 
interstitial glucose (which correlates with plasma glucose). CGM devices can be equipped 
with Bluetooth (for receiving readouts on a smartphone or smart watch). CGM are also 
equipped with alarms for hypo- and hyperglycaemic states which is beneficial for children 
and adolescents or patients with hypoglycaemia unawareness and/or frequent 
hypoglycaemic episodes (2020d). 
2.8. Pharmacological Therapies in T1DM 
Following the discovery of insulin in 1922, exogenous insulin replacement has been an 
effective treatment for T1DM which allows patients to maintain safe blood glucose levels 
and lead a relatively normal life (Banting and Best, 1922). Traditionally, insulin therapy 
is administered via subcutaneous injections, however other administration routes have 
also been studied, such as the respiratory route with the utilisation of inhalers (Mohanty 
and Das, 2017).  
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Insulin therapy has constantly changed over the decades, starting from early insulin 
extracts obtained from animal pancreas and advancing to the development of human 
insulin analogues by molecular biology manipulation. These human insulin analogues 
contain small changes in the amino acid sequence of insulin which implicates in major 
changes in their pharmacokinetic profiles (Mathieu et al., 2017). 
2.8.1. Insulin Regimen 
The goal of insulin replacement therapy is to achieve normoglycemia, where a fasting 
blood glucose should be between 90 and 120 mg/100 mL and a 2-hour postprandial value 
below 150 mg/100 mL (2020c). To achieve these glycaemic values, insulin is given in 
doses that are expressed in units. The convention is that one unit of insulin is responsible 
to reduce the concentration of 45 mg/100 mL blood glucose in a fasting rabbit. A healthy 
person produces normally between 18 and 40 units per day of insulin, which is 0.2-0.5 
units/Kg/day. In T1DM patients, the average requirement of insulin is usually around 0.7 
units/Kg/day (Hirsch, 2005). However, insulin requirements can be subject to change due 
to a number of situations, such as exercise, stress or illness. 
The right technique to administer insulin injections are either at a 45° or 90° angle into a 
fold of skin pinched between fingers. The common areas to inject insulin in the body are 
the anterior thighs, dorsal arms, buttock, and abdomen. However, different injection sites 
have an influence on insulin absorption and consequently, on its pharmacokinetics 
(2020e).   
Insulin preparations are classified according to their duration of action, known as short- 
and rapid-acting, intermediate, or long-acting insulins. The pharmacokinetic profiles vary 
among the insulins available (Figure 2.2).  
A number of insulin regiments (such as split-mixed or basal/bolus) try mimicking normal 
pancreatic insulin secretion patterns. These regiments combine a single injection of an 
intermediate or long-acting insulin (mimicking low basal insulin rate) following multiple 
rapid or short-acting insulin injections (mimicking postprandial insulin rate) (Hilal-
Dandan et al., 2014, Lechleitner and Hoppichler, 2011). 
Non-diabetic subjects produce half of their insulin as a low basal rate and half in response 
to meals. The insulin response to meals occurs after 5 minutes and lasts for 2-3 hours 
following each meal. In T1DM patients the basal dose of insulin is around 40% to 60% 
of the total daily requirement which supresses lipolysis, proteolysis and gluconeogenesis. 
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The remaining dose is then divided in response to meals (Lechleitner and Hoppichler, 
2011). 
 
Figure 2.2. Approximate pharmacokinetic profile of rapid-acting (Aspart and Lispro), 
short-acting (Regular), intermediate-acting (Neutral Protamine Hagedorn-NPH, 
extended zinc insulin) and long-acting (Glargine) insulins. 
2.8.2. Insulin Delivery Systems to Treat T1DM 
Insulin pump therapy or continuous subcutaneous insulin infusion (CSII) is a method to 
deliver insulin at a steady state rate. It is a device the size of a pager that can be attached 
to the belt or placed in a pocket. The infusion is set as a slow, continuous rate throughout 
the day which is known as the basal infusion and/or to release larger amounts of insulin 
at mealtime or when blood glucose levels are high which is known as the bolus dose. The 
bolus dose is calculated using carbohydrate counting. 
All insulin pumps available in the market are “smart pumps” and they have an on-board 
calculator which calculates and corrects the amount of bolus insulin to be injected for any 
given carbohydrate value. Latest-generation insulin open-loop pumps bring CGM 
features attached to the device. The type of insulin used in this device is rapid-acting 
insulin (Dajkovich and Barkley, 2015). 
Insulin pump therapy is still expensive in comparison to conventional pen/syringe insulin 
administration, whilst in countries like Australia, Sweden and the UK insulin pump usage 
rates are below 20% (AIHW, 2012) (Steineck et al., 2015) (Ghatak et al., 2015). The 
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guideline recommendation for CSII use is intended for children under 12 years with 
T1DM if treatment with multiple daily injections is not practical or for any patient with 
T1DM if HbA1c targets are not achieved via multiple daily injections or if hypoglycaemia 
episodes are frequent and not controlled by multiple daily injections (2020d). 
The overall advantages of insulin pumps are the reduction of hypoglycaemic episodes 
and improvement of HbA1c. However, the disadvantages are related to catheter infection 
and pump failure, which increases risk of DKA (Maede and Rushton, 2013, Woerner, 
2014, Johnson et al., 2013). 
While open-loop insulin pumps are available in the market, close-loop devices (artificial 
pancreas) integrated with CGM to infuse insulin accordantly are still only available in 
research. Tubeless pumps (patch pumps) are also being developed and they consist of a 
reservoir of insulin in a tiny pump attached to the skin which communicates with the 
smart calculator and glucose monitor via Bluetooth (Nicholls and Partridge, 2015, 
Alexander and Greene, 2009).  
2.8.3. Common Problems Associated with Insulin Therapy 
Alternation of the injection site is important to prevent lipohypertrophy. Lipohypertrophy 
is caused by the tropic action of insulin and it is a common problem in insulin-dependent 
diabetic patients. It can lead to functional disorders, such as pain, reduced local insulin 
efficacy, and aesthetic problems (Kordonouri et al., 2002).  
Insulin therapy can also lead to potentially dangerous side effects. Hypoglycaemia is 
described as plasma glucose below 2.8 mmol.L-1 in men or 2.6 mmol.L-1 in women. 
Symptoms are autonomic in nature and include sweating, shaking, palpitations, anxiety, 
and neuroglycopenic effects, such as confusion, drowsiness, and slurred speech 
(McCrimmon and Sherwin, 2010). Patients rely on the presence of these symptoms to 
alert them of an hypoglycaemic episode, which can be in turn reduced by eating 
carbohydrates. However, hypoglycaemia can be sometimes overtreated,  resulting in post 
hypoglycaemic hyperglycaemia, also known as the Somogyi effect (Gerich, 1988). 
Physical activity induce hypoglycaemia, for this reason patients are advised to reduce 
insulin intake after exercise (2020g). 
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2.9. Pancreatic Islet Transplantation 
Since 1922, blood glucose levels have been effectively controlled via exogenous insulin 
replacement therapy (Banting et al., 1922). However, it still does not mimic the 
physiological pancreatic insulin secretion pattern, and therefore it can result in the 
occurrence of life threating hypoglycaemic episodes and increased risk of both micro and 
macrovascular complications (Virk et al., 2015, Steineck et al., 2015).  
Nowadays, the treatment of T1DM is shifting towards the replacement of original islets 
via exogenous islet transplantation. Islet and whole organ transplantation are 
recommended for patients with renal failure who also require a kidney transplant or for 
those with life-threatening hypoglycaemic unawareness (Cahill et al., 2019). 
In 2000, a multicentre study called the Edmonton Protocol developed a new 
immunosuppressive regimen that was shown to be safer and less toxic to islet transplanted 
patients with T1DM. This new regimen does not require the use of steroids and has 
reduced the use of calcineurin inhibitors (Shapiro et al., 2000). Follow-up data from 36 
subjects showed that 16 patients were insulin independent for 1 year, 5 remained insulin 
independent for 2 years (Shapiro et al., 2006) however, only 2 patients remained insulin 
independent at 10 years post-transplantation (Brennan et al., 2016).  
Initially, pancreatic islet transplantation was performed using surgical access such as 
laparotomy (Johnson et al., 1999), however nowadays the procedure is performed by 
minimally invasive techniques using percutaneous access and interventional radiology 
(Owen et al., 2003, Venturini et al., 2016, Madoff et al., 2016).  
 




For the transplantation of islets (shown in Figure 2.3), the successful isolation of the islets 
is regarded the most important step for achieving normoglycaemia. Notably, during 
isolation, cells lose their vascularized network and have their ECM disrupted, which 
reduces the viability of the harvested cells (Cheng et al., 2012a). The interaction between 
β cells and ECM is known to influence several aspects of islet functionality, including 
survival, proliferation, and insulin secretion (Theocharis et al., 2016). 
It is calculated that the total number of islets to achieve insulin independency is about 
200,000 islet equivalent (IEQ) (Weir, 2013). Therefore, for one single transplant 
recipient, approximately 2-3 donors are required to obtain enough viable cells. However, 
to overcome the shortage of donors, autologous and xenogeneic cellular sources 
incorporating cell modification and cell encapsulation strategies have been investigated 
(Zamboni et al., 2018b).  
2.9.1. Percutaneous Islet Transplantation 
Percutaneous transhepatic islet transplantation utilizes ultrasound (US) to locate a 
peripheral branch of the right portal vein, after which a catheter is placed under 
fluoroscopic guidance. This facilitates the even distribution of pancreatic islets into both 
lobes of the liver. The portal venous pressure (PVP) is measured prior, during and after 
islet infusion. PVP is maintained below 12 cm H2O/20 mm Hg as higher PVP is directly 
associated to complications such as portal vein thrombosis (PVT) and excessive bleeding 
(Wilhelm et al., 2013). Islets are suspended in a sterile medium containing 200 mL of 
dextran and heparin (35 units/kg) to prevent the instant blood-mediated inflammatory 
reaction (IBMIR) and to reduce the risk of portal vein thrombosis (Baltzinger et al., 2016). 
Where one unit of heparin is an amount approximately equivalent to 0.002 mg of pure 
heparin. After completion of the infusion procedure, venous flow is assessed by a 
portogram to ensure no PVT or bleeding. Upon removal of the catheter from the portal 
vein, the tract is embolised with platinum fibred coils or Gelfoam® plugs to prevent 






Studies have shown that tissue volume and islet size influences infusion safety for 
example tissue volumes <0.25 cm3/kg of islets appear to decrease the risk of bleeding and 
PVT  (Suszynski et al., 2014, Wilhelm et al., 2013). Allotransplanted islets have been 
reported to decrease risk for acute PVP when compared to auto-transplanted islets and 
this has been attributed to the high purification of allotransplanted islets (Kawahara et al., 
2012). 
2.9.2. Post-transplantation Complications 
Next day post-operative imaging in the form of liver ultrasound, is utilised to assess for 
potential complications which include hepatic hematoma, bleeding and PVT (Bozkurt et 
al., 2013).Bleeding is reported to occur in 12% of the transplantations due to puncture of 
the parenchyma around the capsule of the liver or within the peritoneum. Thrombosis is 
reported to occur in 6% of all transplantation cases. Thrombosis can be potentially life-
threatening, but the risk is reduced by the addition of heparin during the islet infusion 
(Owen et al., 2003).  
The acute management of PVT requires the use of anticoagulation therapy, initially with 
low molecular weight heparin followed by warfarin if appropriate. The goal of 
anticoagulation is to prevent clot extension, intestinal infarction, and portal hypertension. 
The recommended duration of anticoagulation therapy does not exceed 6 months in 
patients without a known hypercoagulable state (Robertson and Hayes, 2015).  
Hepatic steatosis (also known as fatty liver) is an extravascular complication of islet 
transplantation. It has been reported in 19% of cases as early as 6 months after islet 
transplantation using US (Low et al., 2015). The hepatic fat accumulation is hypothesised 
to occur in infusions of higher islet mass content or by localised islet cell over activity 
(Venturini et al., 2015b). Hepatic steatosis has been shown to persist for up to 5 years, 
however, there has been reported cases where this resolved spontaneously and cases of 
subsequent reoccurrence (Jackson et al., 2013). 
2.9.3. Islet Transplant Rejection 
After islet transplantation, patients achieve improved metabolic control and insulin 
independence. However, from all transplant patients only a few remain insulin 
independent after the first year of transplantation. A clinical study was conducted in 36 
subjects showing that 16 patients were insulin independent for 1 year after transplantation 
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and 5 remained insulin independent at 2 years after transplantation (Shapiro et al., 2006). 
In long-term follow-up study, 7 participants were enrolled from those initial 36 subjects. 
All subjects demonstrated some islet function for at least 10 years, but only 2 patients 
remained insulin independent  (Brennan et al., 2016). 
Early loss of islet mass upon portal vein infusion, recurrence of insulitis (the hallmark of 
T1DM immunopathogenesis leading to immune-mediated β cell destruction), and islet 
allograft rejection contribute to graft failure overtime (Roep, 2020). In figure 2.4, the time 
frame of detrimental factors leading to early injury and late functional loss after islet 
transplantation is shown. 
 
Figure 2.4. Fate of intrahepatic islets infused through the portal vein.  Graft function is 
lost overtime due to hypoxia, immediate blood-mediated inflammatory reaction 
(IBMIR), auto- and alloimmune rejection (Li et al., 2018). 
Early islet loss is a result of a severe hypoxic environment in the first several days after 
transplantation, where islets rely only on passive oxygen diffusion for survival (Li et al., 
2018). Following transplantation, islets are also in direct contact with the ABO blood 
antigens, platelets, and the complement system, leading to IBMIR (Figure 2.5).  Tissue 
factor (TF) present in the surface of islets interacts with factor VIIa and initiates the 
extrinsic coagulation cascade by the activation and deposition of platelets. This leads to 
the formation of thrombin and the formation of the fibrin clot. The activation of the 
complement proteins C3a and C5a leads to the recruitment and infiltration of 
polymorphonuclear cells (PMNs), such as neutrophils and eosinophils. The accumulation 
of immunoglobulins and complement proteins, such as C3, C4 and C9, on the surface of 
transplanted islets also indicates that the classical complement activation pathway may 




Figure 2.5. Mechanisms of the instant blood-mediated inflammatory reaction (Kanak et 
al., 2014). 
Alloimmune rejection of islet grafts is shown to be associated with granulocyte 
infiltration to the site of transplantation. Neutrophils and eosinophils are usually the first 
leukocytes to infiltrate transplanted organs and are a well-established marker of transplant 
rejection (Moberg et al., 2005, Weir et al., 2012). Fresh isolated islets express pro-
inflammatory cytokines and chemokines such as IP-10, IL-8 and monocyte 
chemoattractant protein-1  (MCP-1) that upon transplantation are known to attract 
leukocytes, neutrophils and macrophages to the transplantation site, respectively (Kanak 
et al., 2014). Moreover, T‐cell alloreactivity plays an important role in transplant rejection 
(Gras et al., 2011). Indirect alloantigen recognition occurs when allogeneic MHC 
molecules from graft cells are taken up and processed by recipient APCs and subsequently 
presented to alloreactive T cells (Figure 2.6). Direct allorecognition, by contrast, uses 
donors’ own APCs to present allogenic MHC molecules to recipients alloreactive T cells 
(Davis, 2004).    
T‐cell alloreactivity also instigates further leukocyte activation and recruitment. Once 
alloantigens are recognize by CD4+ Thelper17 cells, they promote neutrophilia via the 
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production of IL-17 cytokine (Crawford et al., 2020). IL-17 is a potent driver for 
neutrophil infiltration and production of granulopoietic cytokines such as granulocyte 
macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating 
factor (G-CSF), which further promote macrophage activation (Scozzi et al., 2017).  
 
Figure 2.6. Indirect T-cell alloreactivity (Davis, 2004). 
2.10. Future Treatments for T1DM 
A bioartificial endocrine pancreas is proposed as a future alternative to current treatment 
options. This bioengineering approach could theoretically provide an inexhaustible 
source of bio-engineered insulin-producing cells to treat patients with insulin-secretion 
deficiency. These bio-engineered insulin-producing cells have the potential to also 
enhance graft survival and decrease transplant rejection by the combination of a number 
of strategies brought together by regenerative medicine. The conceptual triad for tissue 




Figure 2.7. Tissue engineering an insulin-secreting cellular graft for T1DM treatment. 
In the next chapter, a detailed review of the recent achievements and challenges 
encountered in the development of pancreatic β cell encapsulation and immunoisolation 
strategies will be presented.  These strategies are sought to protect β cells from the host 
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The following chapter presents an in-depth review of literature. The contents of this 
chapter are adapted from the review article published in the International Journal of 
Pharmaceutics. 
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3.1. Cell-based Therapy in T1DM  
Due to lack of donors (under 10,000 organ donors in the USA per year), whole organ and 
islet transplantation is not a viable option for diabetes treatment (Scharp and Marchetti, 
2014). To overcome the shortage of donors, it is necessary to address the ability to expand 
cells from human (auto and allografts) or animal sources (xenografts). 
Endogenous sources of β cells in humans arise in the pancreas. In developmental 
pancreas, most β cells originate from the differentiation of pancreatic precursor cells (duct 
cells which present pancreatic transcription factor PDX-1) (Szabat et al., 2012). Likewise, 
pancreatic stem cells can also differentiate into β cells. However, once terminally 
differentiated β cells are established, their turnover is very limited, and appears to be a 
largely post-mitotic process with very low rates of proliferation after the age of 20-30 
years old (De Tata, 2014). Therefore, adult pancreatic β cells present a long lifespan with 
minimal proliferative capacity (Tuch; and Kannangara, 2008). To address this matter, a 
variety of immortal pancreatic cell lines for in vitro research were created (Skelin et al., 
2010). 
Xenogeneic islet sources, such as from pigs, are an interesting alternative to overcome 
the scarce availability of human pancreatic endocrine tissue (Dufrane and Gianello, 
2012). Porcine pancreatic structure and physiology are compatible with human pancreas 
(Kinasiewicz et al., 2011). Moreover, porcine and human insulin are structurally similar, 
differing by only one amino acid (Brown et al., 1955). For xenogeneic islet 
transplantation, the isolation of neonatal porcine islets is preferred due to the structure 
and high isolation yield (Nagaraju et al., 2015). Concerns regarding xenograft safety, 
focused on the potential for the transfer of pathogens, such as porcine cytomegalovirus, 
with zoonotic capabilities to the transplant recipient and the strong immunological 
response against the xenograft have risen (van der Windt et al., 2012). Nevertheless, 
encapsulation technologies provide a way forward for these xenogeneic grafts (Ludwig 
and Ludwig, 2015). 
3.1.1. Reprogramming non-Pancreatic Cell Sources into Insulin-Producing 
Cells 
Stem cells are found in developing and adult tissue. Embryonic stem cells are pluripotent 
which means they can differentiate into cells representing the three germ layers: 
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endoderm, ectoderm and mesoderm. Differing from embryonic stem cells, adult stem 
cells are multipotent, and they differentiate into multiple cell lineages that constitute an 
entire tissue. Adult stem cells can be found in the bone marrow, adipose tissue, dental 
pulp, and umbilical cord blood (Sumi, 2011).  
Adult somatic cells can be artificially induced into a pluripotent state, following exposure 
to certain reprogramming factors. The current generation of induced pluripotent stem 
(iPS) cells have shown to be functionally equivalent to embryonic stem cells. The main 
advantages of these cells come from their unlimited replication capacity and their ability 
to be reprogrammed or (trans)differentiate into insulin-producing cells (Figure 3.1). 
Several multi-step protocols are in place to differentiate stem cells into insulin-producing 
β cells (Tse et al., 2015). Cultured human iPS cells may take up antigens from xenogeneic 
materials causing humoral rejections of the graft. For this reason, xeno-free protocols 




Figure 3.1. Autologous cell sources used to obtain pancreatic β cells in order to 
overcome the shortage of donors for transplantation in T1DM. 
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3.1.2. Immortal Pancreatic Cell Lines 
Preliminary in vitro research can use a variety of immortal pancreatic cell lines, especially 
in order to overcome limited availability of primary β cells and donor variability. Most 
cells have a finite life span due to replicative senescence, but various transformation 
approaches have been used to produce continuous cell lines with an infinite life span. 
Methods such as induction of pancreatic tumour by irradiation or viral infection, and 
development of transgenic mice with targeted expression of recombinant oncogene in β 
cells have produced numerous immortal cell lines, such as RIN, HIT, β-TC and INS cells. 
However, just a few β cell lines show normal response to glucose concentrations in the 
physiological range, which include MIN-6 cells (Skelin et al., 2010). 
3.2. Pancreatic β Cell Immunoisolation 
Another issue encountered during islet transplantation is life-long systemic 
immunosuppressive drug therapy. These are required to suppress the host immune system 
from attacking both allografts and xenografts which may result in transplant rejection. An 
alternative approach to prevent graft failure and the need for immunosuppressants is β 
cell immunoisolation.  
3.2.1. Transplantation Sites for Intravascular and Extravascular Devices 
An optimal implantation site should provide easy access for implantation and removal,  
immune protection, a physiological route for insulin delivery, a sufficient blood and 
oxygen supply and enough space for a large volume of encapsulated islets and β cells 
(Zamboni and Collins, 2017).  
Many implantation sites have been proposed as shown in Figure 3.2. Intravascular devices 
are normally implanted directly connected to the circulatory system, such as in the portal 
vein of the liver. Extravascular devices, on the other hand, have been reported to be 
implanted in sites such as the renal sub-capsule, subcutaneous spaces, peritoneal cavity, 
intramuscularly, spleen, gastrointestinal wall, bone marrow and immune privileged sites, 
such as testis and thymus (Cantarelli et al., 2013, Merani et al., 2008a). 
For example, the liver remains the gold standard in clinical studies, as it provides close 
contact between the islet graft and the host’s blood stream, ensuring a rapid graft 
oxygenation and exchange of insulin and glucose. However, the infusion of islets into the 
portal vein of the liver can cause hepatic thrombosis and liver ischemia due to the limited 
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available volume for implantation (Venturini et al., 2015a). Intrahepatic islet infusion also 
presents high risk of graft failure via the IBMIR (Cantarelli et al., 2013). Consequently, 
this method also requires anticoagulation therapy to decrease the incidence of blood clots 
and IBMIR. 
 
Figure 3.2. Transplantation sites for islet grafts (Merani et al., 2008b). 
The kidney capsule has been a preferred site for experimental islet transplants in mice 
because the surgical procedure is relatively easier and less invasive than through the portal 
vein. Moreover, transplantation under the kidney capsule is easier to monitor and to 
retrieve by nephrectomy for both histological studies and proof of function of the islets 
(Cantarelli et al., 2013). Unlike the liver, the kidney capsule is an extravascular site. The 
impact on graft oxygenation may pose a limitation within the kidney sub-capsule. 
However, it may also confer a degree of immune privilege, as it is not directly exposed 
to non-specific immune response mediated predominantly by innate and inflammatory 
events, found in intra-liver islet engraftment (Cantarelli et al., 2013). 
3.2.2. Pancreatic Beta Cell Encapsulation 
Cell encapsulation is a method developed to protect pancreatic β cells from the immune 
system using a permselective matrix. This matrix will prevent immune cells, cytokines, 
and antibodies to reach β cells while promoting the diffusion of nutrients, oxygen, 
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glucose, and insulin (Figure 1.1). Many cell encapsulating approaches have been 
developed, such as macroencapsulation, microencapsulation and ultra-thin or 
nanoencapsulation (Figure 3.3). This section will give and overview on macro and micro 
devices but focus will be mainly on nanoencapsulation strategies, such as L-b-L and 
conformal encapsulation (Zamboni and Collins, 2017). 
 
Figure 3.3. Encapsulation strategies for pancreatic islets. 
3.2.2.1. Macroencapsulation 
Macroencapsulation devices are generally large capsules that can measure several 
centimetres in length. These devices can be fabricated from various materials and with 
various geometries, such as tubular chambers, hollow fibres and planar devices (Giraldo 
et al., 2010). The large size of the capsule enables the encapsulation of many embedded 
cells, generally implanted in extra-vascular sites such as the peritoneal cavity (Song and 
Roy, 2016). 
Macroencapsulation research began in 1933, when insulinoma tissue was inserted into 
permselective membranes to determine the role of vascularization or its absence on  
transplanted tissue (Bisceglie, 1934). Since then, numerous macro-devices have been 
reported, with some already available in the market, such as TheraCyte and ViaCyte. 
TheraCyte devices utilize bi-layered polytetrafluoroethylene membranes, to facilitate 
neovascularization, and to provide immune protection (Lee et al., 2009). ViaCyte uses a 
semipermeable membrane (branded as “Encaptra”) to encapsulate pancreatic progenitor 
cells for in vivo differentiation (Ernst et al., 2019). 
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These devices can be easily implanted and removed with minimal risk. On the other hand, 
their major drawbacks are related to islet cell aggregation and limited oxygen and nutrient 
diffusion. These factors may lead to compromised islet viability and eventual graft failure. 
Another limitation associated with such devices is their delayed insulin secretion in 
response to abrupt changes in glucose concentrations (Skrzypek et al., 2017). The time 
lag created by these devices directly affect the physiological kinetics of insulin. 
3.2.2.2. Microencapsulation 
Microcapsules incorporate individual or small groups of islets in a spherical hydrogel 
polymer with a stable mechanical structure. Different methods, such as drop extrusion, 
and microfluidic flow, can produce wide capsule size diameters ranging from 2,000 μm  
to as low as 200 μm, respectively (Giraldo et al., 2010). Ideally, microcapsule size should 
not exceed 300 μm, as this facilitates more effective inward diffusion of oxygen and 
nutrients (Steele et al., 2014). However, a decrease in capsule size as small as 300 µm has 
also been shown to induce a progressively stronger fibrotic response (Ernst et al., 2019). 
Several considerations favour microcapsules over macrocapsules. The spherical 
geometry and low volume of microcapsules offer better oxygen and nutrient transport due 
to a higher surface area-to-volume ratio. Moreover, the small diameter of these capsules 
requires less invasive surgery, being achieved by simple injection into the desired 
implantation site (Kang et al., 2014).  Within the peritoneal cavity, larger (800 µm) 
hydrogel capsules remain free-floating in the peritoneal fluid while smaller (500 µm) 
capsules aggregate and adhere to peritoneal organs (Ernst et al., 2019). 
A variety of animal models used for islet transplantation with or without encapsulation 
has been reported (Sakata et al., 2012). For example, Souza et al. compared the 
transplantation of free islets and encapsulated islets in rodents showing that encapsulated 
islets transplanted into the peritoneal cavity were functional for an average of 100 days 
without the use of immunosuppressant drugs. While non-encapsulated islets were 
transplanted into the liver and they lasted for an average of 167 days with the use of 
immunosuppression drugs (Souza et al., 2011). In 2006, one of the first studies in humans, 
reported allogenic islet transplantation in alginate microcapsules (Calafiore et al., 2006). 
A downside of microencapsulation is the difficulty associated with retrieving the capsules 
(if not impossible) following implantation. Moreover, traditional methods of islet 
microencapsulation can still result in diffusional limitations associated with capsule size, 
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The mean diameter of islets is on average 150 μm and the total number of islets to achieve 
insulin independency is 200,000 IEQ. After microencapsulation, the total volume of one 
encapsulated islet cell can increase dozens of times. If 1000 IEQ is contained in 1 cm2, 
the volume of the implant will measure up to 400 cm2, making the peritoneal cavity the 
only viable for site for transplantation (Weir, 2013). 
In addition, microencapsulation can result in inadequate or incomplete coating of the 
islets. These islets protruding from the capsule are not immunoisolated and can thus 
trigger the immune attack leading to graft rejection (Zhang and He, 2011). 
3.2.2.3. Nanoencapsulation 
Ultra-thin coatings using L-b-L assembly or conformal polymerization directly modify 
the surface of islets to enhance transport and mechanical properties (Zamboni and Collins, 
2017). These coatings aim to cover each islet with a uniform thickness rather than 
controlling the overall capsule diameter like in microencapsulation.  
L-b-L deposition of oppositely charged biomaterials is achieved by the sequential 
adsorption of complementary multivalent molecules, such as polymeric electrolytes, 
nanoparticles, and proteins on the islet or β cell surface (Oliveira et al., 2016). 
Alternatively, a conformal coating technique based on the interfacial polymerization of 
biomaterials to form a  thin (< 500 nm) and cross-linked coating network on the surface 
of islets and β cells can be employed (Zhi et al., 2013). This cyclic stepwise deposition 
method can tailor the final number of layers and coating thickness, thus, dictating the 
permeability and robustness of the coating (Silva et al., 2016a). The development of this 
thin nano-sized membrane minimizes graft size and volume, thereby enabling graft 
transplantation into sites such as the renal capsule and the liver (Yang and Yoon, 2015). 
A serious consideration for electrostatic L-b-L assembly design is cytotoxicity of the 
polymer. It has been widely observed that polycations impair cell viability (Ernst et al., 
2019). The instability of ionic interactions in L-b-L polyelectrolyte membranes are 
acknowledge to be prone to consumption, degradation and loss of selective permeability 
(Calafiore, 2018). However, cytotoxic by-products released during conformal chemical 
crosslinking could potentially disrupt the integrity of cell membrane, causing cell death.  
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3.2.3. Surface Engineering the Plasma Membrane of β Cells 
Researchers are now using surface engineering approaches in order to manipulate the 
cellular membrane through the attachment of biomolecules to cell surface proteins or by 
anchoring biomolecules to the phospholipid bilayer and these studies are detailed in Table 
3. There are two principal methodologies associated with the anchoring of biomolecules 
to cell surfaces. One is by chemical conjugation where amine groups of the cell surface 
proteins are chemically conjugated to linkers carrying bio-functional molecules and the 
second is by the physical insertion or adsorption of hydrophobic moieties such as fatty 
acid tails (that are conjugated to bio-functional molecules) into the lipid bilayer (Kim and 
Tae, 2015)  as shown in Figure 3.4. 
 
 
Figure 3.4. Schematic diagram of surface engineering by chemical conjugation (a and b) 
and physical insertion (c and d) (modified from (Kim and Tae, 2015)). 
Table 3.1: Nanotechnologies for cell-based therapies in T1DM. 







Chitosan (90-150 kDA) 
and alginate (75-100 kDa) 
bilayers with outermost 
layer of phosphorylcoline 
(PC)-modified chondroitin 
sulphate (20 kDa)  
MIN-6 
pseudoislets 
Exclusion of antibody 
probe (150 kDa) using 
deposition of 2-3 
bilayers. Decreased 
protein absorption due 
to PC-modified 
chondroitin sulphate 
(Zhi et al., 2010) 
PC-derivate chitosan and 
PC-derivate alginate with 








function for up to one 
month (Zhi et al., 
2012) 






protection to the 
entrapped β cells from 
oxidative stress, with 
no significant changes 
in cellular metabolic 
activity, oxidant 
capacity, or insulin 
secretion dynamics, 
when compared to 
untreated controls 
(Abuid et al., 2019)  
 15-30 kDa poly-L-lysine 








survival and function 
of encapsulated cells 
(Granicka et al., 2011) 














pancreatic islets via 
hyperbranched 
polymers resulted in 
high coating efficiency 
and stability, as well 
as, islet viability and 
function (Gattas-
Asfura and Stabler, 
2013) 
 three-layers of SH-6-arm-
PEG-NHS, 6-arm-PEG-






L-b-L islets were 
transplanted in a 
xenorecipient (mice) 
showing 100% 
survival rate for 
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150 days after 
transplantation in 
comparison to naked 
islet (poor survival 
time of 77.5 ± 42 days) 




















not affect insulin 
secretion (Kim et al., 
2020) 








showed no foreign 
body responses 
(Gattás-Asfura et al., 
2020) 
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viability is prolonged 
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of human and porcine 
islet surface chemistry   






















(Chen et al., 2011a) 
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phospholipid liposomes 
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(Chen et al., 2011b) 
 Gelatin-catechol 
covalently linked to 6 arm-
PEG-phospholipid 
conjugated with 3 different 
PEG layers (6-arm-PEG-
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of islets and prevention 
of immune cells 
infiltration (Haque et 
al., 2016) 
Others 6 arm-PEG modified with 
catechol (Jeong et al., 
2013, Jeong et al., 2011) 
and 8 arm-PEG-catechol 
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islet xenograft survival 
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The incorporation of 1-
antitrypsin to the 
nanocoating exhibited 
effective anti-
coagulant activities in 









were transplanted to 
the small bowel 
mesentery of healthy 
rats and revascularized 




3.2.4. Nanocoating Functionalization 
In association with surface engineering and ultra-thin cell encapsulation systems, many 
other strategies can be implemented to tackle IBMIR, poor graft vascularization and 
hypoxia. Gene delivery technology can complement cell engineered systems to mask the 
immunological response against islet grafts. Tracking probes are also being researched 
for non-invasive post-transplantation monitoring of graft fate.  The representation of 




Figure 3.5. Bioengineering a nanoencapsulation system. A) Nano-thin coatings may be 
generated by (top right, proceeding clockwise): surface engineering (PEGylation); L-b-
L or conformal assembly of alternating polymer layers deposited directly on the islet 
surface. Nano-coatings can be functionalized with (continuing clockwise): bioactive 
accessories such as insulinotropic agents including GLP-1 (green; insulin shown as blue 
circle); blood vessel recruiting factors (e.g. heparin, orange circles); immunomodulatory 
and thrombolytic agents (red; e.g. soluble complement receptor-1, thrombomodulin, 
urokinase, phosphorylcholine, heparin); or a cellular layer (e.g. endothelial cells, 
immunomodulatory cells). (B) Examples of conformal coating: phase contrast images of 
mouse islets conformally coated with a PEG-alginate composite gel (left) and rat islets 
conformally coated with a PEG-Matrigel composite gel. (C) Example of L-b-L 
nanocoating: brightfield image overlaid with confocal micrograph of 8-bilayer (PLL-g-
PEG/ fluorescein-labelled alginate, green) coating; confocal micrograph showing 
coating localized on peripheral islet extracellular surface (Ernst et al., 2019). 
3.2.4.1.  Immobilisation of Therapeutic Agents 
One unresolved issue is early graft loss due to inflammation triggered by blood 
coagulating on the surface of islets after transplantation. The blood coagulation and 
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complement systems are activated when islets are exposed to fresh blood in the portal 
vein, inducing IBMIR which results in graft loss (Teramura and Iwata, 2008). Systemic 
anticoagulation therapy to control these reactions after transplantation have successfully 
reduced islet loss; however, they are associated with an increased risk of bleeding. For 
this reason, incorporation of anti-inflammatory and antithrombotic agents for local 
release and control of coagulation and IBMIR have been investigated (Zhi et al., 2013). 
Immobilization of heparin (Im et al., 2013), urokinase and thrombomodulin (Chen et al., 
2011a) on engineered cell surfaces has been reported to inhibit coagulation and 
complement activation, thereby reducing IBMIR. Curcumin, an anti-inflammatory drug, 
was co-encapsulated with pancreatic islets inside an alginate microcapsule, resulting in 
reduced fibrotic overgrowth (Dang et al., 2013).  
3.2.4.2. Co-transplantation 
Two separate studies in 2015 report the co-encapsulation of β cells with other cell types, 
such as mesenchymal stem cells (MSC) and hematopoietic stem cells with the objective 
of modulating host immune cells to provide immunotolerance (Schuetz and Markmann, 
2015, Yoshimatsu et al., 2015, Oliveira et al., 2017). Other studies detail the co-
encapsulation of pancreatic β cells with islet accessory cells, i.e. endothelial and 
perivascular cells, in order to the re-establish the vascular network of transplanted islets 
while minimising the occurrence of graft loss due to hypoxia and IBMIR (Del Toro-
Arreola et al., 2016, Avolio et al., 2016, Kim et al., 2011, Li et al., 2013).  
3.2.4.3. Vascularization strategies 
Natural tissues and organs exhibit a 3D architecture which allows cell-to-cell and cell-to-
ECM interactions. Survival of this large 3D architecture relies on blood perfusion within 
an intricate vascular network, delivering oxygen and nutrients while removing carbon 
dioxide (CO2) and metabolites. The adequate vascularization of 3D tissue-
engineered substitutes is a major engineering hurdle in creating artificial organs, as 
vascularisation is considered to be one of the greatest challenges in tissue engineering. 
Post-transplantation success of these tissue substitutes is highly dependent on the ability 
to promote rapid and stable neovascularization (formation of new blood vessels) to 
support the growth, function, and viability of the graft. Researchers rely on the increasing 
knowledge of angiogenic and vasculogenic processes to stimulate vascular network 
formation within 3D tissue constructs. The stimulation of the vascular network can be 
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performed by the incorporation of pro-angiogenic materials or growth factors on the 
development of cellular scaffolds.   
In addition to the co-encapsulation of endothelial and perivascular cells, the incorporation 
of VEGF into the polymeric encapsulant accelerates proliferation and differentiation of 
nearby endothelial cells to produce a neovascular network within the graft at the 
transplantation site (Borg and Bonifacio, 2011). However, vascularization does not occur 
instantly after transplantation and other measures must be in place to provide early oxygen 
supply to the graft (Gholipourmalekabadi et al., 2016). Oxygen generating biomaterials 
are discussed below. 
 
Figure 3.6. Oxygen-releasing systems for local and early oxygenation of pancreatic beta 
cell grafts and vascularization recruitment. Left: haemoglobin-conjugated (red) or 
perfluorocarbon (yellow) functionalized hydrogels; middle: peroxide particulates; and 
right: incorporation of growth factors, such as VEGF for the stimulation of vessel 
formation and recruitment  (Ernst et al., 2019). 
3.2.4.4. Oxygen-releasing Systems 
In an attempt to address poor graft oxygenation oxygen-releasing systems have been 
proposed (Figure 3.6). These systems can be based on the use of peroxides, such as 
calcium peroxide (CaO2), showing to prevent hypoxia-induced β cell death (Pedraza et 
al., 2012, Steg et al., 2016). Haemoglobin-based oxygen carriers and perfluorocarbon 
have been employed as blood substitutes (Jia et al., 2016). However, in 2014, in situ cell 
encapsulation of perfluorocarbonated-HA hydrogel was able to promote fibroblast cell 
growth under hypoxic conditions (Palumbo et al., 2014). Another oxygen-releasing 
system created exclusively for pancreatic islet transplantation, called Beta-O2, utilises an 
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oxygen refuelled macro-chamber (called beta-air) that is composed of two compartments: 
one for islets and other for O2 supply (Colton, 2014). 
3.2.4.5. Gene Delivery Immunosuppressant Strategies 
As discussed, targeting the immune system provides good outcomes in islet 
transplantation however caution must dictate as the immune system plays an important 
role in the surveillance of cancerous cells in the body and when our immune defences are 
lowered, opportunistic infections unfold.  For this reason, the regulation of the immune 
system without the depletion of immune cells or the total ablation of the immune response 
is key for a balanced immunological function. With this in mind, we present the 
possibility of controlling the immune system using the transfection of genetic material to 
encode regulatory proteins for transient or permanent alteration of cell phenotype. For 
example, RNA-based gene therapy can reduce immunogenicity and mutagenesis and has 
proven to be more efficient than DNA-based gene therapy (Hill et al., 2016). For the 
transfection of genetic material, viral and non-viral vectors have been employed. Viral 
vectors (lentivirus, adenovirus and adeno-associated virus) are well suited to deliver 
genes that prevent islet immune rejection (Tian et al., 2007), but pose risks to recipients 
due to their inherent immunogenicity, to combat this they are co-administered with 
immunosuppressant agents (Foldvari et al., 2016). Non-viral gene carriers (such as lipids 
and positively charged polymers) are less efficient gene delivery agents than viruses but 
they possess higher packaging capacities.  
Liposomes carrying CCL22 gene transfected in myocytes on the site of transplantation of 
islets increased local T regulatory cells accumulation and delayed islet graft rejection 
(Vagesjo et al., 2015). The cellular secretion of exosomes has also been investigated as 
potential nanocarriers of genetic material for gene delivery applications. Exosomes 
naturally deliver RNA from cell to cell and they can target specific cell types due to 
receptor-mediated interactions present in the exosome membrane. In this context, 
transfected hematopoietic stem cells derived from bone marrow delivered exosomes 
loaded with silencing RNA to pancreatic islets inducing down-regulation of Fas (Wen et 
al., 2016). 
Gene therapy with IL-10 is of particular interest to investigators because IL-10, a cytokine 
synthesis inhibitor factor, has a critical role in modulating the immune system by down-
regulating the expression of IL-17 and decreasing lymphocyte infiltration on islet grafts 
(Gower et al., 2014, Zhang et al., 2003). Furthermore, IL-10 also decreases the expression 
of IL-23 on dendritic cells, of which IL-23 is essential for the expansion and maintenance 
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of IL-17 producing T helper cells. In allogenic transplant rejection, dendritic cells are 
important immunological cell mediator types because they present alloantigen in the 
lymph node. This initiates the adaptive immune response by activating effector T helper 
cells that destroy the graft. As mentioned previously, dendritic cells also produce 
cytokines (IL-23) that inflict further injury and support the reactivity of alloreactive T 
cells. For these reasons, dendritic cells are the cell type targeted in gene delivery 
therapeutics for allograft immunotolerance (Fan et al., 2015).   
3.2.4.6. Bioimaging Nanotechnology 
Monitoring graft loss, which can occur secondary to immunological or non-
immunological causes, either in the first phase after transplantation or in the later stages 
of a patient’s life is a central issue in transplantation therapy. No imaging methodology 
currently exists to monitor viable islet mass after clinical intraportal islet transplantation, 
but imaging modalities have a prospective role in monitoring graft fate. 
Due to the fact that islets are very small in size (50-600 μm in diameter), have a very low 
density (approximate 1%) and are localized deep in the abdomen, their specific imaging 
can be particularly challenging. Positon-emission tomography (PET), single photon 
emission computed tomography (SPECT) and MRI are all imaging techniques being 
applied to visualize post-transplanted islets. 
PET and SPECT use radiolabelled tracers (Eter et al., 2015) and MRI uses 
superparamagnetic iron oxide (SPIO) (Malosio et al., 2015, Medarova et al., 2009, 
Hathout et al., 2009, Wang et al., 2013, Toso et al., 2008). When analysing the sensitivity 
of these imaging modalities for islets, MRI is shown to have poor islet sensitivity in 
comparison to other modalities because SPIOs are not efficiently taken up by islet cells. 
On the other hand, MRI shows better spatial resolution than PET and SPECT (McCall 
and Shapiro, 2012). 
PET radiolabelled markers have been used to trace viable pancreatic islets (Jodal et al., 
2017). A clinical study evaluated 8 human subjects that underwent intraportal islet 
transplantation using [11C]5-hydroxytryptophan to trace viable islets. The marker uptake 
by the liver as a whole, or in defined hotspots, was correlated to measurements of islet 
graft function (Eriksson et al., 2016). Novel radiotracers such as radiolabelled exendin 
are under pre-clinical testing and they display high affinity to islets and are reported to be 
a promising tracer to visualize transplanted islets by SPECT. Radiolabelled exendin binds 
to GLP-1 receptor on islets. It was observed that radiolabelled exendin accumulated as 
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early as 3 days after transplantation and for up to 3 weeks post-transplantation which 
correlated to graft revascularization (Eter et al., 2015). 
For encapsulated islets, SPIO ferumoxide (Feridex®) has been used to label alginate 
microcapsules. These magnetocapsules facilitated the graft monitoring by MRI over time 
and simultaneously provided immunoprotection to islets (Barnett et al., 2007). Labelling 
of islet cells with SPIO through DNA hybridization with the cell membrane was reported 
for monitoring of transplanted islets by MRI (Kitamura et al., 2013).  
In 2015, quantum dots (QDs), inorganic semiconductor nanocrystals of groups II-VI, III-
V or IV-VI, have been utilised as in vivo imaging probes in animal models (Liu et al., 
2015). The main limitation of QDs is that they require a light excitation source that 
possess low tissue penetration capabilities (up to 1 cm deep) which restricts the detection 
of implants to subcutaneous depths (Iverson et al., 2016). To address this matter, self-
illuminating QDs have been proposed. Bioluminescence resonance energy transfer 
(BRET) QDs have been conjugated to luciferase which induces QD emission (He and 
Ma, 2014). QDs were also attached to the cell membrane by biotin-avidin conjugation 
and by DNA hybridization (Wang et al., 2016a, Banerjee et al., 2016). This technology 
is still in its infancy and it will take considerable time before it reaches human clinical 
trials. Nevertheless, QDs present the potential application for the follow-up analysis of 
transplanted grafts in patients with T1DM. 
3.3. Final Considerations 
This chapter highlighted many tissue engineering strategies utilized for the development 
of bio-engineered insulin-producing cell constructs to treat T1DM. The summarized 
combination of the different approaches presented below is believed to offer an 
appropriate platform for the development of a cell-based therapy for T1DM: 
a) Suitable cellular sources for pancreatic β cell replacement. 
• Reprogramming autogenic cell types to create insulin-producing cells has 
the potential alone to mitigate transplant rejection. However, drawbacks 




b) Suitable transplantation site should provide easy access for implantation and 
removal, immune protection, a physiological route for insulin delivery, a 
sufficient blood and oxygen supply and enough space for hosting the cellular graft 
• Transplantation under the kidney capsule confers an appropriate confined 
space for the cellular transplant, it is relatively close to many blood vessels 
for appropriate oxygen supply and insulin delivery.  
c) Suitable immunoisolation environment 
• Nano encapsulation provides an appropriate environment for cellular 
grafts to re-establish ECM-cell interactions to improve graft functionality 
and survival 
• Nano encapsulation provides an appropriate environment to prevent graft 
failure from immune-mediated rejection and the need for systemic 
immunosuppression 
• Nano encapsulation also decreases graft size and volume for 
transplantation 
• Effective immunoisolation environment is dependent on biomaterial 
selection 
In the next chapter, a compilation of the most recent discoveries and findings associated 
with tailored HA structure/function relationships for cell encapsulation strategies will be 
discussed. The next chapter highlights HA’s role in immunomodulation, vascularization 
and its anti-microbiological properties which are particularly critical to the 
reestablishment of pancreatic β cell functionality after isolation and encapsulation.  
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The following chapter presents an in-depth review of literature. The contents of this 
chapter are adapted from the review article published in Progress in Materials Science. 
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Hyaluronic Acid in Immunoprotection and Immunomodulation: Chemistry, Processing 






HA owes its name to its transparent and bright appearance, named after hyaloid meaning 
“glassy” in Greek. HA was first described in the literature in 1918, when a new 
polysaccharide consisting of glucosamine and glucuronic acid was discovered (Levene 
and López-Suárez, 1918). A few years later, another independent publication reported the 
isolation of an extremely high molecular weight polysaccharide from the vitreous eye of 
cows (Meyer and Palmer, 1934). HA was initially produced by the extraction from 
various animal parts. However, the growing demand for HA shifted the production to 
microbiological sources. In 1937, Kendall et al. isolated HA from streptococci A and C 
(Kendall et al., 1937), which remains to date the most economical and reliable source for 
the industrial production of HA. 
HA – the only non-sulphated GAG – is found in the ECM of many soft connective tissues, 
where it acts as a space filler, lubricant, and osmotic buffer (Clegg et al., 2013, Laurent 
et al., 1996). HA is anionic and contains alternate units of the disaccharide β-1,4-D-
glucuronic acid-β-1,3-N-acetyl-D-glucosamine. The mutual repulsions between the 
carboxyl groups of the glucuronic acid moiety of HA causes it to swell forming a hydrated 
network. The associated plasticity of HA is highly important for tissue reorganization and 
embryonic development (Theocharis et al., 2016).  
Among all GAGs, only HA is biosynthesized at the cell membrane and not within the 
Golgi apparatus. Moreover, HA is also the only GAG not covalently attached to 
proteoglycans (Theocharis et al., 2016). It binds either to its own synthases or to cell 
surface receptors (CD44 and RHAMM) (Acharya et al., 2008), being then involved in 
several cell function responses (Nasreen et al., 2002). 
The size of HA depends on the relative activity of HA synthesizing and degrading 
enzymes. In mammals, there are three hyaluronan synthase (HAS) isoforms (HAS-1, 2, 
and 3) that mainly differ in their enzymatic ability to produce HA of different sizes. HA 
clearance in vivo starts when it binds to HA receptor for endocytosis (HARE) on the cell 
membrane (Pandey and Weigel, 2014). Then, HA is rapidly degraded by physiological 
enzymes called hyaluronidases (HYAL). The majority of HA degradation is obtained by 
HYAL-1 and HYAL-2, where they break the β1→4 glycosidic bond of HA to form LMW 
fragments that possess size-dependent functions (Stern, 2004). HYAL-1 is found in the 
lysosome and utilizes HA as a substrate to generate tetrasaccharides whereas HYAL-2 
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which is found in the plasma membrane (anchored by glycosilphosphatidyl-inositol) 
degrades HA to fragments of about 20 kDa (Stern, 2004). 
HA is a material of increasing significance in bioengineering and biomaterials science 
due to both its physical and chemical properties, that can be processed in a versatile range 
of forms, such as in solution, film or hydrogel (Collins and Birkinshaw, 2008a, Collins 
and Birkinshaw, 2013b). Subsequently, there is no surprise why HA has found a variety 
of biomedical applications concerned with body repair, which include uses in cosmetics 
and cosmeceuticals (Bukhari et al., 2018), visco-supplementation (Bowman et al., 2018), 
wound healing (Graça et al., 2020), drug delivery systems (Choh et al., 2011), tissue 
engineering (Song et al., 2013), cell encapsulation (Peroglio et al., 2012) and 
microfluidics (Burdick and Prestwich, 2011).  
4.1.1. Chemical Modifications of HA 
As previously described, HA is readily degraded into bioactive fragments by enzymatic 
and hydrolytic degradation. The development of hyaluronidase inhibitors – such as 
hyaluromicyn – improve HA structural stability against enzymatic degradation (Kohi et 
al., 2016). Chemical modification and crosslinking strategies are used to decrease HA 
degradation by hydrolysis  (Collins and Birkinshaw, 2007a). HA modification targets the 
following functional groups: the carboxylic acid of the glucuronic acid moiety or the 
hydroxyl of the N-acetylglucosamine moiety (Figure 4.1). Carboxylic acid functional 
groups can be modified by amidation, Ugi condensation or ester formation.  While the 
hydroxyl groups can be modified by ether formation, hemiacetal formation using 
glutaraldehyde, ester formation, carbamate formation or oxidization (Schante et al., 
2011). 
These HA derivatives can be chemically crosslinked by covalent bonds, physically 
crosslinked using non-covalent interactions or by a combination of both methods (Collins 
and Birkinshaw, 2008b). The crosslinking process will form a 3D network able to retain 
large amounts of water – a hydrogel – with properties that resemble those of biological 
tissues, resulting in excellent biocompatibility (Collins and Birkinshaw, 2013a). 
As aforementioned, several chemistries are available, and many others can be envisioned 
for HA modification and crosslinking. However, not all of them are suitable for cell 
encapsulation, due to the need for toxic reagents and/or harsh conditions that will hamper 
cell viability and functionality (Burdick and Prestwich, 2011). It is then necessary to use 
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HA systems that can be produced under physiological conditions, with proper gelation 
kinetics and also with processes that are free of toxic by-products (Xu et al., 2012).  
 
 
Figure 4.1. Chemical structure of HA and common modification reactions. 
In tissue engineering, photo-initiated systems have been extensively utilized for cell 
encapsulation strategies (macro and microencapsulation). These hydrogels result mainly 
from the polymerization of water-soluble monomers in the presence of a multifunctional 
crosslinker by ultraviolet (UV) radiation (photo-crosslinking) or by the reaction between 
complementary groups (Bae et al., 2014, Choi et al., 2015). Although the rationale behind 
the development of these hydrogels is very simple, the resulting hydrogels commonly 
have increased structural stability, longer degradation and high swelling profiles (Collins 
and Birkinshaw, 2008a). 
However, photo-polymerized hydrogels bring a few concerns relating to cell viability for 
cell encapsulation. Cell exposure to UV radiation increases the cellular production of 
reactive oxygen species (ROS) such as superoxide (O2-) and hydrogen peroxide (H2O2). 
60 
 
They may induce lipoperoxidation and damage to DNA (Markovitsi et al., 2010) of cells 
and increase the oxidative degradation of HA (Valachova et al., 2016, Valachova et al., 
2015). The use of photo initiators (such as Irgacure 2959, 2,2-dimethoxy-2-
phenylacetophenone – DMPA, lithium phenyl-2,4,6-trimethylbenzoylphosphinate - LAP 
and eosin Y) in HA gelation have been well described (Poldervaart et al., 2017, Jha et al., 
2010, Gwon et al., 2017, Rosales et al., 2017). However, it is known that these photo-
initiators are cytotoxic in a time and concentration dependent manner (Xu et al., 2015b), 
although LAP is shown to be the most benign (Kessler et al., 2017). 
In relation to the use of photo-initiators in HA gelation processes for cell encapsulation 
strategies, the cell type being encapsulated can influence the construct outcome. For 
instance, different cell types respond differently to photo-initiator’s toxicity. This is 
thought to be due to the variable intracellular anti-oxidative machinery that different cell 
types use to quench ROS (Williams et al., 2005). For example, pancreatic β-cells are 
particularly sensitive to oxidative stress because of their low antioxidant capacity (Drews 
et al., 2010). Therefore, when using photo-polymerization in HA gelation processes for 
cell encapsulation applications, additional protective measures from oxidative stress, such 
as antioxidants and scavenger enzymes, should be put in place to ensure the maintenance 
of β-cell viability (Weaver and Stabler, 2015, Asami et al., 2013). 
Therefore, the development of other covalent crosslinking chemistries is needed to tailor 
the structural stability of HA and produce novel HA derivates that provide more 
biocompatible alternatives to harmful effects associated to, for example, covalent photo-
crosslinking reactions.  
A number of chemical modifications have been developed as an alternative to photo-
polymerization. For nanoencapsulation, for example, the sequential deposition of layers 
can be achieved by guest-host assemblies. For instance, HA has been conjugated to 
cyclodextrin (host) and adamantane or azobenzene (guest), curcubit(6)uril (host) and 
polyamine (guest), such as spermine and 1,6-diaminohexane, to self-assemble into 
hydrogels (Rodell et al., 2013, Park et al., 2012b, Rosales et al., 2018). The non-covalent 
character of guest-host networks confers to hydrogels full reversibility under shear, 
allowing association or self-healing when shear is removed. 
Other smart hydrogels are also under the spotlight because they can be crosslinked in situ 
through covalent crosslinking by click chemistry reactions between polymers with 
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complementary functional groups or by enzymatic crosslinking under physiological 
conditions and showing minimal toxicity. In situ click chemistry crosslinking was 
reported for azide-modified HA and cyclooctyne-modified HA and for tyramine 
conjugated-HA hydrogels formed by the oxidative coupling of tyramines catalysed by 
H2O2 and horseradish peroxidase (Takahashi et al., 2013, Ni et al., 2015, Abu-Hakmeh 
et al., 2016, Xu et al., 2015a, Khanmohammadi et al., 2016). 
HA modification through thiolation has been developed, aiming to create reversible 
hydrogels via thiol/disulphide bond crosslinking reaction (Shu et al., 2002). Converting 
thiol groups into disulphide bonds can be achieved by thiol oxidation and disulphide 
exchange mechanism (Figure 4.2). 
In disulphide exchange mrechanism, aqueous solutions in neutral pH have the conjugated 
base (OH-) as the predominant form, which is strong enough to effectively deprotonate 
any acid with pKa below 16 (pKa of thiol groups are around 9). Thus, the thiol groups of 
the polymer (HA-SH) are ionized to form thiolate anions (-S-). The thiolate is a 
nucleophile (thus being named S-nuc) that attacks the sulphur atom (central sulphur or Sc) 
of the disulphide moiety of the pyridine-modified polymer (HA-PD). It forms a transition 
state before cleaving the original bond and creating the new one. The leaving sulphur (Slg) 
belongs to the pyridine. This mechanism allows the formation of coating layers under 
normal physiological conditions (Fernandes and Ramos, 2004). 
 
Figure 4.2. Disulphide exchange mechanism representation between HA-PD and HA-
SH derivates. 
4.2.HA in the Aid of Pancreatic Islet Immunoisolation 
The physicochemical properties and biological functions of HA can be modulated to 
match the requirements for addressing the cell-specificity delivery needs in cell 
encapsulation strategies. Recent works have reported that HA can efficiently promote 
functional insulin-secreting cells and reduce adverse immune reactions after 
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transplantation. Table 4.1 outlines the most relevant studies and outcomes where HA has 
been used to encapsulate insulin-producing cells for T1DM treatment. 
Table 4.1. HA in cell encapsulation therapies for T1DM.  




Alginate-HA  microcapsules 
enhanced cell viability, 
reduced early apoptosis and 
decreased membrane damage 











diabetes in NOD mice 






The addition of HA in alginate 
microcapsules enhanced the 
insulin release from insulin-
producing cells (Cañibano-




Both the insulin secretion 
values and the viability of HA 
embedded islets were higher 
than of alginate embedded 
islets (Velten et al., 1999) 
 Collagen Rat pancreatic 
islets 
Allogenic transplantation of 
encapsulated islets reversed 
long-term diabetes and 
prevented graft rejection in all 
animals. Explanted grafts 
revealed viable islets in the 
transplant site as well as intact 
hydrogel, with little or no 
evidence of fibrotic 
overgrowth or cellular 




 Pancreatic islets 
Photo-crosslinked 




Butyric acid and 
retinoic acid 
Human adipose 
stem cells and 
pancreatic islets 
Encapsulation showed graft 
revascularization after 
intrahepatic transplantation in 
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syngeneic diabetic rats 
(Cavallari et al., 2012) 
1,680 kDa  HIT-T15 cells This study suggests that HA-
coating increases the insulin 
secretion of HIT-T15 cells by 
the enhancement of 
expression of connexin 43-
mediated gap-junctional 
intercellular communications 









showed improved cell 
viability in comparison to 
alginate only hydrogels 
(Harrington et al., 2017b) 
4.2.1. Intrinsic Pro-angiogenic Capacity of HA in Vascularization 
The post-transplantation success of cell transplantation strategies will rely on the 
vascularization and oxygenation of the graft. Thus, the incorporation of pro-angiogenic 
materials or moieties should be considered. The influence of HA on the angiogenic 
process was reported in the early 1980’s (West et al., 1985). While native HMW HA was 
reported as an angiogenic inhibitor, LMW HA are highly bioactive and stimulate the 
angiogenesis process (Gao et al., 2019). The size of these HA oligomers 
also influences the pro-angiogenic nature of the fragments. Oligomers with 6 to 
10 saccharide units were shown to be proangiogenic (Wang et al., 2019) 
while fragments with only 4 saccharide units were unable to prompt a pro-angiogenic 
response (Cui et al., 2009).  
In the endothelium, HA interacts with endothelial cells that line the interior surface of 
blood and lymphatic vessels. This angiogenic capacity comes from receptor-mediated  
interactions of HA oligomers with the CD44 and hyaluronan-mediated motility 
receptor (RHAMM) of endothelial cells, which triggers endothelial cell proliferation, 
migration, collagen synthesis and cell sprouting (Pardue et al., 2008). A new mechanism 
has been proposed for HA-promoted angiogenesis (Figure 4.3), where HA binds to CD44, 
promoting PKCδ activation. Upon activation, protein kinase C (PKCδ) leads to RHAMM 
and extracellular signal-regulated kinase (ERK) activation.  This leads to the 
transactivation of transforming growth factor β receptor I (TGFβR1). This activation is 
closely related with a decrease on histone deacetylase 3 (HDAC3) expression, 
responsible for the induction of plasminogen activator-inhibitor-1 (PAI-1) and MMP-2. 
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Both PAI-1 and MMP-2 will promote angiogenesis (Park et al., 2012a). Recently, 
Olivares et al. showed that by inhibiting HA synthesis it was possible to supress 
angiogenesis in endometriotic lesions, highlighting the key role of HA in the 
vascularization process (Olivares et al., 2016).  
  
 
Figure 4.3. Proposed signalling cascade of HA-promoted angiogenesis. Adapted from 
(Park et al., 2012a). 
As a result, HA oligomers have been used to increase the angiogenic capacity, and 
consequent vascularization, of other biomaterials (Silva et al., 2016b, Perng et al., 2011), 
and also to enhance wound healing strategies (Wang et al., 2016b). A recent clinical trial 
demonstrated that HA hydrogels enabled the vascularization of free gingival grafts and 
functioned as a scaffold between the recipient’s transplantation bed and the gingival graft, 
reducing graft shrinkage (Cankaya et al., 2020). Another study showed that HA is able to 
sequester growth factors and enables endothelial cells derived from human induced 
pluripotent stem cells to form stable, capillary-like networks (Natividad-Diaz et al., 
2019). In addition, HA-based matrices were also reported to selectively bind to  




Other studies also show that HA hydrogels also upregulated the expression of angiogenic 
markers such as VEGF and fibroblast growth factor 2 (FGF-2) in endothelial cells and 
fibroblasts, respectively, resulting in a neovascular response in vitro (Ciccone et al., 
2019). Scaffolds made of a microfibrous blend of poly(L-lactide-co-ε-caprolactone) and 
HA also increased CD34 expression of endothelial cells, resulting in the formation of 
small vessels (Kenar et al., 2019). Endothelial cells also increased their CD31 expression 
[also called platelet endothelial cell adhesion molecule (PECAM-1)] when cultured on 
HA-modified collagen nanofibers for a vascular tissue-engineered scaffold (Kang et al., 
2019). Furthermore, higher expression of CD31 by endothelial cells, when exposed to 
HA, shows immunomodulatory properties, as  it inhibits the circulation of leukocytes 
(Lertkiatmongkol et al., 2016). HA-modified collagen nanofibers also promoted 
lymphatic endothelium formation by increasing the expression of lymph vessel 
endothelial hyaluronan receptor-1 (LYVE-1) (Gao et al., 2019). 
4.2.2. Intrinsic Immunomodulatory Capacity of HA 
The immune system is a defence mechanism against environmental threats and 
pathogens, it can be divided in the innate and adaptive immune system. When the immune 
system experiences a biological imbalance, several chronic and acute inflammatory 
conditions can be triggered, as well as the development of several autoimmune conditions 
(Zamboni et al., 2018a).  
The immune system also plays and important role in the success of cell and organ 
transplantation. Normally, when an injured or failing organ needs to be repaired or 
replaced using allogenic and xenogeneic sources available, these foreign cellular sources 
are recognized by the host immune system leading to its rejection. However, the immune 
system is not the only player during the inflammation process, the remodelling of the 
ECM plays also an important role by promoting immune cell activation, tissue invasion 
and destruction (Hallmann et al., 2015, Sorokin, 2010).  
In healthy human islets, HA is located outside the endocrine cells. HMW HA, over 1,000 
kDa, are contained in the pericellular matrix of pancreatic islets. It presents anti-
inflammatory, filling, and hydrating functions, thus protecting β-cells from leukocyte-
mediated death. 
In addition, HA can be crosslinked into stable structures that impact leukocyte function 
by the interaction with a diverse group of HA-binding proteins, known as hyaladherins. 
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Tumour necrosis factor stimulated gene 6 (TSG-6) is a hyaladherin that has an important 
function in preventing HA degradation by inhibiting HYALs and enhancing HA binding 
to the cell surface receptor CD44 on lymphocytic cell lines (Baranova et al., 2011). 
The effect of TSG-6 in the development of diabetes has shown to delay autoimmunity 
and enhance tolerogenicity of cells (Kota et al., 2013). When HMW HA alone or in 
association to hyaladherins bind to CD44 receptors on Tregs, it promotes its immune 
suppressive capacity by increasing the transcription factor Foxp3 expression and 
increasing the production of anti-inflammatory cytokines, such as interleukin (IL) 10 
(Ruppert et al., 2014). For instance, HMW HA hydrogels have been shown to decrease 
leucocyte infiltration while increasing angiogenesis at the site of a dental extraction 
(Gocmen et al., 2015). Moreover, HMW HA hydrogels have been reported to increase 
lymphocyte and T helper cell proliferation and activation into an anti-inflammatory state. 
T helper cells increased the secretion of IL-10, a known anti-inflammatory cytokine, 
while decreasing the secretion of IL-2 and IFNγ, known pro-inflammatory cytokines. In 
addition, they also increased monocyte differentiation into M2 macrophage subtype 
(Gomez-Aristizabal et al., 2016). 
However, in T1DM, HA accumulates along the islet microvessels and in regions of 
insulitis, where it forms a network around inflammatory cells. LMW HA, ~250 kDa, is 
highly angiogenic, immune-stimulatory and inflammatory (Jiang et al., 2011, Rayahin et 
al., 2015). For instance, it has been shown that LMW HA fragments activate TLR to 
stimulate inflammatory cells (Jiang et al., 2011). HA is also implicated to be remodelled 
by hyperglycaemia during diabetes. It is hypothesized that during hyperglycaemia, 
thrombospondin-1 activates HAS-2, increasing plasma levels of HA in diabetic patients 
(Vigetti et al., 2014), where platelets are responsible for HA cleavage into LMW HA 
fragments by HYAL-2. These HA fragments would promote leukocyte recruitment and 
adhesion, enhancing the inflammatory milieu within the microvasculature (Shakya et al., 
2015).  
Since neutrophil migration in vivo is a marker for transplant rejection, and it occurs 
through hyaluronate-rich connective tissue matrices, the relevance of studying the 
mechanisms of HA modulation on neutrophil populations is important. Studies have 
shown that exogenous HA (of a minimum MW of 1x104) inhibits neutrophil aggregation 
in a dose-dependent manner, where processes such as inflammation and wound healing 
could be modulated with the application of HA of different MW sizes (Forrester and 
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Lackie, 1981). HA has also shown to inhibit lysozyme release from aggregated IgG 
stimulated neutrophils (Pisko et al., 1983). Soluble HMW HA has also shown to induce 
apoptosis of inflammatory neutrophils and macrophages. Moreover, macrophages which 
immobilized HMW HA were able to be polarized into M2 subtype upon LPS/TLR 
ligation (He et al., 2013). 
4.2.2.1.Modulation of Platelet Activation 
Platelets are one of the main cellular effectors of haemostasis, but they also possess a 
plethora of intracellular mediators (i.e. cytokines, chemokines) as well as surface 
receptors (i.e. integrins, CD44, TLR). These are known for their involvement in 
inflammatory and immune responses as outlined in section 1 (Iannacone, 2016). It is 
known following injury that platelets rapidly interact with the exposed ECM of the vessel 
wall and the surrounding tissues. Since platelets are involved with immunological 
responses and ECM interactions, the influence that HA could potentially have over 
platelet modulation can give new insights into immunomodulation.  
Interestingly, it is reported that platelets enzymatically degrade HA, via HYAL-2, from 
the surfaces of activated endothelial cells into fragments capable of inducing immune 
responses. Platelet activation causes the immediate translocation of HYAL-2 from a 
distinctive population of α-granules to the surface membrane where it exerts a catalytic 
activity  (Albeiroti et al., 2014). 
In diabetes, hyperglycaemia is shown to induce a reduction of the glycocalyx of the 
endothelial cells from the blood vessels which may promote platelet adhesion and 
aggregation. The subsequent HA fragments generated by platelet-derived HYAL-2 
initiate inflammatory and angiogenic signalling by stimulating mononuclear leukocytes 
in the immediate microenvironment to produce pro-inflammatory cytokines, such as IL-
6 and IL-8 (Shakya et al., 2015). 
4.2.2.2.Modulation of Complement Activation 
The complement system is part of the innate immune system and comprises a series of 
proteins that are activated in response to a pathogen to enhance the ability of antibodies 
(adaptive immune system) and phagocytic cells (innate immune system) to fight a threat. 
Its modulation can be linked to autoimmunity and transplant rejection. Thus, it is 
important to establish whether HA plays a role in complement activation and if HA could 
modulate the complement system. GAGs have the ability to modulate complement 
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activation, which is highly dependent on sulphate and negative charge content (Meri and 
Pangburn, 1994). For example, it has been observed that highly sulphated GAGs can 
promote C3 activation while little or no effect was seen with negatively charged GAGs.  
Studies have also suggested that non-modified HA seems to have relatively weak 
anticomplementary activity (Hallgren et al., 1989). 
4.2.3. Structure:Function Properties of HA Hydrogels in Cell Encapsulation Coatings  
In Figure 4.4. it can be seen that the relationship between structure and functional 
properties of hydrogels are closely dependent on polymeric molecular weight, 
concentration, degree of substitution, backbone chemistry, and crosslinking density 
(Collins, 2010).  For example, topography, capsule size, mechanical rigidity, charge 
distribution, and hydrophobicity of nano coatings are parameters that influence islet 
function and host response following transplantation (Ernst et al., 2019). 
In terms of fouling proclivity alone, it has been suggested that the strength and degree of 
hydration layer around the polymer may be negatively correlated with protein adsorption. 
Polymer chain flexibility is also negatively correlated with fibrotic response because of 
steric repulsion. The implant geometry also influences the foreign body reaction (FBR). 
In spherical microcapsules larger spheres (greater than 1500 µm) resist fibrotic deposition 
to a greater degree than smaller spheres. It has also been suggested that smooth-contoured 
implants induce weaker FBR than those with rough edges. Material stiffness also 
positively correlates with the FBR magnitude (Ernst et al., 2019). 
The reestablishment of vasculature is a major limiting factor in attempts to replace or 
regenerate defective tissues. Vascularization is considered one of the greatest challenges 
in tissue engineering. Biomaterials can promote vascularization by changing surface 
roughness, porosity, factor release, and cellular tethering. Surface roughness tends to 
positively correlate with increased vasculature in bulk encapsulation (macro- and micro) 
and larger pores sizes can act as effective scaffolding for vascular sprouting (Ernst et al., 
2019). Hydrogel stiffness can also impact cell attachment and spreading. Generally, HA 
hydrogels with relatively lower storage modulus (G’) are required to achieve spreading 
of a 3D culture, and if stiffer gels are used, micron-sized pores must be introduced for 
cellular attachment and spreading (Lam et al., 2014). 
Hydrogel network mesh size is also an important parameter considering permeability. 
Permeation is a vital factor to consider for the success of tissue engineered constructs in 
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order to avoid graft rejection (Nafea et al., 2011b). It will prevent the inflow of molecules 
such as antibodies as small as IgG (150 kDa), cytokines and chemokines such as IL-1 
(17.5 kDa) and MCP-1 (8 kDa), respectively, while allowing the diffusion of oxygen, 
CO2 (44 Da) and glucose (180 Da), which are essential for cellular survival and function. 
For example, higher polymer and crosslink concentrations correlate to decreased pore sizes, 
which creates matrices with smaller molecular weight cut-off (MWCO) and slower 
diffusion rates (Weber et al., 2009, Bal et al., 2014).  
Higher crosslinking densities in HA hydrogels reduce the mesh size and consequently the 
MWCO, but they also implicate in lower degrees of degradation (Lai, 2014). The stability 
of the cell encapsulating structure can also impact the immune response, as degradation 
can release damage-associated molecular patterns (DAMPs), such as LMW HA 
fragments to the cell surrounding environment (Shakya et al., 2015). 
 
Figure 4.4. Structure-function properties of HA encapsulation systems. 
4.2.4. Intrinsic Antimicrobial Activity of HA 
Implantable device-related infections pose a huge financial burden on healthcare services 
and are associated with increased patient morbidity and mortality (VanEpps and Younger, 
2016). For patients, infections are commonly associated with pain, inflammation, fever, 
and often long-term antimicrobial treatment regimen. However, in some cases the 
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infection can lead to a second operation, resulting in removal of the implant. These 
infections can also lead to more serious conditions, such as the risk of sepsis (spread of 
infection to blood and other organs) which can sometimes be fatal. The development of 
tissue engineered substitutes that possess intrinsic antimicrobial activity against the three 
main classes of microbes (bacteria, fungi, and virus) is vital for the success of implantable 
devices.  
Reduction of bacterial burden at the implantation site may improve the clinical outcome 
for regenerative therapy. In the surgical setting, S. aureus is the leading cause of infection 
associated with implantable biomaterials. Treatment requires long term antibiotic 
administration often with additional surgeries, in order to remove the infected 
components (Ibberson et al., 2016). Several investigators have been interested in the 
interaction between HA and bacteria, particularly relating to invasion and virulence. 
Amongst various polymers tested for antibacterial coatings, HA and its derivates offer 
long-term safety and proven ability to reduce bacterial adhesion and biofilm formation 
(Romanò et al., 2017, Zamboni et al., 2021). HA has been shown to exert bacteriostatic, 
but not bactericidal, dose-dependent effects on different microorganisms in the planktonic 
phase. For example, HMW HA (1.8 MDa) has been demonstrated to decrease the 
proliferation of Gram-positive bacteria such as streptococcus and enterococcus species 
(Ardizzoni et al., 2011). Gram-negative bacteria, such as Escherichia coli, was also 
negatively affected by HMW HA (del Hoyo-Gallego et al., 2016, Pérez-Álvarez et al., 
2019). 
Unlike the extensive study of the antimicrobial activity of HA, only a few studies have 
been conducted to assess the activity of HA in fungi. However, intrinsic antifungal dose-
dependent properties of HMW HA (1.8 MDa) were demonstrated against Candida 
glabrata and Candida parapsilosis (Ardizzoni et al., 2011).  
Although viral infections in surgical setups are not as problematic as those from bacteria 
and fungi, the potential antiviral activity of HA has been studied.  HMW HA (1.800 KD) 
demonstrated strong antiviral activity against Coxsackievirus B5, mumps virus and 
influenza virus A (H1N1). Mild antiviral activity was shown against human simplex virus 
and porcine parvovirus. However, HA did not demonstrate any activity against 
Adenovirus 5, human Herpesvirus-6, porcine reproductive and respiratory syndrome 
virus. In all cases, no virucidal activity of HA was observed (Cermelli et al., 2011). 
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4.3. Final Considerations 
HA shows great potential to address many of the challenges associated with the 
development of a functional β cell encapsulation system for the treatment of T1DM 
patients, which include: 
• Possesses antimicrobial activity; 
• Promotes angiogenesis; 
• Downregulates the immune response; 
• Possesses insulinotropic effects; 
• Forms stable hydrated networks; 
• Can be crosslinked in physiological conditions; 
• Can form ultra-thin coatings by the sequential deposition of several polymeric 
layers. 
In this context, the rationale of in situ crosslinking of low and high molecular weight HA 
with varying crosslinking densities on the surface pancreatic β cells will create a bio-
functional multi-layered nano coating. This coating will support an immune protective 
and immunomodulatory environment to decrease transplant rejection, while enabling 
appropriate stability, stiffness, and mass transport of molecules (MWCO and diffusion) 
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The contents of the following chapter are adapted from the original research article 
published in the Carbohydrate Polymers journal. 
 
Zamboni, F., Ryan, E., Culebras, M., Collins, M. N. (2020) Labile crosslinked hyaluronic 
acid via urethane formation using bis(β-isocyanatoethyl) disulphide with tuneable 







BIED, a di-isocyanate crosslinker, was synthesized based on the reactivity of its 
isocyanate groups for HA hydroxyl moieties. HA with varying molecular weights were 
crosslinked by homogenous and heterogenous methods using BIED. Later, carbon 
nanofibres (CNF) were incorporated to the HA solutions prior to heterogeneous gelation 
to produce films with improved mechanical properties. HA gels were analysed in terms 
of chemical, physical, thermal, and mechanical characteristics. Rheological, swellability, 
and permeability profiles were studied. Results show that BIED successfully crosslinks 
HA. Moreover, the additional disulphide bond centring the crosslinker molecule gives 
these HA gels extra moiety with redox capabilities that can be further exploited in self-
healing and reversible gels for conformal crosslinking approaches. 
  
 




HA is a biocompatible polymer best known for its intrinsic hydrating properties, which 
acts as a space filler, lubricant, and osmotic buffer in the ECM of many tissues in the 
body (Zamboni et al., 2017). Nonetheless, HA is readily degraded in physiological 
conditions due to hydrolysis and enzymatic digestion (Pandey and Weigel, 2014, Collins 
and Birkinshaw, 2007a, Valachova et al., 2016). The rapid turnover of HA in biological 
systems requires HA to be chemically modified to improve its structural stability. This 
facilitates the use of HA in many pharmaceutical and biomedical applications (Burdick 
and Prestwich, 2011). Crosslinking strategies create more robust gels with low 
degradation rates, and the incorporation of inorganic nanoparticles (clay, graphene, 
carbon nanotubes, or silica) improve the mechanical toughness of the HA gels (Huang et 
al., 2018).  
Up to date, there is little literature on HA gel formation using isocyanate crosslinkers, 
although there is an increased interest in crosslinking carbohydrate polymers with this 
group of crosslinkers (Sonker et al., 2018b).  The main advantage of using isocyanates 
such as BIED is related to their excellent reactivity towards hydroxyl groups which 
result in the formation of urethane linkages (Koniev and Wagner, 2015). 
BIED is a linear di-isocyanate that contains two isocyanate groups in total, one at each 
end of the molecule backbone. BIED is categorized as an alkyl-based isocyanate, which 
is known to be significantly slower to degrade by hydrolysis than more conventional aryl-
based isocyanates (Brown et al., 1987). These linear isocyanates also produce upon 
reaction with hydroxyl groups, more stable urethane linkages against thermal degradation 
(Chattopadhyay and Webster, 2009). Alkyl-based isocyanates are also shown to pose very 
little to no cytotoxic effects in comparison with cyclic isocyanates (Touchet and Cosgriff-
Hernandez, 2016). Moreover, BIED contains a central disulphide group in its molecular 
backbone. Upon covalently crosslinking HA, these redox-sensitive moieties can be 
interconverted between disulphide and dithiol groups. This dynamic interconversion 
generates a potential self-healing and reversible crosslinking application for these gels 
(Griesser et al., 2018, Pepels et al., 2013). 
The production of nanocomposite HA hydrogels via the incorporation of CNFs can 
improve the overall mechanical, electrical, and thermal properties of the gels (Feng et al., 
2014). CNFs also offer benefits for wound healing applications as they absorb exudates 
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and regulate wound moisture. This is attributed to their surface area, and porous structure 
(Eatemadi et al., 2016). Interestingly, CNFs are also shown to possess antimicrobial 
properties depend on their structural characteristics, which are also beneficial for wound 
healing applications (Song et al., 2015). 
Herein, HA gels containing covalent crosslinks using BIED have been developed where 
the hydroxyl groups present in the N-acetylglucosamine moiety of HA react with the 
isocyanates to form carbamate linkages. The combination of CNFs embedded in HA 
hydrogel networks have been shown to produce nanocomposite films with improved 
mechanical performance. The CNFs serve as physical cross-linkers as well as reinforcing 
nanofillers in the HA hydrogel films. In the present work we anticipate that 
homogeneously crosslinked HA gels and heterogeneously crosslinked CNF-reinforced 
HA films result in gels with tuneable physical, mechanical, and biochemical properties. 
5.2. Materials and Methods 
5.2.1. Materials 
HA, with an average molecular weight (MW) of 1.20 MDa and 0.1 MDa, was kindly 
supplied by Shanghai Easier Industrial Development Co. LTD.  (Shanghai, China) as dry 
powder. 3,3’-dithiodipropionic acid, hydrazine monohydrate, sodium nitrite, dimethyl 
sulphoxide (DMSO), dithiothreitol (DTT) were purchased from Lennox Laboratories 
Supplies (Dublin, Ireland). The dialysis kit (Pur-A-LyzerTM Mega 1000), deuterium oxide 
(D2O), Ellman’s Reagent (5,5’-dithio-bis-(2-nitrobenzoic acid), fluorescein 
isothiocyanate (FITC) dextranes, phosphate buffered saline (PBS), and all other reagents 
used in this work were of analytical grade purchased from Sigma Aldrich (St. 
Louis, MO, USA). 
5.2.2. BIED Synthesis 
The synthesis of BIED can be divided into three steps. First, 3,3’-dithiodipropionic acid 
(10 g) and ethanol in excess (22 g) were dissolved in toluene (100 mL) with ρ-toluene 
sulfonic acid (2.5%) as the reaction catalyst. The reaction was heated up to boiling and 
temperature was constantly monitored using a thermocouple. The reaction was performed 
under reflux for 5 hours using a Dean-Stark trap to produce diethyl 3-3’-thiodipropionate. 
The yield of the product was obtained by the evaporation of toluene using a rotary 
evaporator (Rotavapor R-210, Buchi, Switzerland), giving a yield of 90%. In the second 
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step, diethyl 3-3’-thiodipropionate (10 g) and hydrazine monohydrate in excess (12 g) 
were dissolved in methanol (13 mL) and heated for 4h under reflux to obtain 
dithiodipropionate dihydrazine after crystalization in an ice bath. The yield of the product 
was obtained by the evaporation of methanol using a Gallenkamp vacuum oven at a 
temperature of 40°C overnight, yield of 97%. In the third step,  dithiodipropionate 
dihydrazine (10 g) was dissolved in 60 mL of hydrochloric acid (HCl 2.5 M) and stirred 
in an ice bath. 16 mL of a sodium nitrite aqueous solution (76%) was added drop wise to 
avoid an extreme exothermic reaction. After, toluene (100 mL) is added to the solution, 
and this induced a phase separation using a separation funnel. The toluene phase 
contained an intermediate product that upon heating produces BIED by curtius 
rearrangement. The toluene is then refluxed for 10 minutes to completely convert acid 
hydrazine into isocyanate (pale yellow liquid). Toluene (boiling point: 110°C) is removed 
from BIED (boiling point: 148°C) by using a rotary evaporator (BUCHI, Switzerland) at 
40°C and 29 mbar for 2 hours (yield of 38%). The overall yield was calculated to be 
33.17%.  
5.2.3. HA Crosslinking 
BIED was used as a HA crosslinker and the crosslinking reaction was performed via two 
distinct methods. In the first method, the crosslinking reaction occurs when all the 
reactants are dispersed in the same phase (DMSO solvent), namely homogenous 
crosslinking. In the second method, the crosslinking reaction occurs when the reactants 
are in two separate phases (the crosslinker has to diffuse through HA films for the reaction 
to occur), namely heterogenous crosslinking. 
5.2.3.1.Homogeneous Crosslinking 
BIED (49.3 mg.mL-1) was added to HA 1.20 MDa or 0.1 MDa solutions (70 mg.mL-1) 
dissolved in DMSO. HCl 1M was used to adjust the pH to 4. The crosslinking reaction 
proceeded upon stirring. 
5.2.3.2.Heterogeneous Crosslinking 
HA solutions of 1.2 MDa 3% (w/v) and 0.1 MDa 3% (w/v) in water were prepared 
overnight at 25°C and 100 RPM. For HA-CNF blends, 2.9 wt.% of HA and 0.25 wt.% of 
CNF were dissolved in distilled water and homogenized using ultrasound-assisted 
dispersion at an amplitude of 10 microns for 10 minutes. The CNFs used in this project 
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are 98% carbon-based, measuring 100 nm in diameter and 20−200 μm in length. Figure 
5.1 shows the SEM image of the CNFs using a TM-1000 tabletop microscope (Hitachi, 
Japan). 
The HA and HA-CNF films were prepared via casting their respective aqueous solution 
onto a clean petri dish, followed by drying at 25°C for 120 hours. The resulting films 
were then cut in pieces of 1 cm2 and subsequently placed in the vacuum oven at 40°C 
(1000 psi) for 3 hours, more details on the films are shown in Table 5.1. 
 
Figure 5.1. SEM image of CNFs used to reinforce HA gels. 
Table 5.1. Cast-moulded HA and HA-CNF films with 1 cm2. 
± S.D. 
Heterogeneous crosslinking was performed on the vacuum dried HA and HA-CNF films. 
The films (1 cm2) were placed in 10 mL of acetone-water solution (80:20 by volume 



























respectively) containing 400 mg.mL-1 of BIED, pH was adjusted using 2.0 M 
hydrochloric acid (pH of 3.0). The crosslinking reaction was allowed to proceed for 72 
hours at RT. Crosslinked films were washed with deionized water several times before 
being dried for 3 hours at 35°C in a fan oven.  
5.2.4. Surface Roughness Analysis of HA Films 
The surface roughness and topology of the films were recorded, in contact mode at room 
temperature, using a Thorlabs EDU-AFM1/M atomic force microscope (New Jersey, 
USA). The measurements were performed using monolithic silicon AFM probe with 
aluminum reflective coating (ContAl-G, Budgetsensors), in the same room, at room 
temperature and ambient pressure. The experiments were conducted on square areas of 
20 mm x 20 mm, in 100 x 100 pixels resolution, at a scan speed of 100 pixels/s. The AFM 
micrographs were analysed using the Gwyddion 2.56 software. The average surface 
roughness value was calculated from three lines drawn across the AFM image for each 
sample. 
5.2.5. Chemical Characterization 
All spectra were recorded on a Perkin Elmer spectrum 100 FT-IR spectrometer operating 
in Attenuated Total Reflectance (ATR) mode (Perkin Elmer, MA, USA). Each FT-IR 
spectrum was scanned twenty times with a resolution of 2 cm–1. The ranges used were 
from 4000 cm–1 to 650 cm–1.  
5.2.6. Mechanical Characterization 
The rheological properties of HA gels produced from homogenous crosslinking were 
evaluated by the Discovery Hybrid Rheometer (DHR-2) (TA Instruments, DE, USA) 
using parallel plate geometry of 25 mm at 25°C. Prior to oscillatory frequency 
measurements, a strain sweep analysis was performed using a strain range of 0.01-0.1-1-
10-100-1000%, at a fixed frequency of 1 Hz to obtain the linear viscoelstic region of the 
gels (0.01-1%). Then, a frequency sweep was conducted in the frequency range of 0.1-10 
Hz. 
HA films produced from heterogeneous crosslinking were dried in the vacuum oven at 
40oC (1000 psi) for 2 hours and their mechanical properties analysed using dynamic 
mechanical analysis (DMA) Q800 1535 (TA Instruments, DE, USA), operating in the 
DMA Controlled Force mode with a gauge length of 12.74 mm. The stress/strain test was 
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performed on samples maintained at an isothermal temperature of 25oC, and a force ramp 
rate of 3.0 N.minute-1 to an upper force limit of 18.0 N. 
5.2.7. Swelling Profile 
HA gels were prepared as described previously and dried in an oven at 70°C for 24 hours. 
The HA dry samples were weighed and incubated in 4 mL of PBS with pH 7.4 at RT. 
Hydrogels were removed at various time intervals; excess solution was wiped off and 





where Wd is the dry weight and Ws is the weight of the sample after the incubation time. 
All swelling measurements were carried out in triplicate. 
5.2.7.1.Crosslinking Density 
HA hydrogels were dried in an oven at 70°C, overnight. The dried gels were subsequently 
swollen in PBS until they reached their equilibrium water content. Crosslink densities 
were assessed by measuring volumetric swelling and applying a simplified version of the 
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where Mc is the average molecular weight between crosslinks, ρp is the density of the dry 
polymer (1.229 g/cm3) and ρs is the density of PBS. QM is the swelling ratio determined 
experimentally by comparing the mass of the material before and after immersion,  is 
the specific volume of the dry polymer as the inverse of density, V1 is the molar volume 
of the solvent (18 cm3/mol for PBS), and χ is the Flory polymer solvent interaction 
parameter (0.473). 








The swollen hydrogel mesh size ξ (nm), was determined with the following equation 
adapted from Collins et al (Collins and Birkinshaw, 2008a): 







5.2.8. Degree of Substitution of HA Gels 
HA gels (MW 1.2 MDa and 0.1 MDa) were reduced to produced HA derivates bearing 
free thiol groups (HA-SH). First, gels had their pH adjusted to 7 using a solution of 
sodium hydroxide (NaOH 1 M), and then treated with DTT at a 1:1 ratio in comparison 
to BIED used to crosslink the gels. Samples were heated for 20 minutes at 90°C under 
stirring conditions to reduce the disulphide bonds of the gels. Gels gradually changed into 
a solution. HA-SH was precipitated from the solution using acetone in a ratio 2:1. The 
precipitate was re-dissolved in DMSO and dialysed against deionized water for 3 days at 
RT. Deionized water was changed every day to promote constant diffusion of DTT and 
DMSO out of the dialysis chamber. HA was freeze dried to obtain a lyophilized powder. 
Briefly, the dialysed sample was placed in a shelf freeze dryer (AdVantage BenchTop 
Freeze Dryer by Virtis, USA) and let to freeze at -40°C overnight before drying. Drying 
was conducted in four temperature stages. The temperature was held at -20°C for 6 hours 
under vacuum (200 mTorr), then the temperature was increased to -10°C for 1.5 hours, 
following another temperature increase to 5°C for 2 hours. This finally reached 25°C, 
after which HA-SH was obtained as a white powder. HA-SH was then stored under 
nitrogen in the freezer at -20°C. 
The lyophilized powder of HA bearing free thiol groups was analyzed regarding the 
degree of thiolation using the Ellman’s Reagent. Briefly, a stardant curve of L-cysteine 
was prepared using a solution buffer (0.1 M Na2PO4, 1 mM EDTA, pH 8.0). Then, 
aliquots of the standard curve samples were incubated with Ellman’s solution for 15 
minutes. HA samples were prepared the same way as the standard curve and they were 
all read using a microplate reader at 412 nm. Absorvances were used to create a linear 




The lyophilized powder of HA bearing free thiol groups was analysed regarding the 
degree of substitution using Proton Liquid Nuclear Magnetic Resonance (NMR). Jeol 
ECX 400 NMR (Jeol USA, Inc) was used to analyse the samples. Samples were diluted 
in 1 mL of D2O. 128 scans were performed under RT with a 15 Hz sample spinning and 
45° tip angle. 
5.2.9. Permeability Test 
For the permeability test, 0.1 and 1.2 MDa films were heterogeneously crosslinked using 
BIED. The permeability experiment consists of HA-BIED crosslinked films separating 
the donor solution from the acceptor solution. The donor solution contains 2 mg.mL-1 of 
three distinct FITC-dextranes with molecular weights of 4,000 Da and 150,000 Da, 
whereas PBS 1X is used as the acceptor solution. An in-house permeation chamber made 
of polylactic acid (PLA) was 3D printed for these experiments using 3D printer 
MakerGear M3ID (USA) and Simplify3D software as shown in Figure 5.2. The two 3D-
printed parts clip the gel in the middle, separating the top chamber (with the donor 
solution) from the bottom chamber (with the acceptor solution). Both chambers hold a 
volume of 261 μL. The detection of FITC-dextran in the acceptor solution is measured at 
time intervals of 15 minutes, 30 minutes, 1 hour, 3 hours and 6 hours using a fluorescence 
plate reader (SynergyMx, BioTek, EUA). with an excitation wavelength of 485 nm and 
emission of 535 nm. A standard curve (0.066, 0.0032, 0.0016, 0.0008, 0.0004, 0.0002 
mg/mL) for each FITC-dextran was measured and the linear eqution was obtained to 
convert the fluorescence from the acceptor solution into equivalent concentration. from 
All tests were executed at RT (Hsu et al., 2018). The calculation of the permeability 
coefficient was determined according the equation below: 
𝑑𝐶𝐴
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Where dCA/dt is the exchange of the concentration of the substance within the acceptor 
side over time (the slope); CD is the concentration of the donor solution; P is the 
permeability coeficient; A is the permeation surface; and VA is the volume of the acceptor 





Figure 5.2. 3D-printed permeation chambers. Dimensions: a=11.27mm, b=0.9mm, 
c=5.5mm, d=1.55mm, e=0.7mm, f=0.7mm, g=5.5mm, h=0.7mm, i=0.7mm, j=0.9mm, 
k=13mm, l=1.55mm, m=2mm. 
5.2.10. Thermo-chemical Characterization  
The non-crosslinked and crosslinked HA and HA-CNF films were dried in the vacuum 
oven at 40oC (1000 psi) for 2 hours and analysed using a differential scanning calorimeter 
(Perkin Elmer DSC 6). The experiment was carried out at 20 cc.mm-1 of nitrogen gas flow 
with an increasing temperature from 0oC to 200oC at a rate of 10oC.minute-1. Triplicate 
samples were tested to ensure reproducibility. 
5.2.11. Statistical Analysis 
Data are presented as mean ± standard deviation (s.d.) and analysed using two-way 
analysis of variance (ANOVA). p-value < 0.05 (*) was considered significant. 
5.3. Results and Discussion 
5.3.1. BIED Synthesis 
The stepwise chemical reactions leading to BIED synthesis is shown in Figure 5.3. At 
every reaction step, products have been chemically confirmed using FT-IR. In Figure 5.4, 
each spectrum shows the characteristic bands from each reaction product. For example, 
in step 1 the starting material is a carboxylic acid that is converted into an ester. The bands 
for carboxylic acid do not appear following the completion of the reaction (O-H broad 
stretching band between 3,300-2,500 cm-1) and the characteristic band for the ester, such 
83 
 
as the C=O stretch band at 1,735 cm-1 becomes apparent. In step 2, the characteristic ester 
band now disappears, and new bands relating to the product appear. These bands are 
related to N-H stretch 3,400-2,800 cm-1 overlapping with the primary amine (-NH2) 
stretch band at 3,180 cm-1 and 3,320 cm-1 and the carbonyl of the acylamino at 1,622 (Xu 
et al., 2017). Step 2a involves a reaction between the dithiodipropionate dihydrazine and 
nitrous acid (which is formed in situ between the reaction of sodium nitrite and 
hydrochloric acid) producing an intermediate compound called acyl azide. The azide (-
N3) asymmetric stretching vibration band is shown in Figure 5.4 and was previously 
described in the literature at 2,162 nm (Tanver et al., 2015).  After the acyl azide 
compound is extracted from the aqueous solution using toluene via phase separation, it is 
subsequently heated and converted into BIED by the Curtius rearrangement mechanism. 
BIED shows a characteristic broad and strong band at 2,262 cm-1 associated to 
isocyanates (Beck et al., 2009).  
 
Figure 5.3. Stepwise synthesis reaction to produce BIED. 
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Figure 5.4. FT-IR spectra of the reaction products from the BIED synthesis. 3,3’-
dithiodipropionic acid, diethyl 3-3’-thiodipropionate dithiodipropionate dihydrazine and 
BIED. 
5.3.2. HA crosslinking 
The synthesized di-isocyanate compound was then used to react with HA either by 
homogenous (bulk gel formation) or heterogenous crosslinking (film gelation), shown in 
Figure 5.5. The hydroxyl groups of the N-acetylglucosamine moiety of HA are targeted 
by the isocyanate to form urethane linkages as shown in the schematic reaction in Figure 
5.6A. The formation of these urethane linkages is verified by FT-IR and confirms 




Figure 5.5. Representative image of BIED-crosslinked HA gels. Homogenously 
crosslinked gels (a). Heterogeneously crosslinked HA films (b) and CNF-reinforced HA 
films (c). 
The FT-IR spectrum of BIED clearly depicts spectral bands at 2270 cm-1 which is 
characteristic of the isocyanate functional group (C-N-O), 1731 cm-1 which indicates an 
ester carbonyl group (C=O) stretching, 1516.2 cm-1 (C=C bond), 1260.3 (O-H bending) 
and 1030 cm-1 (C-N group) in accordance with the literature. The FT-IR spectra of non-
crosslinked HA and HA-CNF clearly shows the characteristic OH vibration band at 3346 
cm-1 and the broad carbonyl band of the amide-carbonyl functional group at 1618 cm-1 
(Dhanasingh et al., 2010). Once the crosslinking reaction with BIED occurs, HA 
crosslinked gels show the appearance of the characteristic carbonyl urethane group (C=O 
stretching) at 1729 cm-1, carbamate group (C-N) at 1564 cm-1, and C-O-C at 1228 cm-1 
(Wong and Badri, 2012). The carbonyl band at 1729 cm-1 is regarded to be free of 
hydrogen bonding (Bahadur et al., 2016). Furthermore, the absence of the characteristic 
isocyanate band at 2262 cm-1 indicates a fully crosslinked HA, where there was no 


































Figure 5.6. A) Schematic reaction of BIED crosslinking HA via urethane linkages. B) 
Representative FT-IR spectra of BIED in black, HA not crosslinked in red, HA 
crosslinked (c) in green, HA-CNF not crosslinked in blue, and HA-CNF crosslinked (c) 
in turquoise. 
The thermal behaviour of HA and HA-CNF gels are shown in Figure 5.7. Unmodified 
HA is used as a control group and it shows the presence of a broad endothermic peak 
around 110°C, which is associated with the loss of moisture remaining after the initial 
drying procedure and an exothermic peak representing degradation around 230°C, in 
agreement with the literature (Collins and Birkinshaw, 2007b). On the other hand, the 
thermal behaviour of HA-CNF blend not crosslinked revealed the presence of two narrow 
exothermic peaks at around 230°C and 260°C, which indicates that the degradation of 
HA is disrupted by the interaction with CNF. 
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The thermal behaviour of both crosslinked HA and HA-CNF films shows a sharp 
endothermic peak at around 195°C and 185°C, respectively which is attributed to the 
scission of the disulphate bond.  





























Figure 5.7. Representative DSC thermograms of HA not crosslinked, HA crosslinked 
(c), HA-CNF not crosslinked, and HA-CNF crosslinked (c). 
5.3.2.1. Viscoelastic Profile of Homogenously Crosslinked HA Gels 
The stiffness of homogenously crosslinked HA hydrogels was evaluated by the 
determination of the storage (G’) and loss moduli (G’’), where G’ represents the elastic 
component of the gel and G” represents the viscous component of the gel (Figure 5.8). All 
gels produced in this study show G’>G”, indicating they were successfully crosslinked. 
Results show that 0.1 MDa gels have higher storage modulus (20 KPa) while 1.2 MDa 
gels have lower storage modulus (2 KPa).  This significant difference between the storage 
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modulus of gels was also observed by other studies. They show that gels with higher MW 
in fact decreases G’ and stiffness (Amorim et al., 2020).  
 
Figure 5.8. Rheological profile of BIED-crosslinked HA gels with 0.1 MDa and 1.2 
MDa. 
5.3.2.2. Mechanical Profile of Heterogeneously Crosslinked HA Films 
For the tensile test results the films were subjected to the same test conditions and 
representative stress-strain plots of each film are shown in Figure 5.9 A and B. The 
Young’s moduli for all films were calculated and results are shown in Figure 5.9C. As 
expected, HA MW strongly influences the mechanical properties of the films. High MW 
HA films (1.2 MDa) show decreased Young's modulus, in comparison to low MW HA 
films (0.1 MDa). Other studies have also observed the same tendency of HA films to 
decrease stiffness as a function of MW size (Amorim et al., 2020). 
Although, for all samples, crosslinking the films with BIED, drastically increased the 
mechanical strength of the films. The low MW HA-CNF (C) films have the highest 
modulus, due to the reinforcing effect of CNF combined with BIED crosslinking to HA.  
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Figure 5.9: Representative stress-strain plots of various HA films A) 1.2 MDa, B) 
0.1MDa and C) Young’s modulus of 0.1 and 1.2 MDa HA films. Statistical analysis 
was performed using ANOVA followed by post-hoc Tukey’s HSD test where p-value < 
0.05 shows statistical difference between groups (#) and within groups (*). 
5.3.2.3.  Analysis of the Degree of Substitution 
Due to the disulphide bond located in the centre of the crosslinker chain, the gel can be 
reduced back into a solution by the conversion of the disulphide bond into free thiol 
groups using DTT (Figure 5.10). The product of this reduction generates HA derivates 
carrying free thiol groups (HA-SH), which can be assessed for the degree of thiolation. 
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The degree of thiolation for homogeneously crosslinked HA 0.1 MDa was 594.3 μM.mg-
1 (± 198) of HA as opposed to 166.15 μM.mg-1 (± 14.04) from homogeneously crosslinked 
HA 1.2 MDa, therefore explaining the difference in crosslink densities and subsequently 
gel stiffness (~ 20 kPa for 0.1 MDa and ~ 2 kPa for 1.2 MDa). It is hypothesised that the 
thiolation degree decreases with increasing molecular weight because the longer a single 
polymeric chain is, it increases the formation of hydrogen bonding resulting in higher 
viscosity. Also, longer polymeric chains are more likely to become entangled, which 
makes the sites for crosslinking difficult to reach, thus, causing lower reaction activity 
(Cao et al., 2019). 
Confirmatory NMR analysis of HA derivates after the reduction of the disulphide bonds 
of HA gels are shown in Figure 5.11. NMR spectra shows the appearance of peaks at 
approximately 2.75 ppm for CH2 groups related to the -CH2CH2SH radical of the urethane 
linkages.  The control CH3 group of HA appears at approximately 2.05 ppm. The 
spectrum is in accordance with the literature (Bian et al., 2016). 
 
Figure 5.10. Schematic reduction reaction of the disulphide bond of the crosslinked HA 




Figure 5.11. Representative NMR spectra for pure HA (control) and HA-SH derivate. 
5.3.2.4. Swelling Characterization 
The speed at which gels swell to their equilibrium water content is presumed to be a 
function of crosslink density and polymeric concentration (Figure 5.12).  
When comparing crosslinking density, it is observed that LMW HA gels show lower 
swelling ratio than HMW HA gels, this is mainly attributed to the fact that LMW HA 
gels are more efficiently crosslinked than HMW HA gels, as shown by the 
quantification of thiol groups and the theoretical calculation of crosslinking density 
(Table 5.2). A similar influence of crosslinking density was also observed in other 
































Overall, hydrogel swelling ratios decrease with decreasing molecular weight, which is 
due to increased crosslinking density and the formation of tighter network structures with 
an increasing number of covalent crosslinks (Hegger et al., 2017). However, although low 
molecular weight hydrogels (0.1 MDa) display higher crosslinking densities, they are also 
faster to degrade due to smaller and less entangled polymeric chains where glycosidic 
bonds are more likely be exposed and degraded by hydrolysis than in HMW HA gels 
(Cao et al., 2019). 
The gels initially turned white in colour, and then a colourless swelling front moved 
inwards, separating the highly swollen surface from the less swollen core of the gel and 
gradually the entire gel turned colourless and was swollen evenly. This colour 
phenomenon was also described by (Collins and Birkinshaw, 2008b) and it is presumed 
to be due to molecular rearrangement as the water diffuses through the material.  
 
Figure 5.12. Swelling profiles of BIED-crosslinked HA gels with 0.1 MDa and 1.2 
MDa. 
5.3.2.4. Matrix Characterization 
In general, increasing effective crosslinking density decreases mesh size and average MW 
between crosslinks (Collins and Birkinshaw, 2010) and produces hydrogel matrices with 
smaller MWCO and slower permeation rates (Weber et al., 2009, Bal et al., 2014). Hence, 
knowing these matrix parameters (shown in Table 5.2) is imperative for applications such 
as drug delivery and cellular scaffolding. Here, the characterization of homogeneous 












































BIED-crosslinked HA gels shows that LMW HA gels display much smaller mesh sizes 
than HMW HA due to their higher crosslink densities resulting from their higher degrees 
of thiolation. As mentioned, BIED in HMW HA has lower reaction activity due to the 
longer polymeric chains that are more likely to become entangled, which makes the sites 
for crosslinking difficult to reach (Cao et al., 2019). 
It is envisaged that the homogeneous crosslinking carried out in this study can potentially 
be used to encapsulate drugs. Additionally, the use of DMSO can pose little constraint 
for drug encapsulation, as DMSO dissolves a large variety of polar and non-polar small 
molecules, making it an important drug solvent for topical pharmaceutical formulations 
(Tetko et al., 2013). Furthermore, DMSO possesses permeabilizing properties which 
enhance drug delivery though the skin without harmful effects (Marren, 2011). DMSO is 
also largely used in cryobiology as the cryoprotectant of choice for most animal cell 
systems. Nevertheless, cell exposure to DMSO show apparent cell toxicity specifically 
associated with plasma membrane changes, such as membrane fluidity and dysfunction, 
leading to programmed cell death (Awan et al., 2020).  
Homogeneously crosslinked HA gels, due to the use of DMSO, are particularly difficult 
have DSMO removed from the gels through lyophilization and evaporation. The 
difficulty DMSO evaporation is due to its high boiling point (189 °C), limiting the use of 
these gels as cell scaffolds. However, to circumvent this issue, the conversion of these 
gels into solution by reducing the gel disulphide bond allows the purification of the HA-
thiol derivates through dialysis (Black et al., 2014). Re-crosslinking the HA-thiol 
derivates can be facilitated by the oxidation of the thiol groups into disulphide bond for 
reversible or self-healing gel forming properties and are suitable for cell encapsulation 
(Fernandes and Ramos, 2004, Pepels et al., 2013). This is particularly interesting for the 
development of L-b-L coatings, which will be further discussed in chapters 8 and 9. As 
seen in Figure 5.10, the reduction of BIED-crosslinked HA is possible, and produces HA-
bearing thiols.  The degree of substitution of these HA derivates are shown in Table 5.2 
and the results correlate to the calculated crosslinking density. 











(μM.mg-1 of HA) 
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0.1 17.3 ±0.9 4,900 (± 520.1) 0.00025 (± 2.6839E-05) 594.3 (± 198) 
1.2 113.9 ±18.8 71,198.1 (± 22452) 0.000017 (± 6.65833E-06) 166.15 (± 14.04) 
± SD 
5.3.3.1.Permeability of HA Films 
The MWCO determines the minimum molecular weight, correspondingly minimum size, 
of a solute that is completely excluded by the semipermeable membrane (Nafea et al., 
2011a). MWCO is dictated by the mesh size and affects diffusion and permeation rates 
of molecules (such as antibodies and cytokines). Thus, the study of gel permeation rates 
to solutes of different sizes is particularly important to tissue engineering and drug 
delivery applications. 
To mimic the penetration rate of IgG (150 kDa) and MCP-1 (8 kDa) through the HA 
hydrogel, two FITC-labelled dextranes of similar molecular weight were utilized to 
determine permeation rates through the LMW and HMW HA films. The results shown in 
Figure 5.13 demonstrate the delay of permeation of 150 KDa dextran in LMW HA gels 
(p<0.05) in comparison to HMW HA gels. Moreover, HMW HA gels were inefficient to 
delay the permeation of both 4 KDa and 150 KDa. The equal permeation rate for both 
dextranes means that the mesh size of the gels was significantly larger than the size of 
these two particles, thus both particles pass freely through the film. 
IgG is the most abundant immunoglobulin (80%) in the body and previous studies have 
shown that membrane barriers for IgG are enough to prevent graft rejection in transplants. 
This indicates that blocking cytokines and chemokines may not be a requirement for 
immunosuppression in allotransplantation (Steele et al., 2014).  
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Figure 5.13. Permeation rate of low and high molecular weight dextranes through 
crosslinked HA films. Statistical analysis was performed using ANOVA followed by 
post-hoc Tukey’s HSD test where p-value < 0.05 shows statistical difference (*). 
5.3. Final Considerations 
This study has demonstrated the novel use of crosslinking HA of both low and high 
molecular weights with the di-isocyanate BIED.  This was achieved through the 
formation of urethane linkages between the HA chains, as described earlier in the 
chapter. The main advantage of using BIED over other isocyanate crosslinkers is that it 
has a disulphide bond in the middle of the molecule backbone, which can be reduced into 
free thiol groups, and possibly re-oxidized into disulphide bond for reversible or self-
healing gel forming properties. This is particularly interesting for the development of L-
b-L coatings, which will be further discussed in chapters 8 and 9.  
Results have shown that gels can be tailored with mechanical and stability properties 
depending on HA content, HA molecular weight and crosslinking density. This is 
particularly useful when designing network systems which can be applied in a variety of 
uses for pharmaceutical applications. Specifically for drug delivery systems, the use of 
DMSO applied in the homogenous crosslinking methodology to create these can 
dissolves a large variety of polar and non-polar small molecules. 
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However, creating gels using aprotic solvents such as DMSO can pose limitations for 
bioengineering applications as tissue scaffolds. In this context, the heterogenous 
crosslinking of HA gels through BIED diffusion circumvents the associated limitation of 
DMSO use from homogenous crosslinking methods. Although heterogenous crosslinking 
is not as effective as the homogenous method, the mechanical properties of these gels can 
be improved through the inclusion of CNFs. 
In the next chapter, focus will be given to the characterization of heterogeneously 
crosslinked HA gels regarding their suitability for biological applications. 
Biocompatibility and cell proliferation studies will be conducted, together with 
immunological response analysis via immune cell activation and pro-inflammatory 
cytokine production quantification. Lastly, the potential antimicrobial activity of HA and 
CNF will be assessed.    
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Chapter 6: Newly 
Crosslinked HA Hydrogels: 



















The contents of the following chapter are adapted from the original research article 
published in the journal of Carbohydrate Polymers. 
 
Zamboni, F., Okoroafor, C., Ryan, M. P., Pembroke, T., Strozyk, M., Culebras, M., 
Collins, M. N. On the Bacteriostatic activity of hyaluronic acid composite films. 






Herein, the biological characterization of the heterogeneously crosslinked HA films is 
assessed.  HA films with varying molecular weights were crosslinked using BIED, a di-
isocyanate-based crosslinker, which is highly reactive for the hydroxyl moieties of HA. 
These heterogenous-crosslinked films are envisaged to support cell growth as they do not 
require toxic solvents involved in their production, contrary for those crosslinked through 
homogenous reactions. Cell viability, cell proliferation, immune activation and 
antimicrobial activity assessments were performed. Results show that heterogenous-
crosslinked HA films are biocompatible. Moreover, immunological, and antibacterial 
responses are dependent on HA molecular weight. In the future, these gels can be 
potentially exploited for a number of applications that include wound dressings, skin 
grafts, catheter coating for biofilm inhibition, cell encapsulation, and drug delivery.  











HA is an important ECM component due to its hygroscopic nature it provides hydration 
and tumescence to all tissues in the body. Moreover, HA regulates a diversity of 
biological processes by triggering signalling pathways associated with the adhesion, 
proliferation, migration, and differentiation of cells (Amorim et al., 2021). Distinct cell 
responses are largely influenced by HA size, generated upon degradation by 
hyaluronidases or free radicals, and its interaction with different cell membrane receptors 
(Nusgens, 2010). 
Due to its remarkable physicochemical properties and biological relevance, HA is being 
used in numerous biological applications concerning tissue repair (Liu et al., 2019b, 
Gokila et al., 2018). The ability of HA to modulate the immune system, which is primarily 
dependent on its molecular size, can be exploited for the development of HA-based 
biomaterials for enhanced  bio integration and adequate tissue healing (Zamboni et al., 
2018b). High MW HA is shown to elicit anti-inflammatory and immunosuppressive 
functions (Ruppert et al., 2014) while low MW HA is shown to be highly angiogenic, 
immune-stimulatory and pro-inflammatory (Jiang et al., 2011, Rayahin et al., 2015). 
HA and its derivates also offer potential long-term safety and ability to reduce bacterial 
adhesion and biofilm formation (Romanò et al., 2017). HA is shown to be bacteriostatic, 
but not bactericidal, and exhibits dose-dependent effects on different microorganisms in 
the planktonic phase (Harris and Richards, 2004). 
Staphylococcus aureus (S. aureus) is a Gram-positive, non-motile, non-spore forming 
facultative anaerobic coccid bacterium. The microorganism is approximately 0.5-1.5μm 
in diameter and in physiological conditions grows by aerobic respiration at a temperature 
range from 15oC to 45oC (Jorgensen et al., 2015). They are normally found on the skin 
and mucous membranes of the nose in 30% of the healthy human population, normally 
displaying no symptoms (Bhattacharya et al., 2015). These bacteria are transmitted via 
contaminated surfaces, air-borne and direct contact to predisposed humans. They are also 
easily spread in hospitals, particularly in surgical wards (Forster et al., 2013).  
S. aureus are usually detected in the top layer of wounds and are the most common 
bacterium isolated from chronic wounds (Gjodsbol et al., 2006). The interaction between 
keratinocytes, fibroblasts, Langerhans cells and endothelial cells during wound healing 
remodelling promotes colonization of Gram-positive bacteria such as S. aureus (Serra et 
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al., 2015). They are also opportunistic pathogens that cause a variety of self-limiting to 
life-threatening diseases in humans. S. aureus as a bacterium is among the most common 
cause of staphylococcal infections and is responsible for various diseases including mild 
skin infections (impetigo and folliculitis), invasive diseases (wound infections and 
osteomyelitis, and toxin mediated diseases (such as food poisoning, scaled skin syndrome 
and toxic syndrome) (Bukowski et al., 2010, Mitchell and Howden, 2005). S. aureus 
infection largely impacts orthopaedics, trauma, and cardiology with treatment consisting 
of complex and long-term antibiotic courses (Ibberson et al., 2016).  
In this context, it is necessary to evaluate the biocompatibility of the novel 
heterogeneously BIED-crosslinked HA films developed in Chapter 5.  In the present work 
we anticipate that these gels are adequate for cell growth as they do not contain toxic 
solvents involved in their production in contrary to homogenously crosslinked HA gels. 
Herein, the biological analysis of the heterogeneously crosslinked HA films is assessed. 
Cell viability, cell proliferation, immune activation and antimicrobial activities are 
performed, and the information obtained from these tests are imperative to ensure the 
biocompatibility of these gels.  In the future, these gels can be potentially exploited for a 
number of applications that include wound dressings, skin grafts, catheter coating for 
biofilm inhibition, cell encapsulation, and drug delivery.  
6.2. Materials and Methods 
HA, with an average molecular weight (Mw) of 1.20 MDa and 0.1 MDa, was kindly 
supplied by Shanghai Easier Industrial Development Co. LTD.  (Shanghai, China) as dry 
powder. 3,3’-dithiodipropionic acid, hydrazine monohydrate and sodium nitrite were 
purchased from Lennox Laboratories Supplies (Dublin, Ireland). Enzyme-linked 
immunosorbent assay (ELISA) tests for mouse GM-CSF and human TNFα were 
purchased from BioLegend. 4,6-Diamidino-2-phenylindole (DAPI), and dihydrochloride 
was purchased from ThermoFisher Scientific.  CNFs, methanol, hydrazine monohydrate, 
3,3'-dithiopropionic acid, sodium nitrite, concentrated sulfuric acid, hydrochloric acid, 
acetone, toluene, phosphate buffer saline (PBS), Alamar blue (AB), 
ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA), sodium phosphate 
dibasic dihydrate, Dulbecco’s modified Eagle Medium (DMEM), Roswell Park 
Memorial Institute (RPMI) medium, trypsin-EDTA 0.25%, foetal bovine serum (FBS), 
L-glutamine and antibiotics and all other reagents used in this work were of analytical 
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grade purchased from Sigma Aldrich (St. Louis, MO, USA). L929 fibroblast cell line 
derived from mouse was purchased from the European Collection of Authorized Cell 
Cultures (ECACC 85011425). NIH/3T3 fibroblast cell line derived from mouse (ATCC 
CRL-1658), THP-1 monocyte cell line derived from human (ATCC TIB-202), and 
Staphylococcus aureus (ATCC 29213) were purchased from the American Type Culture 
Collection. 
6.2.2. Heterogenous Crosslinking of HA Films 
The heterogeneous crosslinking of low MW (0.1 MDa) and high MW (1.2 MDa) HA 
films and CNF-reinforced HA films was previously described in section 5.2.3.2. Briefly, 
HA films of (1 cm2) were placed in acetone-water (80:20 by volume respectively) solution 
containing 400 mg.mL-1 of BIED. The crosslinking reaction was allowed to proceed at 
25oC for 72 hours at an acidic environment (pH 3.0). After the reaction, HA films were 
washed with distilled water and dried at room temperature, until further use. Prior to all 
biological tests, these films were sterilized using UV radiation for 1 hour each side within 
an aseptic environment using laminar flow. After sterilization, films were allowed to re-
swell for 30 minutes at 37°C in the incubator using the appropriate cell growth medium. 
6.2.3. Cell Culture 
Fibroblast cells of L929 and NIH/3T3 lineages were cultured in DMEM, while  
monocytes of THP-1 lineage were cultured in RPMI media. Both media types were 
complemented with 10% FBS, 1% streptomycin-penicillin solution and 2 mM of L-
glutamine. Cells were incubated at 37oC with 5% CO2 in a humidified atmosphere and  
medium was replenished every three days until 80% confluency was reached. Cells 
(where otherwise specified) were trypsinized and seeded into the various test conditions. 
6.2.4. In Vitro Cell Viability and Proliferation Assessment 
For the study, NIH/3T3 cells were assessed for viability/proliferation by a resazurin-based 
metabolic activity assay. Due to resazurin redox nature, in which the its oxidized form 
(substrate) contained in the medium is reduced (product) by the various components of 
the cellular respiration chain (when cells are dead, they lose the ability to convert the 
substrate into product), the reduced form of resazurin is proportional to the number of 
viable cells present in the different planes of a 3D microenvironment, being able to 
provide a quantitative analysis of cell viability and, assuming that the metabolic activity 
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maintains constant throughout the testing conditions, quantification of cell proliferation 
is also possible.  
Cells at a concentration of 50.000 cells.mL-1 were seeded onto HA films of 0.1 MDa and 
1.2 MDa, and CNF-reinforced HA films in a 24 well-plate. For the continuous monitoring 
of cell culture overtime, cells were incubated for 1 day, 3 days and 7 days, and then 
resazurin was added to the media at a concentration of 10%. The well plates were returned 
to the incubator and aliquots of the media were taken 20 minutes after resazurin addition 
as specified by the manufacturer. Fluorescence readings of the aliquots were performed 
in a 96 well-plate at the excitation and emission wavelengths of 540 nm and 590 nm, 
respectively, using a SynergyMx plate reader (BioTek, EUA). 
Cells were incubated in growth medium containing CNF at concentrations of 0.25%, 
0.1%, 0.05%, 0.01% and 0.005% (w/v) for 1 day, 3 days and 7 days. Resazurin was added 
as described above. After the incubation period, the fluorescence originated from the 
reduction of resazurin by the cells was read in a microplate reader (SynergyMx, BioTek, 
EUA) at the excitation and emission wavelengths of 535 nm and 615 nm, respectively. 
6.2.3.3. In Vitro Cell Attachment Analysis 
L929 cells, at a concentration of 50.000 cells.mL-1, were seeded onto HA 1.2 MDa and 
0.1 MDa crosslinked films for 24 hours and 48 hours. Cell nucleus was stained using 
DAPI. Cell fluorescence imaging was captured using cellSens software and the BX60 
fluorescence microscope (Olympus, Japan). 
Cell attachment analysis of NIH/3T3 cells in cell medium containing different 
concentrations of CNF (0.25%, 0.1%, 0.05%, 0.01% and 0.005% (w/v)) was assessed by 
optical microscopy at 1 day, 3 days and 7 days of incubation using a CKX41 Olympus 
inverted microscope (Tokyo, Japan) equipped with a DFK 31AU03 camera (The Imaging 
Source Europe GmbH, Germany) and IC Capture software (The Imaging Source Europe 
GmbH, Germany). For this test, NIH/3T3 cells, at a concentration of 50.000 cells.mL-1, 
were seeded in 24 well-plates. 
6.2.4. In Vitro Cytokine Quantification 
For the immune activation analysis, L929 fibroblast cells at a density of 50,000 cell.mL-
1 were seeded onto crosslinked films of HA 1.2 MDa and 0.1 MDa for 24, 48 and 72 
hours. After the incubation period, supernatant was collected by centrifugations and 
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analysed for the production of GM-CSF, a cytokine that induce macrophage 
differentiation as part of the immune response chain, using an ELISA kit as described by 
the manufacturer (BioLegend). THP-1 cells at a density of 50,000 cell.mL-1 were seeded 
onto HA 1.2 MDa crosslinked films for 24 hours, with or without lipopolysaccharide 
(LPS) stimulation challenge (1:1000). After the incubation period, supernatant was 
collected by centrifugation and analysed for the production of TNF-alpha, a pro-
inflammatory cytokine as described by the ELISA kit manufacturer (BioLegend). 
Briefly, a 96-well plate was incubated with the respective capture antibody (mouse GM-
CSF or human TNFα) overnight at 4°C. On the following day, the 96-well plate was 
washed with a washing buffer (PBS 1X + 0.05% Tween 20) for four times and residual 
buffer was blotted by firmly tapping the plate upside down on absorbent paper. All 
subsequent washes were performed similarly. Next, the 96-well plate was blocked for 
non-specific binding using the assay diluent and incubated at RT for one hour using a 
microplate shaker. While the plate was being blocked, the experimental samples and 
mouse GM-CSF or human TNFα standard solutions were prepared. Prior to their 
incubation, the 96-well plate was washed. The experimental samples and standard 
solutions were incubated for 2.5 hours at RT. Next, the plate was washed, and the 
detection antibody (mouse GM-CSF or human TNFα) was added to each well and 
incubated for an additional 1 hour at RT. After four wash cycles, avidin- horseradish 
peroxidase was added to the wells and incubated for 30 minutes at RT. After four washes, 
bound antibody complexes were developed using a freshly made tetramethylbenzidine 
(TMB) solution. TMB solution was incubated for 15 minutes at RT and protected from 
light. After that, a stop solution (1M H2SO4) was added to the wells to stop the developing 
reaction. Absorbance was measured at 450 and 570 nm using a SynergyMx plate reader 
(BioTek, EUA). 
6.2.5. In vitro Antimicrobial Study 
S. aureus was cultured in Luria Bertani (LB) Broth to monitor the growth kinetics by 
spectrophotometry. 10 g of LB broth was dissolved in a bottle containing 500 mL distilled 
water (according to manufacturer's specification) and sterilized via autoclaving. Then 5 
mL of the sterilized LB Broth was poured into a set of sterile tubes and inoculated with 
inocula from sub-cultured strains of S. aureus. The vacuum dried non-crosslinked and 
crosslinked HA and HA-CNF films were sterilized via UV radiation for 1 hour prior to 
addition into the inoculated tubes and placed in the incubator at 37oC to allow the 
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microorganisms to grow. Aliquots of 200 μL of the cultured media from each sample was 
added into cuvettes pre-filled with 800 μL of fresh medium, and the optical density 
(OD600) of each sample was recorded every hour for 4 hours.  
Mean growth rate (MGR) was obtained as the slope of the linear region after plotting the 
ln OD x time for each sample, and the mean relative growth index (MRGI) was calculated 





Where the MGR of S. aureus only is the control. 
6.2.6. Statistical Analysis 
Data are presented as mean ± standard deviation (s.d.) and analysed using one-way 
analysis of variance (ANOVA) followed by post-hoc Tukey’s HSD test. P-values < 0.05 
(*) were considered significant. 
6.3. Results and Discussion 
6.3.1. Biocompatibility 
Previously in this study, HA was homogeneously crosslinked with BIED using DMSO as 
the solvent for the system reaction. This condition might not pose any constraint for the 
encapsulation of drugs, as drugs are normally hydrophobic, but for cellular applications, 
gels need to be free of organic solvents such as DMSO. In this instance, HA films were 
heterogeneously crosslinked with BIED via diffusion. These gels were easily dried, and 
solvents evaporated, which is a preferred method for cell seeding and analysis of 
biocompatibility. 
As some isocyanates are shown to be cytotoxic, the evaluation of cytotoxicity of gels 
crosslinked with of isocyanates is imperative.  In the literature, other materials such as 
PVA, PEG and agar were crosslinked with other isocyanates and showed no cytotoxic 
effects (Teramura et al., 2007, Qian et al., 2015, Xu et al., 2015c, Xu et al., 2015d, Sonker 
et al., 2018b). In recent years, different isocyanates were used to crosslink HA. For 
example, modified star-shaped poly(ethylene oxide-stat-propylene oxide) carrying 
reactive isocyanate functional groups at the distal ends of the arms and modified 
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polycaprolactone and polylactide acid bearing isocyanates were able to react with HA but 
no cytotoxicity evaluations were performed (Dhanasingh et al., 2010, Chen et al., 2010). 
The incorporation of CNFs in HA hydrogel formulations allows the possibility to obtain 
very tough and electrically conductive hydrogels. However, there is a concern about the 
toxic effects of  carbon nanotubes (CNTs) and, therefore, hydrogel biocompatibility. 
Studies have reported that CNF toxicity seems to be dose‐dependent, but cytotoxicity 
could be reduced when CNFs are functionalized and/or incorporated in hydrogel 
networks (Mihajlovic et al., 2019). For this reason, a dose-dependent assessment of 
NIH/3T3 cell viability after exposure to cell medium solutions containing different 
concentrations of CNF was performed. In Figure 6.1A, all testing conditions show 
increased proliferation over time. Interestingly, the group with higher CNF concentration 
(0.25% w/v) showed a similar proliferation profile to the control group.  
The proliferation of NIH/3T3 fibroblasts on different HA films is shown in Figure 7b. 
Overall, all samples increased proliferation over time. The reinforcement of HA films by 
the addition of CNF does not show negative effects on cell proliferation, which is 
supported by other publications (Steel et al., 2020, Bhattacharyya et al., 2008). However, 
it is observed that crosslinked films displayed a smaller increase in proliferation than their 
non-crosslinked counterparts. CNF and CNT  have been shown to increase adhesion of 








Figure 6.1.  a) Cell viability of NIH/3T3 fibroblasts exposed to different concentrations 
of CNF suspended in cell culture medium using resazurin-based assay b) Continuous 
cell proliferation assessment of NIH/3T3 fibroblasts on different HA films with or 
without CNF reinforcement using resazurin-based assay. Not crosslinked (NC); 
Crosslinked (C).  
Optical micrographs of the cell attachment to different substrates are shown in Figure 6.2. 
Interestingly, cell attachment does not seem to differ when CNF content in the cell culture 
medium is increased. For HA crosslinked films, it is observed that cells attach to the 
surface of the films independently of HA MW. This could be explained due to cell-
mediated interactions via CD44 and RHAMM cell surface receptors on NIH/3T3 cells 
with HA crosslinked films (Zamboni et al., 2017). CNF-reinforced HA crosslinked films 






Figure 6.2. Cell attachment of NIH/3T3 cells after 7 days incubation on different 
substrates. A) Control; B) 0.005% CNF suspended in cell culture medium; C) 0.01% 
CNF suspended in cell culture medium; D) 0.05% CNF suspended in cell culture 
medium; E) 0.1% CNF suspended in cell culture medium; F) 0.25% CNF suspended in 
cell culture medium; G) 0.1 MDa HA crosslinked films; and H) 1.2 MDa HA 
crosslinked films. Arrows show: Cell attached to the well (#), cell attached to the 
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surface of the HA film ( ), and CNF precipitate (*). Magnification 400X. Scale bar: 50 
µm. 
6.3.2. Immunomodulatory Analysis 
For tissue engineering applications, it is also worth to analyse the response of the immune 
system to novel materials. In the literature, HA is said to be a material capable to modulate 
the immune system (Zamboni et al., 2018b). In Figure 6.3A and B, fibroblast activation 
was assessed by the quantification of cytokine production. Fibroblasts secrete GM-CSF, 
a cytokine that induce macrophage differentiation as part of the immune response chain. 
Figure 6.4 shows cells stained with fluorescent DAPI at 24 and 48 hours after being 
seeded onto crosslinked HA films. It can be noticed that the number of cells increase 
overtime. 
Fibroblasts are present in all tissues but predominantly in connective tissues and are 
important producers and regulators of the ECM components. Moreover, fibroblasts also 
act as sentinels that elicit immunological responses by aiding the immune system. In 
Brief, fibroblasts act as sentinels to produce inflammatory mediators in response to 
several pathogens. Fibroblasts can express TLRs to sense microbial components and 
respond accordingly by synthesizing molecules that perform antimicrobial activity. Also, 
they can produce proinflammatory cytokines and chemokines to induce and recruit 
inflammatory cells (Bautista-Hernandez et al., 2017).  
For this reason, this study decided to analyse the activation of fibroblasts and the 
production of GM-CSF, as it plays an important role in immune responses, survival, 
cancer pathogenesis, proliferation of macrophages, erythrocytes, eosinophils, 
megakaryocytes, and multipotent progenitors. The expression of GM-CSF is associated 
with inflammatory diseases, such as rheumatoid arthritis (Hamilton et al., 1992). 
Additionally,  fibroblasts are well known to highly express CD44, which are receptors for 
HA (Quintanilla et al., 2014). Previous studies, were able to demonstrate that HA mediate 
GM-CSF mRNA expression and protein secretion via CD44 receptors on eosinophiles 
(Ohkawara et al., 2000). To date, there is no literature that has analysed the influence of 




CNF are also shown to decrease the production of nitric oxide and pro-inflammatory 
cytokines by macrophages (Khang, 2015). This auger well for the films produced in this 
study and their ability to potentially mitigate inflammatory reactions, especially when 
targeting wound healing and skin derivate applications.  
Results show that GM-CSF production is concentration-dependent of CNF dispersed in 
the cell medium (Figure 6.3a). Solutions of CNF at 0.005% do not show increase GM-
CSF production by L929 fibroblasts in comparison to the control group. Moreover, all 
HA films, independently of MW and CNF-reinforcement, show comparable GM-CSF 

















































































































































Figure 6.3. Modulation of L929 activation and production of GM-CSF through CNF 
content (a) and different HA films (b). Statistical analysis was performed using 
ANOVA followed by post-hoc Tukey’s HSD test where p-value < 0.05 shows statistical 




Figure 6.4. L929 cells fluorescently stained using DAPI. Cell attachment on the surface 
of 0.1 MDa and 1.2 MDa HA films crosslinked with BIED at 24 and 48 hours after 
incubation. Magnification 100X. Scale bar: 100 µm. 





























Figure 6.5. THP-1 monocyte activation and production of TNFα at 24 hours after 
incubation with HA 1.2 MDa. Statistical analysis was performed using ANOVA 
followed by post-hoc Tukey’s HSD test where p-value < 0.05 shows statistical 
difference (*). 
Further along the immunological response chain, monocytes are next in line. Within the 
first days of inflammation (acute), TNFα production in monocytes is observed during the 
first 24 hours. Once monocytes are activated, they differentiate into macrophages that can 
be further polarized into the M1 subset (pro-inflammatory) within 1-3 days or into the 
M2 subset (pro-healing and angiogenic) within 3-9 days (Yang et al., 2014). 
Figure 6.5 shows the influence of HMW HA on the activation of monocytes to produce 
TNFα. It can be seen that no significant increase in TNFα secretion is observed for all 
test groups in comparison to the control group (well plate). Neither non-crosslinked nor 
BIED-crosslinked HA elicited TNFα production. Once monocytes are challenged with 
LPS, a significant (p<0.05) spike in TNFα is observed in all groups, however, BIED-
crosslinked HMW HA shows to protect monocytes from LPS-induced TNFα production. 
Previous studies have already established that HMW HA has the ability to suppress 
inflammation due to LPS exposure in macrophages (Rayahin et al., 2015). 
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Interestingly, these results are able to give an insight on the modulation of the immune 
system by HA and HA crosslinked with isocyanates such as BIED. Going forward, there 
is a demand to continue to further study more complex approaches to elucidate the 
mechanism of immune modulation of these cells by HA. For the moment, these results 
can only give a hint of HA-BIED crosslinked immunomodulatory capacity and 
speculation of its applications. For example, cellular grafts of LMW HA-BIED 
crosslinked show decreased fibroblast production of GM-CSF, thus these grafts could be 
potentially transplanted into any tissues abundant of fibroblasts. On the other hand, 
cellular grafts of HMW HA-BIED crosslinked show no monocyte activation and TNFα 
production, even, slightly protecting LPS induction, thus being potentially transplanted 
in tissues with direct blood contact. 
6.3.3. Antimicrobial Activity 
The non-crosslinked and crosslinked HA and HA-CNF films show antimicrobial activity 
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Figure 6.6. Mean growth rate of S. aureus for each HA hydrogel formulation.  SA is the 
control group containing only S. aureus in LB broth. Statistical analysis was performed 
using ANOVA followed by post-hoc Tukey’s HSD test where p-value < 0.05 shows 
statistical difference between groups (#) and within groups (*). 
When comparing the MGR between the control (SA) group and the HA samples from 
both MWs tested, it shows that all crosslinked samples significantly decrease MGR 
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(p<0.05), thus having a higher bacteriostatic activity. The decrease of MGR for 
crosslinked samples is not associated with the crosslinker itself. The MGR of S. aureus 
cultured in LB broth containing only BIED at the same concentration used to crosslink 
HA films is 0.0202 (p>0.05). Both 1.2 MDa and 0.1 MDa HA (N) films do not show 
bacteriostatic activity (p>0.05).  
The bacteriostatic effect between low and high MW HA groups, shows that 1.2 MDa HA 
samples [HA (C) and HA-CNF (N)] present significant higher bacteriostatic effects than 
their low MW counterparts (p<0.05). Pointing out the highest decrease in MGR is related 
to crosslinked 1.2 MDa HA films (0.016 ± 0.00055). S. aureus produces hyaluronidase 
(a.k.a. hyaluronate lyases) encoded in the hysA gene, which cleaves the β-1,4 glycosidic 
bond of HA by β-elimination in a processive manner. This results in unsaturated 
disaccharides as the final product of complete digestion. It has been hypothesized that the 
bacteriostatic effect of HA is due to the saturation of the bacterial hyaluronidase owing 
to the excess of HA. This prevents the bacteria from proliferating, secondary to elevated 
levels of ECM component, which needs to be digested in turn affecting tissue 
permeability (Carlson et al., 2004). The increased bacteriostatic effect observed in the 
crosslinked HMW HA shows the dependency of the hyaluronate lyase to degrade the 
HMW HA network into small fragments, which is less evident for LMW HA. The 
addition of CNF to the HMW HA crosslinked network can decrease the number of 
interactions between HA and the bacteria, this compromises the digestion of HA through 
bacterial hyaluronate lyases, therefore reducing the bacteriostatic effect. 
In table 6.1, the comparison between the mean growth indexes and mean doubling time 
are shown. The antibacterial findings of this research are in agreement with the earlier 
study of Pirnazar et al. This showed that the three different MW formulations of 
recombinant HA used in their experiment exhibited varied bacteriostatic effects on S. 
aureus depending on the MW and concentration of HA (Pirnazar et al., 1999).  




Mean Relative Growth 
Index 
Mean Doubling Time 
(minutes) 
 Control 100% 32.4 














HA (N) 99.1% 33.3 








6.4. Final Considerations 
Crosslinking HA films with BIED produced a gel-like biomaterial whose mechanical 
properties and functionality makes it suitable for various biomedical applications. More 
so, experimental tests revealed that the addition of CNFs (0.25 wt.%) to HA films 
significantly improved the film mechanical property and demonstrated no harmful 
cytotoxic effects. 
Moreover, these films are able to modulate cells from the immune system. HA films did 
not elicit fibroblast activation through the evaluation of GM-CSF production.  GM-CSF 
content in cell culture supernatant of various HA films tested was similar to the control 
group. Regarding the modulation of monocytes, HMW HA films were unable to activate 
these cells showing an anti-inflammatory effect, where the release of TNF-α (pro-
inflammatory cytokine) from monocytes in culture with HMW HA films was absent.  
Furthermore, the study of the antimicrobial activity of these films revealed that they 
possess bacteriostatic properties against S. aureus, where crosslinked HA-CNF films 
exhibited the highest antibacterial effect without any bactericidal effect. 
In conclusion, the combined benefits of mechanical properties, together with fibroblast 
proliferation, immunomodulation and bacteriostatic activity of HA films crosslinked 
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Abstract 
Surface engineering the plasma membrane of cells creates tailored sites with specific 
functions that include anchorage sites for biomolecules, cell-tagging fluorophores, and 
cell encapsulation. Protein-anchorage or physical adsorption of fatty acid into the lipid 
bilayer are two of many approaches that have been developed to create these plasma 
membrane modifications. Herein, the plasma membrane of pancreatic β cells is 
engineered using Maleimide-PEG-Lipid (Mal-PEG-Lipid).  Firstly, Mal-PEG-Lipid is 
synthesized by the reaction between maleimide-PEG-NHS and dipalmitoyl-glycerol-
phosphatidyl ethanolamine (lipid) which has been confirmed by FT-IR analysis. Three 
different concentrations of Mal-PEG-Lipids (50, 250 and 500 µg.mL-1) and two 
incubation times (30 minutes and 1 hour) were analysed for the optimization of single 
cell surface modification. Characterization of cell viability through live/dead assay, 
plasma membrane disruption through Annexin V assay, and Mal-PEG-Lipid membrane 
uptake and release were performed. Results show that cell viability analysed by 
calcein/propidium iodide staining does not significantly differ in all concentrations and 
incubation times tested. Plasma membrane disruption shows higher Annexin V binding 
to Mal-PEG-Lipid at 500 µg.mL-1 for 1 hour, which correlates to higher Mal-PEG-Lipid 
uptake by the plasma membrane (confirmed by the fluorescence analysis of cells 
incubated with FITC-tagged Mal-PEG-Lipid). The stability of the Mal-PEG-Lipid at the 
plasma membrane shows that for all concentrations and incubation periods analysed, Mal-
PEG-Lipid release to the cell medium did not increase over time, suggesting that 
palmitoyl hydrophobic insertion to the plasma membrane is stable. These results show 
that optimal Mal-PEG-Lipid surface engineering (500 µg.mL-1 for 30 minutes) of the 
plasma membrane can provide anchorage-sites to a variety of molecules as the maleimide 




The transplantation of pancreatic β cells, pancreatic islets and whole pancreas has 
effectively improved the quality of life of end-stage renal failure type 1 diabetic patients 
(Light and Tucker, 2013). However, graft issues remain to be resolved in terms of 
improving graft survival, managing innate and adaptive immune responses, and 
decreasing life-long immunosuppressant drug therapy (Teramura et al., 2020). To 
enhance the function and improve the efficacy of cell-based therapeutics, a variety of cell 
surface engineering strategies have been developed to modify the surface of cells.  A 
variety of materials have been studied which include therapeutic molecules, artificial 
receptors, and multifunctional nanomaterials (Abbina et al., 2017). Surface modification 
has the potential to create cell membrane synthetic sites mimicking surface receptors and 
proteins for the anchorage of specific biomolecules, cell-tagging fluorophores, and cell 
encapsulation coatings. The latter is particularly interesting in applications that envisage 
to hide the cell surface when exposed to immunological surveillance especially important 
in transplantation therapy. 
Surface modification of the cellular plasma membrane can be achieved through chemical 
covalent conjugation and noncovalent physical bioconjugation. Noncovalent 
bioconjugation can be achieved through biotinylation, electrostatic interaction and lipid 
membrane fusion (Liu et al., 2019a). In vitro studies using biotin/streptavidin linker 
(biotinylation) are not appropriate for clinical applications. Xenogeneic proteins such as 
avidin and streptavidin are highly immunogenic in vivo. A less immunogenic alternative 
to biotinylation is PEG-maleimide, commonly referred to as PEGylation (Wang et al., 
2015a). A study in 2016 reported that PEG molecular weight influences the 
immobilization and cellular uptake of bio-functional molecules. Low molecular weight 
PEG (1 kDa) was unable to prevent protein adsorption in contrast to 5 kDa PEG. 
Interestingly, high molecular weight PEG (40 kDa) was also unable to prevent protein 
adsorption and this was attributed to strong static repulsion of chains making them 
difficult to pack at high densities (Teramura et al., 2016). 
In noncovalent bioconjugation, the selection of an appropriate fatty acid for lipid 
membrane fusion is based on three main variables: size of the hydrocarbon chain, 
saturation of hydrocarbon chain and the number of hydrocarbon chains. In the literature, 
using two long fatty acid chains to surface engineer the cell membrane has been described 
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to increase the anchorage and decrease the dissociation rates from the cell surface (Itagaki 
et al., 2015).  
Herein, the plasma membrane of pancreatic β cells is engineered using Maleimide-PEG-
conjugated with two palmitoyl fatty acid chains (Mal-PEG-Lipid). Mal-PEG-Lipid is an 
amphiphilic molecule designed to resemble a phospholipid, where the Mal-PEG portion 
is hydrophilic, and the lipid portion is hydrophobic. Mal-PEG-lipids are inserted in the 
cell membrane by lipophilic interactions. In vitro cell surface engineering of pancreatic 
β cells (MIN-6 line) is assessed for biocompatibility, membrane disruption and stability 







7.2. Materials and Methods 
7.2.1. Materials 
Maleimido propionyl-polyethylene glycol-n-hydroxysuccinimide ester (Mal-PEG-NHS), 
dipalmitoyl-glycerol-phosphatidyl ethanolamine (DPPE), FITC, L-cysteine, Live/Dead 
Viability/Cytotoxicity assay, were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Annexin V-Alexa Fluor 568 was purchased from BD Life sciences (Berkshire, England, 
UK). All other consumables necessary for cell culture including cell culture medium, 
pipettes, flasks and plates were purchased from Thermofisher. Pancreatic MIN-6 cells 
were kindly donated by Dr. Joaquim Miguel Oliveira from the I3Bs Research Group at 
the University of Minho, Portugal. 
7.2.2. Production of Mal-PEG-Lipids 
Mal-PEG-NHS 50 mg is dissolved in chloroform together with 5 mg of DPPE to react 
under stirring for 24 hours at RT. The Mal-PEG-Lipid product is purified by precipitation 
in diethyl ether. Chemical characterization of Mal-PEG-Lipids was performed using FT-
IR spectroscopy. All spectra were recorded on a Perkin Elmer spectrum 100 FT-IR 
spectrometer operating in Attenuated Total Reflectance (ATR) mode (Perkin Elmer, MA, 
USA). Each FT-IR spectrum was scanned twenty times with a resolution of 2 cm–1. The 
ranges used were from 4000 cm–1 to 650 cm–1. 
Mal-PEG-lipids were labelled with FITC.  Firstly, Mal-PEG-Lipid (25 mg) reacts with 
cysteine (0.6 mg) dissolved in a solution of acetone and ethanol (1:1) at a pH 6.5, 
overnight. The pH<7 favours the reaction between the maleimide and the thiol group of 
cysteine to form a thioether bond over the reaction of maleimide and the primary amine 
of cysteine. The Cys-Mal-PEG-Lipid product is purified by precipitation in diethyl ether. 
Then, Cys-Mal-PEG-Lipid reacts with 4 mg of FITC dissolved in acetone overnight. 
pH>5 is required for the amino group of cysteine to react with isothiocyanate to form a 





7.2.3. MIN-6 Culture 
A cell number of 1x107 cells were cultured in T75 flasks using high glucose DMEM, 
supplemented with 10% FBS, 1 % antibiotic/antimycotic, 10 mM sodium pyruvate and 
50 µM β-mercaptoethanol. Cell media was replenished every 3 days until cell confluency 
was reached. MIN-6 cells at 30-40 passages were used. 
7.2.4. Cell Surface Modification 
MIN-6 cells at a density of 1x106cells.mL-1 were incubated with Mal-PEG-Lipid in three 
concentrations (50, 250 and 500 µg.mL-1) for two treatment times (0.5 and 1 hour). Right 
after Mal-PEG-Lipid incubation, cell viability was assessed using Live/Dead 
Viability/Cytotoxicity assay (calcein AM at 2 µM, ethidium homodimer-1 at 4 µM) and 
visualized using fluorescence microscopy. 
7.2.5. Cell Surface Modification Stability 
The stability of the surface modification was assessed using FITC-tagged Mal-PEG-
Lipid. Cells were incubated with FITC-tagged Mal-PEG-Lipid as described above. After 
the incubation period, 45,000 cells were seeded in 24 well-plates. Over time, FITC-tagged 
Mal-PEG-Lipid can be released from the cell membrane to the medium, demonstrating a 
decrease in stability. The fluorescence intensity of free FITC-tagged Mal-PEG-Lipid 
released to the media at 0, 3 and 24 hours was measured in a 96-well plate by a plate 
reader with an emission of 570 nm and excitation of 490 nm. The release of FITC-tagged 
Mal-PEG-Lipid from the plasma membrane was also assessed by cell attachment to the 
well-plate at different time points (0, 3 and 24 hours) using a brightfield microscope. 
7.2.6. Surface Integrity Evaluation 
After surface modification of MIN-6 cells using Mal-PEG-Lipid, surface integrity of the 
plasma membrane was evaluated using Annexin V-Alexa Fluor 568. Negative control 
cells, positive apoptotic control cells (induced by heat-shock at 70°C for 5 minutes), and 
surface modified cells are incubated at a density of 1x106 cells.mL-1 in annexin-binding 
buffer (10 mM HEPES, 140 mM NaCl and 2.5 mM CaCl2, pH 7.4).  After, Annexin V-
Alexa Fluor 568 (25 µg.mL-1), sytox green (2 µg.mL-1) are added to the cell suspension 
and incubated for 15 minutes at RT. After incubation, cells are washed with annexin-
binding buffer. The combination of nuclear staining using sytox green distinguishes 
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necrotic (nuclear staining) from apoptotic cells. Cells were visualized using ImageXpress 
Micro Confocal and MetaXpress software (Molecular Devices, CA, USA). 
7.2.7. Statistical Analysis 
Data are presented as mean ± standard deviation (S.D.) and analysed using one-way 
analysis of variance (ANOVA) followed by post-hoc Tukey’s HSD test. P-values < 0.05 






7.3. Results and Discussion 
7.3.1. Mal-PEG-Lipid Synthesis  
Mal-PEG-NHS reacts with DPPE through a nucleophilic substitution reaction that occurs 
between the NHS and the primary amine from the ethanolamine. The primary amine is 
deprotonated and acts as a nucleophile (Figure 7.1).  
 
Figure 7.1. Reaction of MAL-PEG-NHS and DPPE. The nucleophilic substitution 
reaction occurs between the NHS and the primary amine from the ethanolamine forming 
MAL-PEG-Lipid. 
DPPE is preferred for the synthesis of Mal-PEG-Lipid because it contains two chains of 
palmitoyl. Palmitoyl lipids have a saturated long fat acid chain (C16) that occurs naturally 
in the cell membrane (Freedman, 2012). It is also an important site for protein anchorage 
via protein palmitoylation (Guan and Fierke, 2011). The confirmatory FT-IR spectra of 
Mal-PEG-Lipid bond is shown in Figure 7.2. Mal-PEG-NHS spectrum shows 
characteristic NHS bands at around 1808, 1781, 1739 cm-1 and the ether band from PEG 
at 1109 cm-1 (Peng et al., 2010). Whereas DPPE shows characteristic primary amine 
stretch band at around 3600 cm-1 and NH bend band at around 1700 cm-1. Upon the 
reaction between the primary amine of the ethanolamine from DPPE and the NHS group 
of Mal-PEG-NHS, a new band at around 1686 cm-1 appears, which is related to weak 






















Figure 7.2. Chemical characterisation of Mal-PEG-Lipid through FT-IR Spectroscopy. 
7.3.2. Cell Surface Modification 
MIN-6 cells had their plasma membrane modified using a Mal-PEG-Lipid. After the 
surface modification, cell viability was assessed using Live/Dead assay (Figure 7.3). Cell 
viability was not affected by surface modification using the various concentrations and 
incubation times (Figure 7.4). Although cell surface modification is not accompanied by 
cell death, it is possible that plasma membrane can be potentially disrupted after surface 
engineering which can lead to an early apoptotic state.  Plasma membrane disruption 
evaluation was performed using Annexin V. When plasma membrane disruption occurs, 
phosphatidylserine (only found in the inner leaflet of the plasma membrane) is 
externalized to the outer membrane and binds to Annexin V, demonstrating an early 
apoptotic state. The results shown in Figure 7.5 demonstrates that surface engineering the 
plasma membrane of MIN-6 cells with 50, 250, and 500 µg.mL-1 of Mal-PEG-Lipids for 
30 minutes or 1 hour does not disrupt the plasma membrane. The number of cells stained 
with Annexin V is comparable to the control group. Positive necrotic cells (Figure 7.5b) 
shows colocalization of fluorescence staining marked by sytox green (nucleus) and 






Figure 7.3. Cell viability by Live/Dead assay of surface modification using Mal-PEG-
Lipids after incubation for 30 minutes at concentrations 50, 250 and 500 µg.mL-1 (C,E 
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and G respectively) and 1 hour at concentrations 50, 250 and 500 µg.mL-1 (D, F and H 
respectively). A and B are control cells with no surface modification. 
 






















Figure 7.4. Viability of MIN-6 cells after surface modification using Mal-PEG-Lipid for 
30 minutes and 1 hour at concentrations 50, 250 and 500 µg.mL-1. Statistical analysis 
was performed using ANOVA followed by post-hoc Tukey’s HSD test where p-value ≥ 






Figure 7.5. Plasma membrane disruption and early apoptosis assay using Annexin V 
after MIN-6 surface modification with Mal-PEG-Lipid. A) Control; B) Control dead 
cells; C) 50 µg.mL-1 for 30 minutes; D) 50 µg.mL-1 for 1 hour; E) 250 µg.mL-1 for 30 
minutes; F) 250 µg.mL-1 for 1 hour; G) 500 µL µg.mL-1 for 30 minutes; and H) 500 
µg.mL-1 for 1 hour. Magnification 4X. 
7.3.3. Plasma Membrane Uptake of FITC-tagged Mal-PEG-Lipids 
To show the incorporation of Mal-PEG-Lipids to the plasma membrane of MIN-6 cells, 
Mal-PEG-lipids were fluorescently tagged using FITC (Figure 7.6 and 7.7). All groups 
demonstrated homogenous fluorescence throughout their plasma membrane, which 
indicates that cell modification occurred evenly. In the control group, cell morphology is 
shown to be rounded and unattached to the culture plate at time 0, however after 24 hours 
cells start to attach to the bottom of the well plate and display elongated morphology. All 
groups incubated with FITC-tagged Mal-PEG-Lipid show rounded morphology and were 




Figure 7.6. Surface modification of MIN-6 cells just after incubation with FITC-tagged 
Mal-PEG-Lipid for 30 minutes at 50, 250 and 500 µg.mL-1 (C, E and G, respectively) 
and at 24 hours after incubation with FITC-tagged Mal-PEG-Lipid for 30 minutes at 50, 
250 and 500 µg.mL-1  (D, F and H, respectively). A and B are control cells with no 







Figure 7.7. Surface modification of MIN-6 cells just after incubation with FITC-tagged 
Mal-PEG-Lipid for 1 hour at 50, 250 and 500 µg.mL-1 (C, E and G, respectively) and at 
24 hours after incubation with FITC-tagged Mal-PEG-Lipid for 1 hour at 50, 250 and 
500 µg.mL-1 (D, F and H, respectively). A and B are control cells with no surface 
modification at 0 and 24 hours, respectively. 
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7.3.4. Stability of FITC-tagged Mal-PEG-Lipid in the Plasma Membrane of MIN-6 
Cells 
The plasma membrane is a dynamic structure, where its components are in constant 
turnover. For this reason, the effect of incubation time and concentration on the stability 
of Mal-PEG-Lipid on the cell membrane of MIN-6 cells was evaluated by the release of 
FITC-tagged Mal-PEG-Lipid from the plasma membrane to the cell medium (Figure 7.8). 
In the first 24 hours after cell surface modification, there was no significant release of 
FITC-tagged Mal-PEG-Lipid over time for all groups. However, a trend can be observed 
from cells incubated with the lowest concentration (50 µg.mL-1) of FITC-tagged Mal-
PEG-Lipid that release of FITC-tagged Mal-PEG-Lipid is slightly higher for cells 
incubated for 30 minutes in comparison to cells incubated for 1 hour. 
In the literature, structural differences in fatty acid chains influence the hydrophobic 
interactions within the cell membrane. A study comparing PEG-lipids carrying different 
fatty acid chains showed that as the chain becomes longer, an increase in anchorage and 
a decrease in the dissociation rates from the cell surface is observed. Moreover, PEG-
lipids containing double fatty acid chains showed better anchorage and dissociation rates 
than PEG-lipids containing single chains. Regarding the degree of unsaturation, it was 
observed that unsaturated fatty acids on the cell surface are more stable than saturated 
fatty acids with the same alkyl chain length (Itagaki et al., 2015). This highlights that 
long-lasting cell surface engineering is still a significant challenge. Other factors 
contributing to the lifespan of surface engineered cells include: the dynamic nature of the 
plasma membrane by continuous lipid and protein internalization and degradation to be 
later resynthesized by de novo synthesis  (Stephan and Irvine, 2011). Also, when 
pancreatic β cells are exposed to increasing concentrations of palmitic acid, these lipids 
are incorporated in the plasma membrane, and this triggers the activation of cell functions 
and various biosynthesis routes such as for ceramide, phospholipid, sphingolipid 
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Figure 7.8. The effect of incubation time and concentration on the stability of FITC-
tagged Mal-PEG-Lipid on the cell membrane of MIN-6 cells evaluated by the release of 
FITC-tagged Mal-PEG-Lipid to cell medium. Statistical analysis was performed using 
ANOVA followed by post-hoc Tukey’s HSD test where p-value < 0.05 shows statistical 
difference (*). 
When analysing the fluorescence intensity of MIN-6 cells after incubation with FITC-
tagged Mal-PEG-Lipid at 50, 250 and 500 µg.mL-1 for 30 minutes and 1 hour (Figure 
7.9). It can be seen that immediately after incubation of FITC-tagged Mal-PEG-Lipid, the 
higher the concentration of FITC-tagged Mal-PEG-Lipid used, the higher is the cellular 
uptake shown by the higher fluorescence intensity. When the time of incubation is 
compared, increasing the incubation period from 30 minutes to 1 hour shows that 
fluorescence intensity also increases related to higher cellular uptake. The practical 
significance of these results leads to the surface engineering optimization of the plasma 
membrane of MIN-6 cells, where a balance between concentration and incubation time 
(500 µg.mL-1 for 30 minutes) demonstrates high cell surface uptake, minimal surface 
damage, and higher stability. This is particularly important for the L-b-L and conformal 
coatings, where the Mal-PEG-Lipids serve as anchorage-sites to a variety of molecules 
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as the maleimide moiety reacts with primary amines and thiol groups to create stable 







































Figure 7.9. Fluorescence intensity of MIN-6 cells after incubation with FITC-tagged 
Mal-PEG-Lipid at 50, 250 and 500 µg.mL-1 per 1x106 cells for 30 minutes and 1 hour. 
Statistical analysis was performed using ANOVA followed by post-hoc Tukey’s HSD 




7.4. Final Considerations 
The surface modification of single cells was successfully performed through the insertion 
Mal-PEG-Lipid into the plasma membrane of MIN-6 cells. The results showed that Mal-
PEG-Lipid did not induce cell toxicity.  Moreover, little plasma membrane disruption was 
observed by the Annexin V assay. The stability of the Mal-PEG-Lipid also showed that 
two chains of palmitoyl fatty acids attached to Mal-PEG-NHS improved the molecule 
insertion to the plasma membrane where release of the molecule from the cell surface to 
the medium was not observed. For future work, the optimal Mal-PEG-Lipid concentration 
and incubation time for surface engineering was selected as 500 µg.mL-1 for 30 minutes.  
Overall, surface engineering the plasma membrane of cells with Mal-PEG-Lipids can 
provide anchorage-sites to a variety of molecules that contain primary amines and thiol 
groups into their structure, as maleimide moiety reacts with these groups to create stable 
conjugates. This is particularly interesting for the development of L-b-L coatings, which 
will be further discussed in chapter 8. 
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Chapter 8: In Vitro 
Conformal Multilayer 
Encapsulation of 
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In the previous chapter, it has been shown that the plasma membrane of pancreatic β cells 
can be engineered using Mal-PEG-Lipid at a concentration of 500 µg.mL-1 for 30 
minutes. Earlier it has also been shown that HA with 0.1 and 1.2 MDa molecular weights 
can be modified to produce derivates carrying free thiol (HA-SH) and pyridine groups 
(HA-PD). Here, cell encapsulation is carried out by the successive deposition of HA-SH 
and HA-PD derivates onto the surface of the modified pancreatic β cells, where Mal-
PEG-Lipid serves as an anchorage site in the plasma membrane for the HA layers as 
described in the previous chapter. Each HA layer is crosslinked with the next layer via a 
bimolecular nucleophilic substitution (SN2) reaction until forming a 2, 6, and 10-layered 
coatings. The inner layers of the coating contained LMW HA derivates with higher 
degrees of substitution to produce membranes with smaller mesh sizes, while the outer 
layers used HMW HA derivates to induce anti-inflammatory responses. In vitro 
characterization of the cell encapsulation coating was assessed regarding stability, 
cytocompatibility, glucose challenge and insulin release. Results showed cell 
encapsulation does not hamper pancreatic β cell viability. Moreover, results show that the 
10-layered cell coating is permeable to the diffusion of glucose and insulin, where cells 
were able to release insulin in response to glucose concentration variations. In conclusion, 
this novel multi-layered HA coating has shown suitability for the encapsulation of 
pancreatic β cells providing an appropriate environment for cell function and protection 
from mediated-immune cell attack. 










Together with surface engineering, pancreatic β cell encapsulation is a promising strategy 
to improve graft survival and decrease alloreactivity and xenoreactivity after 
transplantation (Knopf-Marques et al., 2016). Pancreatic β cells, such as MIN-6 cells, 
have been encapsulated in a variety of encapsulation methods using many biomaterials 
including natural polymers (alginate, chitosan, agarose, collagen) and synthetic polymers 
(PEG and PVA) (de Vos et al., 2014, Iacovacci et al., 2016). 
However, little research has been conducted in the encapsulation of pancreatic MIN-6 
cells using HA. For example, MIN-6 cells have been encapsulated by a droplet-
generating microfluidic device using various combinations of dextran-tyramine gels, one 
of which included HA in its composition (Kamperman et al., 2017a, Kamperman et al., 
2017b). In another study, MIN-6 cells were encapsulated in alginate microgels, which 
were embedded within a HA matrix for the development of a responsive microneedle 
system for the physiological delivery of insulin (Gu and Ye, 2019). HA was also used to 
develop a synthetic insulin-secreting cell with glucose responsive nano particles 
containing insulin. The biocompatibility study for these synthetic cells were performed 
using MIN-6 cells, showing no toxicity of HA microgels in all concentrations used (Di 
et al., 2015). Pseudo islets from MIN-6 cells were PEGylated and embedded within a gel 
containing HA and other ECM components for increased vascularization (Marchioli et 
al., 2017).  
Nonetheless, to achieve long-lasting immunoisolating coatings, HA structural stability 
needs to be improved through chemical modifications. These chemical modifications 
include the utilization of numerous crosslinking methods, such as, chemical crosslinking 
by covalent bonds, physical crosslinking by non-covalent interactions or crosslinked by 
a combination of both (Buwalda et al., 2014, Collins and Birkinshaw, 2008b). In this 
landscape, thiolation of HA can confer moieties that can be crosslinked under 
physiological conditions, with proper gelation kinetics and absence of toxic by-products 
(Xu et al., 2012). This becomes more critical to cells with low proliferation capacities, 
such as pancreatic islets and β cells (Drews et al., 2010). While, it has been shown in 
Chapter 5 that, the thiol groups of HA derivates can be oxidized to form disulphide bonds 
by a disulphide exchange mechanism. This mechanism allows the sequential deposition 
of several ultra-thin polymeric layers on the surface of pancreatic β cells and islets 
(Teramura et al., 2007). 
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Herein, HA derivates carrying free thiol (HA-SH) and pyridine groups (HA-PD) are 
developed aiming to create multiple nano coatings for cell encapsulation of MIN-6 cells. 
The successive deposition of HA-SH and HA-PD derivates is possible due to prior surface 
engineering of MIN-6 cells utilizing Mal-PEG-Lipids. These Mal-PEG-Lipids serve as 





8.2. Materials and Methods 
8.2.1. Materials 
HA, with an average molecular weight (MW) of 1.20 MDa and 0.1 MDa, was kindly 
supplied by Shanghai Easier Industrial Development Co. LTD.  (Shanghai, China) as dry 
powder. Mal-PEG-NHS, DPPE, 2,2’-dithiodipyridine, DTT, lactate dehydrogenase 
(LDH), 3-aminopropyltriethoxysilane (APTES), D2O and human serum (from male AB 
plasma, USA origin) were purchased from Sigma Aldrich (St. Louis, MO, USA). 
Rat/mouse insulin ELISA kit was purchased from EDM Millipore Corporation (Billerica, 
MA, USA). Annexin V-Alexa Fluor 568 was purchased from BD Life sciences 
(Berkshire, England, UK). All other consumables necessary for cell culture including cell 
culture medium, pipettes, flasks and plates were purchased from Thermofisher. 
Pancreatic MIN-6 cells were kindly donated by Dr. Joaquim Miguel Oliveira from the 
I3Bs Research Group at the University of Minho, Portugal. 
8.2.2. Production of Mal-PEG-Lipids 
Mal-PEG-NHS 50 mg is dissolved in chloroform together with 5 mg of DPPE to react 
under stirring for 24 hours at room temperature. While the Mal-PEG-Lipid product is 
purified by precipitation in diethyl ether. 
8.2.3. Production of HA Derivates 
As previously described in Chapter 5, HA is first crosslinked using BIED, where the 
hydroxyl groups of the N-acetylglucosamine moiety of HA are targeted by the isocyanate 
to form urethane linkages. HA (0.1 MDa and 1.2 MDa) was dissolved in DMSO for a 
final concentration of 70 mg.mL-1 and reacted with BIED (49.3 mg.mL-1). HCl 1M was 
used to adjust the pH to 4. The crosslinking reaction proceeds upon stirring. Then, the 
disulphide bond of these gels is reduced using DTT to form HA derivates bearing free 
thiol groups (HA-SH).  
HA-pyridine derivate (HA-PD) was produced from the reaction of HA-SH derivates with 
2,2’-dithiodipyridine. Briefly, 2,2’-dithiodipyridine (20mg) is added to HA-SH (0.1 and 
1.2 MDa) dissolved in methanol. The solutions are stirred for 12 hours at 4°C under 
nitrogen atmosphere to produce HA-PD. Then they are dialysed against PBS 1X for 3 
days at room temperature where PBS is changed every day. HA-PD was freeze dried to 
obtain a lyophilized powder. Briefly, the dialysed sample was placed in a shelf freeze 
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dryer (AdVantage BenchTop Freeze Dryer by Virtis, USA) and let to freeze at -40°C 
overnight before drying. Drying was conducted in four temperature stages. The 
temperature was held at -20°C for 6 hours under vacuum (200 mTorr), then the 
temperature was increased to -10°C for 1.5 hours, following another temperature increase 
to 5°C for 2 hours. This finally reached 25°C, after which HA-PD was obtained as a white 
powder. HA-PD was then stored under nitrogen in the freezer at -20°C. 
Chemical characterization of HA derivates was performed using FT-IR spectroscopy. All 
spectra were recorded on a Perkin Elmer spectrum 100 FT-IR spectrometer operating in 
Attenuated Total Reflectance (ATR) mode. Each FT-IR spectrum was scanned twenty 
times with a resolution of 2 cm–1. The ranges used were from 4000 cm–1 to 650 cm–1.  
8.2.4. MIN-6 Culture 
MIN-6 cells (1x107 cells) between 30-40 passages, were cultured in T75 flasks using high 
glucose DMEM, supplemented with 10% FBS, 1 % antibiotic/antimycotic, 10 mM 
sodium pyruvate and 50 µM β-mercaptoethanol. Cell media was replenished every 3 days 
until cell confluency was reached. 
8.2.5. Conformal Cell Coating 
MIN-6 cells at a density of 1x106.mL-1 were incubated with Mal-PEG-Lipid at 500 
µg.mL-1 for 30 minutes. After cells were centrifuged at 1,000 RPM and washed with PBS 
1X, and the supernatant was removed. Cells were incubated in solutions containing 1.8 
mg.mL-1 of different HA derivates in DMEM. The first conformal layer was deposited 
onto the surface of the cells by incubating HA-SH 0.1 MDa for 10 minutes. After, cells 
were centrifuged and washed with PBS 1X they were incubated with HA-PD 1.2 MDa 
for 10 minutes. This first cycle produces the first bilayer. For the second bilayer, cells 
were incubated with HA-SH 0.1 MDa for 10 minutes. After, cells were centrifuged and 
washed with PBS 1X as before and they were incubated with HA-PD 1.2 MDa for 10 
minutes. For the third bilayer, cells were incubated with HA-SH 1.2 MDa for 10 minutes.  
After, cells were centrifuged and washed with PBS 1X and incubated with HA-PD 1.2 
MDa for 10 minutes. For the fourth and fifth bilayers, cells were incubated with HA-SH 
1.2 MDa for 10 minutes. After, cells were centrifuged and washed with PBS 1X and 
incubated with HA-PD 1.2 MDa for 10 minutes. After cell encapsulation, cell viability 
was assessed using trypan blue. 
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8.2.6. Multilayer Contact Angle and Stiffness Measurements 
Glass slides were carefully cleaned with detergent (5% by volume), flushed thoroughly 
and ultrasonicated in distilled water for 10 minutes. Then, the slides had their surface 
etched using freshly prepared piranha solution (37% H2SO4 + 30% H2O2 + distilled water) 
(1:1:5 by volume) for 3 minutes. Glass slides were rinsed with distilled water and 
immersed in a freshly prepared solution of 37% HCl, 30% H2O2 and distilled water (1:1:5 
by volume) for 5 minutes for the oxidation of the surface. Subsequently, the slides were 
washed thoroughly with distilled water, ethanol and acetone, one after another. After the 
glass slides were dried in an oven at 110°C for 1 hour, they were immediately modified 
by immersion in a 5% APTES solution in anhydrous toluene for 5 minutes. After several 
rinsing washes with toluene and acetone, the modified glass slides were dried in an oven 
at 110°C for 1 hour.  Mal-PEG-NHS and HA multi-layer coating deposition on the surface 
of silanization-treated glass slides follows the protocol described previously in section 
7.2.9. Briefly, NH2-bearing glass slides were dipped in a solution of Mal-PEG-NHS (500 
µg.mL-1) for 30 minutes. NHS reacts with primary amines to form a stable thioester bond. 
After three cycles of washes in distilled water, glass slides were dipped in solutions 
containing 1.8 mg.mL-1 of different HA derivates in distilled water for 10 minutes to 
create coatings of 1, 3 and 5 bilayers. 
KSV contact angle test apparatus together with CAM software were used to calculate the 
contact angles of 1µL droplets of water in the surface of unmodified and modified glass 
slides prior to Mal-PEG-NHS and HA multi-layer coating deposition. 8 measurements 
were performed per sample. Stiffness of the different coatings was measured using a 
Thorlabs EDU-AFM1/M atomic force microscope (New Jersey, USA). The 
measurements were performed using monolithic silicon AFM probe with aluminum 
reflective coating (ContAl-G, Budgetsensors), at room temperature and ambient pressure. 
Force of adhesion was calculated as follows: 
𝐹𝑎𝑑 = 𝐾 ∗ 𝐶𝑝 ∗ ∆𝑧𝑝 
Where K is the cantilever spring constant (0.2 N.m-1), Cp is a factor (0.26*10-6 m.V-1), 
and Δzp is the deflection of the cantilever from snap-in to pull-off point. 
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8.2.7. In Vitro Cell Encapsulation Protection Against Cytokine-Mediated Cytotoxicity 
Human blood serum and heat inactivated blood serum (56°C for 30 minutes) were diluted 
at a ratio of 1:4 in FBS-free DMEM. Diluted serums were incubated with MIN-6 naked 
cells (control), surface engineered cells (Mal-PEG-Lipid only), and encapsulated cells (1 
bilayer, 3 bilayers and 5 bilayers) for 24 hours at 37°C. After incubation, encapsulated 
cells were washed thrice with PBS 1X. Encapsulated MIN-6 cells were assessed for 
viability. Supernatant was assessed for LDH activity. The percentage of LDH released 
from encapsulated MIN-6 cells to the culture medium was calculated as described by the 
manufacturer.  
8.2.8. Glucose Challenge and Insulin Release 
Surface modified and encapsulated MIN-6 cells were exposed to static glucose 
stimulation at specified time points. Cells were placed in a low glucose concentration 
medium (2.5 mM) for 40 minutes followed by incubation in a high glucose concentration 
medium (25 mM) for 40 minutes. Cells in high glucose media were tested for insulin 
release profile by using a mouse insulin ELISA kit as described by the manufacturer. 
Briefly, an anti-mouse insulin pre-coated 96-well plate was incubated with the 
experimental samples and standard insulin solutions for 2.5 hour at RT. Next, the plate 
was washed four times with washing buffer and the biotin-conjugated monoclonal anti-
insulin antibody was added to each well (1:80 dilution) and incubated for an additional 1 
hour at 37°C. After four wash cycles, horseradish peroxidase-conjugated streptavidin 
(1:400 dilution) was added to the wells and incubated for 45 minutes at RT. After four 
washes, bound antibody complexes were developed with TMB substrate for 15 minutes 
at RT and were protected from light. Absorbance was measured at 450 and 550 nm using 
a SynergyMx plate reader (BioTek, EUA). 
8.2.9. Statistical Analysis 
Data are presented as mean ± standard deviation (S.D.) and analysed using one-way 
analysis of variance (ANOVA) followed by post-hoc Tukey’s HSD test. P-values < 0.05 




8.3. Results and Discussion 
8.3.1. Production of HA Derivates 
HA derivates carrying free thiol (HA-SH) were developed from the reduction of 
disulphide bonds of BIED-crosslinked HA gels, shown in chapter 5 (Figure 5.10). HA-
bearing pyridine groups (HA-PD) on the other hand, were developed from the reaction of 
HA-SH derivates with dithiodipyridine, as shown in Figure 8.1. The confirmatory 
chemical characterization of the HA derivates was performed using FT-IR analysis. 
Figure 8.2 shows that HA-PD presents the characteristic C=C and C=N bands of pyridine 
at around 1750 cm-1 and 1550 cm-1, respectively. 
 























Figure 8.2. FT-IR spectra of pure HA, dithiodipyridine, and HA derivates containing 
thiol and pyridine moieties (HA-SH and HA-PD, respectively). 
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8.3.2. Multilayer Conformal Coating 
Prior to the successive deposition of HA-SH and HA-PD derivates, the plasma membrane 
of MIN-6 cells was engineered utilizing Mal-PEG-Lipids. The maleimide group of the 
Mal-PEG-Lipid is located outside the plasma membrane, and it is free to react with the 
thiol groups of HA-SH derivate. This reaction forms a thioether bond and adheres the first 
HA layer (Figure 8.3). For the implementation of the second HA layer, pyridine groups 
of HA-PD derivate react with the remaining free thiol groups of HA-SH derivate that did 
not react with Mal-PEG-Lipid in the first layer.  This reaction occurs via a disulphide 
exchange mechanism that utilizes a bimolecular nucleophilic substitution (SN2) reaction 
that allows the formation of crosslinks between the HA-SH and HA-PD in physiological 
conditions (aqueous medium and neutral pH) (Fernandes and Ramos, 2004). The two HA 
chains connect with each other through the formation of a disulphide bridge, where 
pyridine molecules leave the reaction. This mechanism can be continuously used to build 
up several layers. 
 
Figure 8.3. Maleimide reaction with free thiol groups of HA-SH derivate forming stable 
thioether bonds. 
8.3.3. Characterization of Multilayer Conformal Coatings 
Conformal coating techniques are based on the interfacial polymerization of biomaterials 
to form a  thin (< 500 nm) and crosslinked coating network on the surface of islets and β 
cells (Zhi et al., 2013). This cyclic stepwise deposition method can tailor the final number 
of layers and coating thickness, thus, dictating the permeability and robustness of the 
coating (Silva et al., 2016a). Due to the nanometric size of the coatings, direct assessment 
of contact angle, thickness, and stiffness is difficult to obtain from encapsulated cells. In 
this regard, the stepwise deposition of multiple layers mimicking the cell encapsulation 
was performed using pre-treated silanized glass slides (Figure 8.4a). Silanization of glass 
is performed to modify the surface of glass slices by the introduction of primary amines. 
APTES covalently binds to the surface of glass slides creating a silane bond. The 
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introduction of the primary amine to glass slides can be further exploited for conjugation 
with Mal-PEG-NHS. NHS reacts with primary amines to create stable amide bonds. The 
sequential deposition of HA layers via disulphide exchange mechanism is performed as 
usual on the surface of Mal-PEG-glass slides.  
Silanization of glass slides is an efficient way to insert amine moieties on the surface of 
the glass slides, this technique has been extensively described in the literature for a variety 
of applications that include immobilization and detection of IgG antigens, DNA 
microarrays, etc (Huan et al., 2017, Phaner-Goutorbe et al., 2011). 
Contact angles measurements of untreated, pre-treated silanized glass slides, Mal-PEG-
coated glass slides, and HA coated glass slides with different number of layers (1 bilayer, 
3 bilayers and 10 bilayers) are shown in Figure 8.4b. The contact angle of glass slides 
significantly increased after silanization, making the glass slide more hydrophobic. This 
confirms successful silanization treatment of glass slides (Huan et al., 2017). Moreover, 
the sequential deposition of HA on the surface of treated glass slides greatly decreased 
contact angle in comparison to Mal-PEG-NHS coating. Coating the glass slides with 
























































































































Figure 8.4 a) Surface modification of glass slides through silanization. NH2-bearing 
glass slides react with Mal-PEG-NHS for the deposition of multi-layers of HA to mimic 
cell encapsulation. Contact angle (b) and Force-Distance Curves (c) of treated glass 
slides mimicking multilayer conformal cell coating protocol. 
The sequential deposition of multiple coatings on the surface of pre-treated glass slides 
enabled the analysis of different coatings via AFM. In Figure 8.4c, the force-distance 
curves of the coatings were recorded and the points of interest for the calculation of 
stiffness measurements are highlighted as the snap-in and pull-off points. In Table 8.1, 
the calculated force of adhesion for the different coatings are shown. All coatings show 
significantly higher force of adhesion when compared to uncoated glass slides (pre-
treated silanized glass slides).  
Table 8.1. Force of adhesion measurements obtained from AFM Force -
Distance curves . 
Surface Treatment Force of Adhesion (nN) 




8.3.4. In vitro Multilayer Conformal Cell Encapsulation  
Differing molecular weights of HA were used to build the coatings of MIN-6 cells. In 
Chapter 5, it was demonstrated that LMW HA (0.1 MDa) gels have higher degrees of 
modification 594.3 μM.mg-1 (± 198) of HA as opposed to HMW HA 166.15 μM.mg-1 (± 
14.04). This in turn produces gels with lower mesh size and higher mechanical moduli 
(Zamboni et al., 2020). However, LMW HA when degraded produce pro-inflammatory 
cues that are detrimental to transplants (Jiang et al., 2011). 
With this rational in mind, cells were encapsulated in two, three or five HA bilayers.  The 
deposition of the coatings was designed to have the inner layers containing LMW HA 
and outer layers containing HMW HA (Figure 8.5). The inner layer inherent purpose is 
to produce smaller mesh sizes which contributes to block inflammatory cell recognition 
and cytokine infiltration through the coating, while the outer layers containing HMW HA 
induce anti-inflammatory responses, a perfect match to protect the cellular graft and 
decrease graft rejection upon transplantation.  
Mal-PEG-NHS coated Glass 75 ± 3.05 
1 Bilayer-coated Glass 76 ± 4.44 
3 Bilayer-coated Glass 73 ± 7.95 




Figure 8.5. Composition design of the encapsulation coating layers. 
In order to analyse the viability of cells after encapsulation, trypan blue cell count was 
performed (shown in Figure 8.6). The decrease in viability after the cell encapsulation is 
significant for all three groups (1, 3 and 5 bilayers) in comparison to the control group.  
However, the decrease of viability is still acceptable, and it is above 80%. 
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Figure 8.6. Viability of MIN-6 cells after surface modification using 500 µg.mL-1 Mal-
PEG-Lipids for 30 minutes, and cell encapsulation using 1, 3 and 5 bilayers of HA. 
Statistical analysis was performed using ANOVA followed by post-hoc Tukey’s HSD 
test where p-value < 0.05 shows statistical difference between groups (*) and control. 
The functionality of the encapsulated cells was examined in terms of their ability to 
diffuse glucose through the coating and secrete insulin accordingly. As shown in figure 
8.7, the static low glucose stimulation of encapsulated cells and control cells (naked cells) 
at day 1, day 7 and day 14 after encapsulation resulted in similar insulin secretion (not 
significant change). However, very distinct insulin secretion patterns are observed for 
high glucose challenge. On day 1 after encapsulation, all groups show similar insulin 
secretion, with the exception of the HA 5 bilayers group, which shows significant smaller 
insulin secretion content than the other groups. However, on day 7 after transplantation, 
the encapsulated cell group containing 5 bilayers shows spike in insulin secretion in 
comparison to the other groups. By day 14 after transplantation, the insulin secretion of 
all encapsulated groups is significantly lower than the control group. 
There are two main reasons for immortal cell lines to lose the ability to secrete insulin. 
Sudden loss of glucose-induced insulin secretion can occur following several passages. 
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MIN-6 cells at low passage (between 30-40) present optimal insulin response, in contrary 
to high passage cells (between passage 60-70). High passage MIN-6 cells lose their ability 
to secrete insulin possibly due to an outgrowth of cells with a poor response to glucose 
and decrease in gene expression of Sirt3 and Nampt. These metabolic changes contribute 
to decreased glucose and lipid oxidation (Cheng et al., 2012b). Functional loss, measured 
by glucose-stimulated insulin secretion, can also be correlated with decreased cell-cell 
interactions (Giraldo et al., 2010). 
The higher insulin secretion content of the control group is sought to be a consequence of 
β cell aggregation. It is well known that MIN-6 cells attach to the well only a few hours 
after cell seeding. During culture, these cells have a different spreading profile than other 
adherent cell types (i.e. fibroblasts). MIN-6 cells will aggregate in clusters mimicking the 
formation of islets. The cell-cell interaction within these cell clusters boost insulin release 
by these cells at day 14, in contrary to encapsulated cells which maintain a single cell 
structure. 
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Figure 8.7. Glucose stimulated insulin release from MIN-6 cells encapsulated using 500 
µg.mL-1 Mal-PEG-Lipids for 30 minutes, 1, 3 and 5 bilayers of HA at day 1 (a), day 7 
(b) and day 14 (c) after encapsulation. Statistical analysis was performed using ANOVA 
followed by post-hoc Tukey’s HSD test where p-value < 0.05 shows statistical 
difference between groups (*) and control. 
The immunoisolation of pancreatic β cells requires a biocompatible semi-permeable 
membrane encapsulating cells to protect them from direct contact with the host’s immune 
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system. As discussed in previous chapters, direct immune cell recognition of allogenic 
and xenogeneic cellular grafts can lead to transplant rejection. Moreover, small biological 
molecules such as antibodies, cytokines and chemokines can also induce graft failure by 
cellular death. However, studies have shown that membrane barriers for IgG are enough 
to prevent graft rejection in transplants. This indicates that blocking cytokines and 
chemokines may not be a requirement for immunosuppression in allotransplantation 
(Steele et al., 2014). 
In this regard, the different cell coatings developed in this project were examined to test 
their ability to protect MIN-6 cells against cytokine-mediated cytotoxicity. Encapsulated 
cells were incubated with human blood serum (mismatched species to induce xenogeneic 
recognition) and cellular death was quantified by the release of the intracellular enzyme, 
lactate dehydrogenase, to the cell medium. As shown in Figure 8.8, cytokine-mediated 
cytotoxicity was observed in all groups incubated with complete serum in comparison to 
heat-inactivated human serum. However, at day 7 and day 14 post-encapsulation, the 5-
bilayered encapsulation coating was the only group able to significantly reduce cell death, 
proportional to a decrease of LDH content in the medium, in comparison to the control 
group. This finding corroborates the significance of encapsulating pancreatic β cells in 
multi-layered nano-coatings. As expected, the higher the number of layers in a coating, 
the higher is the protection against the components of the immune system.  
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Figure 8.8. Viability of MIN-6 cells was assessed after exposure to heated inactivated 
and complete human serum at day 1 (a), day 7 (b) and day 14 (c) after encapsulation 
using LDH activity assay. Statistical analysis was performed using ANOVA followed 
by post-hoc Tukey’s HSD test where p-value < 0.05 shows statistical difference (*). 
 




HA derivates carrying free thiol (HA-SH) and pyridine groups (HA-PD) were 
successfully developed from the reduction of disulphide bonds of BIED-crosslinked HA 
gels. Prior to the successive deposition of HA-SH and HA-PD derivates, the plasma 
membrane of MIN-6 cells was engineered utilizing Mal-PEG-Lipids. Lipids are inserted 
in the plasma membrane of MIN-6 cells while the hydrophilic Mal-PEG portion of the 
molecule serve as anchorage sites for the HA layers. Maleimide reacts with the thiol group 
of HA-SH derivates and create a stable thioether bond. The next layer of HA-PD is 
deposited on the surface of MIN-6 cells and reacts with the remaining free thiol groups 
of HA-SH through disulphide exchange mechanism. The successive deposition of HA-
SH and HA-PD creates multiple nano coatings for cell encapsulation of MIN-6 cells. 
As observed from the results shown in this chapter, the 1-layered, 3-layered and 5-layered 
coatings have acceptable cell viability decrease following single cell encapsulation. 
Moreover, insulin secretion in response to glucose stimulation in all three coatings are 
similar to the control group at day 7 after encapsulation. A decrease of insulin secretion 
is observed for cells encapsulated within 5-layered coatings at day 14 after encapsulation, 
however an increase in cell protection is observed against cytokine-mediated cytotoxicity 
from cells encapsulated within 5-layered coatings. 
Overall, the cell encapsulation of MIN-6 cells through disulphide exchange mechanism 
of HA-SH and HA-PD derivates enables a novel safe encapsulation method that can be 
tailored regarding HA MW and number of coatings. The balance between the 
structure:function properties of these coatings suggests that improved immunoisolation is 
achieved through a minimum of 5 bilayers, but the insulin secretion might be delayed due 
to the increased thickness of the coatings. This is especially true to single-cell 
encapsulation. Further studies should be carried out to assess the appropriate 
structure:function properties of these coatings if encapsulating pancreatic islets or pseudo 
islet aggregates. 
In the next chapter, the in vivo evaluation of the functionality and graft survival of MIN-
6 cells encapsulated within a 5-bilayered coating through the transplantation in the renal 
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Female mice (Black 6 strain) (C57BL/6) aged 6 weeks were subjected to low dose 
streptozotocin (STZ) treatment for five consecutive days to mimic T1DM with insulitis. 
At two weeks, evaluation of the elevated glucose levels was used to confirm diabetes. 
The diabetic mice were then subject to the transplantation of pancreatic β cells (MIN-6 
line). Four groups of mice were studied. The first group were injected with saline-only 
(SHAM group), the second and third groups were injected with MIN-6 single cells and 
Mal-PEG-lipid modified MIN-6 single cells (500 µg.mL-1 for 30 minutes), respectively, 
while the fourth group were injected with HA-coated MIN-6 single cells (5 bilayers). At 
seven- and fourteen-days following transplantation, the mice were euthanized. The renal 
and pancreatic tissues were then collected and histologically analysed. The induction of 
diabetes in female mice, through five daily STZ injections resulted in inconsistent 
hyperglycaemia, where 20% of mice were unable to achieve hyperglycaemia (blood 
glucose levels falling between 100-149 mg/dL), 32% of the mice displayed little increase 
in blood glucose levels (150-199 mg/dL), and 48% of the mice successfully presenting 
high blood glucose levels above 200 mg/dL (hyperglycaemia). Moreover, surface-
modified cells and encapsulated cells were unable to revert diabetes, failing to decrease 
blood glucose hyperglycaemia into the physiological range. In conclusion, incomplete 
diabetes induction in female mice is associated with sex dimorphism and hormonal 
interferences. Furthermore, transplant failure of encapsulated cells may be associated 
with deprived cell-cell interaction, which leads decreased β cells functionality, where 
insulin secretion is dependent on cell-cell interaction. 













Streptozotocin STZ is a broad-spectrum antibiotic with unique toxic selectivity for β cells 
in the pancreas, being used clinically for the treatment of metastatic insulinomas. STZ 
uptake into rodent pancreatic β cells is mediated by GLUT2 receptor. STZ is equally 
diabetogenic whether administered to fed or fastened mice (Chaundhry et al., 2013), 
showing no competition with glucose for the GLUT2 receptor. 
Outside its therapeutic application, STZ has been used since early 1960’s in diabetes 
research in order to induce hyperglycaemia in rodents via selective destruction of β cells. 
This effect is attributed to the nitroso moiety in STZ. Once inside the cell, this nitroso 
group act as a nitric oxide (NO) donor to create reactive oxygen species and induce cell 
death. 
However, the cell death pathway greatly differs by the STZ posology adopted for the 
induction of hyperglycaemia in mice.  When delivered by intraperitoneal injection as a 
single high dose (180-190 mg/kg body weight), STZ causes massive β cell necrosis within 
2-3 days after administration. One moderate dose (150 mg/kg body weight) in 
conjunction of high fat diet can also accelerate β cell endoplasmic reticulum stress which 
mimics T2DM with high toxicity and mortality rate. Whereas multiple low dose of STZ 
mimics T1DM with insulitis and no important toxicity (Chaundhry et al., 2013). 
Different doses and administration routes are used according to the rodent strain and 
gender. STZ response from different mouse strains shows hierarchical response as 
following:  DBA > C57BL/6 > MRL/MP > 129/SvEv > BALB/c. Strain variability is 
attributed to differences in immune response. C57BL/6 immune response is Th1 
dependent, while BALB/c is Th2 dependent. Islets of STZ induced C57BL/6 mouse 
produce INF-γ and TNF-α (Th1 type cytokine) and have reduced IL-4 and IL-10 levels 
(Th2 type cytokine), while opposite findings are reported for BALB/c (Cantarelli et al., 
2013). 
STZ protocols for diabetes induction produce a reliable T1DM animal model, specifically 
applied in pre-clinical research related to the transplantation of allogenic and xenogeneic 
pancreatic β cells. However, from the array of immortal pancreatic β cell lines available 
for transplantation, MIN-6 cells originated from transgenic C57BL/6 mouse insulinoma 
and expressing an insulin-promoter/SV40 T-antigen construct are one of the few 
immortal cell lines to retain  glucose-stimulated insulin release (Kinoshita et al., 2001).  
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Herein, the administration of a low dose STZ injection for five consecutive days is 
selected for the induction of pancreatic β cell destruction which resembles autoimmune 
T1DM in female C57BL/6 mice leading to hyperglycaemia. The transplantation of single-
encapsulated cellular grafts developed in the previous chapters is key to assess the in vivo 
suitability of HA conformal multi-layered nano coatings.  These coatings are designed to 
protect pancreatic β cell from the host immune system, while maintaining cell 
functionality and physiological insulin secretion patterns in response to blood glucose 





9.2.Materials and Methods 
9.2.1. Animals 
Female mice of Black 6 strain (C57BL/6) aged 6 weeks were housed in ventilated cages 
of no more than 5 mice per cage and were housed with free access to food and water, at 
a controlled temperature of 23°C with 12 hours light-dark cycles. Mice were kept at the 
Life and Health Sciences Research Institute at the University of Minho, Portugal. All 
procedures were performed in accordance with the European Directive 86/609/EEC and 
approved by the University of Minho Animal Ethics Committee (SECVS 074/2016) and 
the Portuguese National Authority (DGAV 014072).  
9.2.2. Model for Diabetes Induction 
All mice were subjected to low dose STZ treatment to mimic T1DM with insulitis. An 
STZ solution was freshly prepared using sodium citrate pH 4.5 prior to be administered 
intraperitoneally (50 mg/kg of body weight) once a day for five consecutive days. At the 
time of the injections, mice were kept ad libitum fed regimen. Diabetes development was 
assessed by the measurement of blood glucose levels (Freestyle Precision Neo, Abbott).  
9.2.3. MIN-6 Graft Transplantation  
Diabetic mice were subject to the transplantation of pancreatic β cells (MIN-6 line). Four 
groups of mice were used. Mice injected with saline-only (SHAM group), mice injected 
with MIN-6 single cells, mice injected with Mal-PEG-Lipid modified MIN-6 single cells, 
and mice injected with HA-coated MIN-6 single cells with 5 bilayers. 
Prior to the surgery, intramuscular (IM) injection (100 µl) of 90 mg/kg ketamine 
(Imalgen; Meriel, Lyon, France) in combination with 0.65 mg/kg of the α2 adrenergic 
receptor agonist medetomidine (Domitor; Pfizer, Paris, France) were used for anaesthesia 
and sedation, respectively. Shaving and incision under the left rib was performed. The 
left kidney was injected with 10 µL of saline or cell suspension preparations with cell 
density of 750,000 cells per mice. Mice were sutured and they were given an IM injection 
(50 µl) of atipanezole 1 mg/kg (Antisedant; Pfizer, Paris, France) as a sedative reversor. 
In post-operatory recovery, mice were kept resting under warm light. 
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9.2.4. Blood Glucose Control 
Mice were assessed for up to 14 days post-transplantation to analyse diabetes reversion 
through the measurement of blood glucose levels twice a week. Blood samples were 
collected from pricking the cheek with a needle. The blood droplet was placed in a 
glucose strip and measured using a glucometer (Freestyle Precision Neo, Abbott).  After 
follow-up, mice were sacrificed for renal and pancreas dissection and histological 
analysis. 
9.2.5. Dissection of Renal and Pancreatic Tissues 
Mice were euthanized via CO2 inhalation at different time points. 7 days and 14 days after 
transplantation mice from each group (n=5) were sacrificed for the collection of renal and 
pancreas tissues to determine leukocytic infiltration degree. Renal and pancreatic tissues 
were retrieved and fixed using 4% formalin solution. Fixed kidneys and pancreas were 
embedded in paraffin and cut in 5 µm thick sections using a microtome. 
9.2.6. Histology 
Haematoxylin and eosin were used to analyse graft-localized cell infiltration and 
inflammation. All images were acquired using a CKX41 Olympus inverted microscope 
(Tokyo, Japan) equipped with a DFK 31AU03 camera (The Imaging Source Europe 
GmbH, Germany) and IC Capture software (The Imaging Source Europe GmbH, 
Germany).  
9.2.7. Statistical Analysis 
Data are presented as mean ± standard deviation (s.d.) and analysed using one-way 
analysis of variance (ANOVA) followed by post-hoc Tukey’s HSD test. P-values < 0.05 
(*) were considered significant. 
9.3.Results and Discussion 
9.3.1. Animal Model for Diabetes Induction 
Diabetes was induced in female mice by 5 consecutive STZ injections (Figure 9.1). In 
table 9.1, the blood glucose levels of the female mice after 14 days of the injections are 
shown. The blood glucose levels of 20% of all mice subjected to the induction were 
unable to achieve hyperglycaemia after 14 days of the last STZ injection, with blood 
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glucose levels falling between 100-149 mg/dL. 32% of the mice displayed little increase 
in blood glucose levels (150-199 mg/dL), however still falling into a non-diabetic 
category. 48% of the mice were successfully induced with diabetes, showing high blood 
glucose levels above 200 mg/dL (hyperglycaemia). These findings of incomplete diabetes 
induction in female mice are thought to be associated with sexual dimorphism assigned 
to oestradiol hormone. 
 
Figure 9.1.  A) Intraperitoneal injection of STZ. B) Mice are kept in cages with ad 
libidum fed regimen. 





Sex differences in physiology begin early in development, due to a combination of genetic 
and hormonal cues which continue after puberty. In multiple rodent models of diabetes 
in which β cell failure occurs, sex dimorphism is observed. It has been shown that female 
mice of Black 6 strain (C57BL/6) are more resistant to become diabetic after induction 
with STZ. They will develop insulitis, with modest hyperglycaemia (around 200 mg/dL) 
after 14 days following the injections. While male mice develop diabetes with severe 
hyperglycaemia (> 400 mg/dL) during the course of the 5 days of injection (Leiter, 1982). 
Therefore, the extent of diabetes-associated hyperglycaemia is more pronounced in males 
than females (Chandramouli et al., 2018). In the literature, this difference is mainly 
assigned to Oestradiol, the major female oestrogen steroid hormone, which is presumed 
to protect β cell from oxidative stress-induced apoptosis (Cantarelli et al., 2013). 
Moreover, when male and female mice were transplanted with two different stages of 
pancreatic cells derived from human embryonic stem cells (endocrine progenitors and 
insulin-positive cells), the in vivo maturation of both cell populations into insulin-
secreting cells was accelerated in female recipients than in male hosts. The oestradiol-2 
(E2) hormone was the promoter of a faster β cell maturation (Gannon et al., 2018). 
In humans, women tend to have an increased glucose-stimulated insulin secretion (GSIS) 
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2018). E2 hormone also influences the immune system, which plays a central role in the 
development of T1DM. The immunological effects of E2 on innate immune system show 
to be protective against innate immune pro-inflammatory responses and prevents 
apoptosis of islets. E2 also protect islets from the adaptive immune response, where E2 
hormone promotes the expansion of immunosuppressive Treg cells. In ketosis-prone 
diabetes (KPD is a form of T2DM), a male predominance is also observed. Interestingly, 
the rare women developing KPD were in an anovulatory state, with decreased E2 levels 
(Gannon et al., 2018). 
Endocrine pancreas cell composition is known to vary according to pancreatic anatomical 
location and amongst different species (Dolensek et al., 2015). Moreover, the proportion 
of different hormone-producing cells in the pancreas also differs between males and 
females of the same species, possibly also contributing to the female resistance to diabetes 
induction. Studies suggest that islets from women have an average of 6% more β cells 
than men, moreover, islet transplantation from female donors also show better outcomes 
than with islets obtained from male donors (Gannon et al., 2018). 
Animal research across all disciplines predominantly uses male subjects instead of mixed 
or only female subjects. The incorporation of only male subjects in animal research is 
likely to lead to poorer treatment outcomes for women in the future, as studies have 
already revealed marked differences between male and females in many basic biological 
processes (Beery, 2018). The National Institute of Health (NIH) in the USA has been 
developing policies encouraging the use of both male and female animal research subjects 
and consideration of sex and biological variables (Clayton JA and Collins, 2014). 
Although the results shown in this project have great variability regarding diabetes 
induction and hyperglycaemia achievement, it corroborates that more research and 
adaptation of current protocols have to be changed in order to better characterize disease 
models in female subjects.  
Moreover, the great variability of hyperglycaemia within female mice (reported in table 
9.1) is sought to be a consequence of each individual rodent reproductive cycle. In rodents 
the reproductive cycle, called the estrous cycle, lasts approximately 4-5 days (in humans 
it is called the menstrual cycle, and lasts approximately 28 days). The estrous cycle has 
four stages (proestrus, estrus, metestrus, and diestrus). Each stage lasts for approximately 
one day (Byers et al., 2012). Proestrus stage corresponds to the pre-ovulatory day, when 
E2 increases and consequently, during the night, luteinizing hormone (LH) and follicle-
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stimulating hormone (FSH) surge and ovulation occurs. In the estrus stage, E2 remains 
elevated throughout the morning and falls back to basal levels in the afternoon. In the 
metestrus stage, plasma E2 concentration is low. Finally, in the diestrus stage, E2 levels 
start to increase (Caligioni, 2009). Considering that 52% of all mice did not achieve 
hyperglycaemia, and 48% of the mice were successfully induced with diabetes, showing 
high blood glucose levels, it may be possible that the start of the estrous cycle (high E2 
levels) coinciding with the start date of STZ injection, decreases the efficacy of STZ 
induction. While starting the STZ induction in the metestrus stage, where low levels of 
E2 are found, may increase STZ-induced cell toxicity and higher diabetes induction 
efficiency rates. 
9.3.2. In vivo Transplantation in the Renal Subcapsular Space 
In mice, the kidneys are located retroperitoneally, where the left kidney is readily visible 
and can be accessed more easily in comparison to the right kidney, which is located under 
the small intestine and adjacent to the liver (Delaney et al., 2018). In the kidneys, the 
adrenal glands are in close proximity to each renal cranial pole, and they can be 
distinguished by the light orange coloration due to steroid hormone production (La Perle 
and Dintzis, 2018). The kidneys in rodents are unilobular, unipapillary and unipyramidal, 
in contrast to human kidneys which are multilobular, multipapillary and multipyramidal. 
On a cross-section of the kidney, four main structures can be seen: the capsule, the cortex, 
the medulla, and the papilla which extends deep into the renal pelvis. The capsule is made 
of epithelial and fat tissue, In the renal cortex, the glomeruli (with an average diameter of 
73.4 µm) and the proximal convoluted tubules can be found. In the medulla (pyramid) 
the medullary capillary plexus is found. Little interstitial connective tissue is found in the 
kidney of rodents in contrast to kidneys of humans (Delaney et al., 2018). In this study 
MIN-6 cells were injected into the sub-capsule membrane of the kidney as single-cell 
treatments as shown in Figure 9.2.  
Five mice have died at day 3 post-transplantation. Of the ten mice for each group, three 
mice died from the group implanted with Mal-PEG-lipid cell surface modification, one 
mouse died from the group implanted with HA encapsulated cells, and one mouse died 
from the SHAM group. These demises are likely to be related to stitch opening and 
infection at the incision site. After the transplantation, mice had their blood glucose 





Figure 9.2. MIN-6 cell transplantation. A) Abdominal viscera of female mice (Cook, 
1965). B) Intramuscular administration of anaesthetics. C) Topical application of 
Vaseline to protect eyes from drying during surgery, lateral hair removal for incision. 





































Figure 9.3. Post-transplantation blood glucose levels for mice groups euthanised at day 
14. Statistical analysis was performed using ANOVA followed by post-hoc Tukey’s 
HSD test where p-value < 0.05 shows statistical difference within cell only group (*) 
over time. 
 
In figure 9.3, although there is no significant difference on blood glucose levels for the 
different groups over time (apart from cells only group), it can be seen that at day 0 (prior 
to transplantation) mice had reached mild hyperglycaemia (200-300 mg/dL), except for 
the cell surface modification group which was just below 200 mg/dL. However, if we 
observe the SHAM group on day 3 after transplantation, we can notice an ongoing rise 
on blood glucose levels. This result suggests that diabetes induced by STZ was not 
complete after 14 days as suggested by the literature (Leiter, 1982, Chandramouli et al., 
2018). On day 7, we can observe a slight decrease of blood glucose level, which is 
associated with β cell recovery due to an incomplete β cell destruction (Cantarelli et al., 
2013). When analysing the pancreas of mice, islets are unevenly distributed throughout 
the pancreas, and are present in both interlobular (Figure 9.4a) and periductal/perivascular 
(Figure 9.4b) locations (Liggitt and Dintzis, 2018). In the islets of mice, β cell populations 
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are typically clustered in the centre of the islet and surrounded by other islet cell types, 
whereas in humans all islet cells are homogenously intermingled (Liggitt and Dintzis, 
2018). 
Regarding the morphology of the islets after treatment with STZ, their architecture is 
expected to be largely disrupted (Micucci et al., 2014, Han et al., 2017). However, as seen 
in Figure 9.4, islets did not show morphological changes nor boundary irregularities. 
Moreover, no infiltration of immune cells was observed in the histological analysis of the 
pancreas of STZ-induced diabetic mice. In this scenario, considering the results 
presented, diabetes induction cannot be assured only 14 days after STZ injections. We 
should consider extending the induction for at least 21 days after STZ injections or 
increasing the daily dose of STZ. 
 
9.4. Histological images of pancreatic tissue from STZ induced diabetic female mice on 
day 7 (a) and day 14 (b) after transplantation, where (c) shows higher magnification for 
day 14 after transplantation. Islets are circled in red. 
In figure 9.3, results show that non-encapsulated single cells (cells only group) were able 
to decrease hyperglycaemia over time to normal physiological levels (<200 mg/dL). This 
was not observed in mice transplanted with encapsulated and surface modified cells. We 
hypothesise that non-encapsulated cells were able to interact with each other and were 
probably able to form clusters to mimic a pseudo-islet. This hypothesis has been 
confirmed in the histological analysis of the renal tissue after transplantation. In Figure 
9.5 a and b, the saline transplanted group (SHAM) shows the normal appearance of the 
renal capsule and the underlying renal cortex. In Figure 9.5 c and d, the histological 
analysis of the mice transplanted with naked cells, show that the MIN-6 cells are grouped 
and located between the renal capsule and the renal cortex. Images also show graft 
infiltration with leukocytes. Infiltration of immune cells have also been reported by other 
studies at the 2-week transplantation mark. The degree of leukocyte infiltration is 
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maximum at the first two weeks after transplantation and decreases after that (Plesner et 
al., 2005).  
Unfortunately, MIN-6 cells were not able to be found in the histological images of various 
slices of the kidneys of mice transplanted with encapsulated and surface engineering cells. 
This finding confirms our hypothesis that surface modified and encapsulated cells were 
deprived from cell-cell interaction, unable to form clusters similar to islets. This has also 
implications in β cells functionality. Functional loss (measured by insulin expression, 
insulin content, and glucose-stimulated secretion) is correlated with decreased cell-cell 
interaction (Giraldo et al., 2010). Other studies have also demonstrated this pattern of 
functionality associated to MIN-6 cell aggregates and single cells. Encapsulation using 
poly(ethylene glycol) diacrylate (PEGDA) of either MIN-6 cell aggregates or MIN-6 
single cells showed a 4-fold higher insulin secretion in response to glucose for aggregated 
MIN-6 cells when compared with encapsulated single cells (Bernard et al., 2012). Fukuda 
et al encapsulated MIN-6 single cells using fibronectin and gelatin by a L-b-L approach 
but only after the formation of 3D spheroids, the insulin secretion, and the expression of 
GLUT2 increased (Fukuda et al., 2018). Dispersed MIN-6 cells were encapsulated in 
dextran-tyramine microgels, and within one day of subsequent cell culture, cells 
centralized and aggregated. MIN-6 cells remained viable and functional (Kamperman et 
al., 2017b). Interestingly, the functionality of encapsulated MIN-6 aggregates is reported 
to be heavily reduced compared to free-floating aggregates (Marchioli et al., 2017). 
Another important point to highlight is that MIN-6 cells are anchorage dependent cells. 
When single cells are encapsulated, they are denied attaching to one-another or to 




Figure 9.5. Histology analysis of the kidneys after 14 days post-transplantation of MIN-
6 single cells. Saline group (A and B) and cells only group (C and D). Immune cell 
infiltration is shown (*). Lower magnification 10X, scale bar 100 µm. Higher 
magnification 40X, scale bar 50 µm. 
9.4. Final considerations 
Overall, studies have proposed that diabetes is achieved when levels of blood glucose are 
higher than 200 mg/dL. Reversion of diabetes and transplantation success is defined as 
the ability to reach non-fasting blood glucose levels under 250 mg/dL within five days 
after transplantation. Graft rejection is defined as two consecutive measurements above 
300 mg/dL in mice after normoglycemia was achieved. If more detailed definitions are 
required, transplant function can be normalized for pre-transplant glycemia and the 
outcome can be classified as: 1) full function (non-fasting blood glucose concentration < 
50% of pre-transplant concentration); 2) partial function (non-fasting blood glucose 
concentration between 50% and 80% of pre-transplant concentration); and 3) no function 
(non-fasting blood glucose concentration > 80% of the pre-transplant concentration) 
(Cantarelli et al., 2013). 
T1DM induction disease protocols established using male mice do not demonstrate a 
viable option to induce diabetes in female mice. The results shown in this chapter agree 
that female mice are more resistant to diabetes induction through STZ administration.  
The levels of blood glucose shown in this project are not consistently raise above normal 
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physiological ranges. This result is hypothesized to be a consequence of sexual 
dimorphism characteristics and hormonal interferences. Nevertheless, the use of female 
subjects in this study is important to highlight sex-related deviations in protocols to induce 
diabetes in mice. 
Moreover, during the procedure of injecting the cellular grafts into the kidney capsule, 
the gauge of the syringe left a sizeable puncture after retrieving the needle. It was 
observed leakage of some cell suspension outside the kidney capsule. This finding may 
also have contributed to the failure of reversing diabetes after transplantation of the cell 
grafts. In order to decrease graft loss during transplantation the use a gel foam or surgical 




Chapter 10: Conclusions, 





10.1. Conclusions and Limitations 
In this project, the synthesis of BIED, a di-isocyanate crosslinker and the gelation of HA 
have been successfully conducted. It demonstrates an innovative crosslinking method 
through the formation of urethane linkages between isocyanate groups of the crosslinker 
and hydroxyl groups present in the HA chain. These HA gels have been developed 
through homogeneous and heterogenous crosslinking methodologies creating very 
distinct gels. These gels have potential to be further developed for applications that 
include drug release and skin wound dressings. The main advantage of using BIED over 
other isocyanate crosslinkers is that it possesses a disulphide bond in the middle of its 
molecular backbone. This feature enables the reduction of the disulphide bond into free 
thiol groups, its re-oxidation for reversible or self-healing gel forming properties. 
In recent years, the role of biomaterials in cell encapsulation exceeds solely a barrier to 
provide immunoisolation. The role of biomaterials is now sought to modulate the 
interaction of the surrounding biological environment with the cellular graft in order to 
create long-lasting immune tolerance. In this landscape, HA, a known modulator of the 
immune system, has been successfully modified to create derivates capable to encapsulate 
pancreatic β cells for T1DM treatment.  
The HA derivates developed in this project are able to assemble in nano-layers through a 
disulphide exchange mechanism, where disulphide bonds are recreated without the use 
of strong oxidizing agents and catalysts. This method utilizes a bimolecular nucleophilic 
substitution (SN2) reaction that allows the formation of crosslinks between a thiol-
modified and pyridine-modified polymeric material in physiological conditions (aqueous 
medium and neutral pH) (Fernandes and Ramos, 2004). Furthermore, this method also 
brings high tailorable interfaces, where the number and the composition of each layer can 
be specifically designed to improve cell encapsulation functionality. This method of 
encapsulation is biocompatible and provides stronger crosslinking bonds when compared 
to simple ionic interactions observed in L-b-L surface deposition of polyelectrolytes. 
The in vitro encapsulation of MIN- 6 cells via surface modification using Mal-PEG-Lipid 
and through conformal deposition of nano-coatings of HA derivates was successfully 
performed. Results show neglectable detrimental effects to cells during the process of 
encapsulation. Moreover, encapsulated cells showed resistance to immune mediated cell 
death with increasing number of coating layers in comparison to the control group (naked 
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cells), while maintaining in vitro functionality. Cells were able to secrete insulin when 
stimulated with glucose.  However, the in vivo studies assessing the transplantation of 
these cells under the kidney capsule of mice showed unsatisfactory results. 
The diabetes induction of female mice through five daily STZ injections did not show 
consistent hyperglycaemia. This result is sought to be a consequence of sexual 
dimorphism and hormonal interferences. Using male mice could give more robust and 
reliable data, nevertheless, animal research using female mice can lead to better 
understanding of disease and treatment outcomes used to prevent or treat diabetes. 
10.2. Future Work 
This work presented insightful prospects regarding using female subjects in diabetes 
research and the transplantation of pancreatic β cells into the kidney capsule. However, 
further studies could be conducted to assess the optimization of disease-inducing 
protocols for female mice and the comparison of single-cell versus pseudo-islet 
aggregates encapsulation. 
a) Design appropriate diabetes model for female mice. Suggested T1DM inducing 
protocol modifications: 
• Increase the daily dose of STZ above 50 mg/kg. Optimization of the dose 
has to be conducted regarding hyperglycaemia development; 
• If maintaining the 50 mg/kg dose a day, it may be advisable to increase 
the number of induction days above the 5 consecutive daily injections; 
• In order to guarantee complete diabetes induction without β recovery, the 
post-induction period should be increased from 14 days to 21 days; 
• Assess the interference of the estrus cycle in the efficacy of STZ induction 
of diabetes in female mice. 
b) Lack of cell-cell interaction may affect transplantation outcome and diabetes 
reversion, where deficient insulin secretion is unable to control hyperglycaemia. 
To confirm the hypothesis of the decreased functionality of encapsulated single-
cells due to lack of cell-cell and cell-ECM interactions: 
• Development of pseudo-islet aggregates using MIN-6 cells; 
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• Encapsulation of pseudo-islet; 
• Assessment of glucose-induced insulin secretion; 
• Transplantation of encapsulated pseudo-islet; 
• Histological assessment of pseudo-islet aggregates under the kidney 
capsule of female mice. 
Fundamental materials research has been completed in this project, showing great scope 
for project expansion. Where these novel HA derivates can be studied for many other 
applications that include wound healing dressings with antimicrobial properties, scaffolds 
for skin grafts, gels for anti-inflammatory drug delivery, and cell encapsulation of many 
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